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Abstract 
Nonribosomal peptides and polyketides form important classes of 
pharmaceutical agents. Several architectures of biosynthetic machinery exist 
for the construction of these structurally diverse molecules. Many attempts to 
engineer these proteins have concentrated on the multimodular type I 
polyketide synthases (PKS) and nonribosomal peptide synthetases (NRPS). 
Here, work was carried out to express the NRPS module responsible for starter 
unit formation from indanomycin biosynthesis in E. coli. Three synthetic 
genes, for IdmI, IdmJ and IdmK, were cloned and subsequently used in 
expression trials. Despite multiple attempts, IdmI was always expressed as an 
insoluble protein. IdmJ was expressed as a soluble protein, and an unexpected 
post-translational modification was found and investigated. Mutagenesis 
studies suggested that the unknown post-translational modification was 
occurring at a cysteine 127. IdmK, the carrier protein, was expressed in a 
soluble form with good yield. Analysis by mass spectrometry showed that, 
surprisingly, E. coli was able to phosphopantetheinylate IdmK, which is 
required for a functional module. Preliminary structure determination was 
carried out by X-ray crystallography. A complete 3D structure was obtained 
using NMR spectroscopy of the [
15
N] and [
13
C, 
15
N] labelled protein. Structure 
determination was performed using CS-ROSETTA, which only uses chemical 
shift data, and ARIA, which assigns ambiguous NOE distance restraints. Both 
structure calculations produced comparable structures for IdmK. The structure 
showed a 3 α-helix bundle, with the same topology, lengths and locations of 
helices as other carrier proteins. Initial investigations into holo-IdmK suggest 
that the phosphopantetheine co-factor is directed into the hydrophobic core of 
the protein. This research has set up the system for future studies to engineer 
the pathway for novel product biosynthesis.  
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Introduction 
1 
 
1. Introduction 
1.1 The Golden Age of Antibiotics 
In 1928 Alexander Fleming made the serendipitous discovery of penicillin (Fleming, 
1929). Following this, in the 1940’s, Howard Florey and Ernst Chain started 
exploring the pharmaceutical benefits of penicillin, discovering its antibacterial 
properties (Chain et al., 1940). Penicillin targets peptidoglycan cell wall biosynthesis 
of bacteria and is therefore most active against Gram positive bacteria (Yocum et al., 
1980). Between the discovery and development of penicillin, in 1935, scientists at 
the German company IG Farben discovered, developed and commercialised a 
synthetic sulfonamide drug named prontosil (4-[2,4-diaminophenyl)azo] 
benzenesulfonamide) for the treatment of Gram-positive bacteria by acting in a 
bacteriostatic manner and targeting folate synthesis (Domagk, 1935). These drugs 
sparked a cascade of discovery of a variety of pharmaceutically beneficial 
compounds; this is referred to as the “golden age” of antibiotics. The “golden age” of 
antibiotics was really in full stride between the 1950s and 1960s with a large 
percentage of antibiotics still in use today being discovered in this period (Davies, 
2006). Figure 1 shows a timeline of antibiotics in use today, the majority of which 
were discovered during this era.  
Since the discovery of antibiotics such as penicillin, overuse and misuse in the field 
of medicine and in intensive animal farming has caused a large increase in resistant 
strains of bacteria, rendering some of these well-established treatments generally 
ineffective. A combination of horizontal gene transfer and mutation has armed 
bacteria with an arsenal of mechanisms for antibiotic resistance (Davies, 2006). 
Some examples of mechanisms of resistance include: (1) efflux pumps which will 
remove the drug from the cell, this occurs in fluoroquinolone resistance (Hooper, 
1999; Davies and Davies, 2010); (2) modification of the drug itself rendering it 
inactive, which plays a key role in penicillin resistance (Fisher et al., 2005; Wright, 
2007); and (3) alteration of cellular metabolic pathways, bypassing the process the 
drug has inhibited, this occurs in sulfonamide resistance (Skold, 2000).  
 
Figure 1.1- A timeline of the discovery of antibiotics that are still in use today. Drug classes (normal) and examples (bold) with chemical 
structures are shown above. Drugs highlighted in purple boxes are synthesised by non-ribosomal peptide synthetases (NRPS) and Type I 
modular polyketide synthases (PKS) (Section 1.4 and 1.5), those highlighted in blue boxes are partially synthesised by NRPS or PKS and those 
not highlighted are synthesised by other methods. Figure adapted from Davies (2006). 
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Some bacterial strains, such as Staphylococcus aureus, are known to be resistant to a 
number of antibacterial drugs and are therefore called multidrug resistant organisms 
(MDRO). Multidrug resistance (MDR) leaves only a very limited range of treatments 
available, such as vancomycin (Figure 1.1) for the treatment of the methicillin-
resistant Staphylococcus aureus (MRSA) superbug (Alekshun and Levy, 2007). 
Now, with the “golden age” of antibiotics well and truly over, we have seen a 
decrease in the number of new antibiotics discovered and a combination of the 
financial drain and strict Food and Drug Administration requirements has caused a 
plummet in the investment the pharmaceutical industry (Davies, 2006). In 1990 there 
were 18 pharmaceutical companies researching antibiotic treatments; today, there are 
just four; AstraZeneca and GlaxoSmithKline (United Kingdom), Novartis 
(Switzerland) and finally Sanofi-Aventis (France) (Cooper and Shlaes, 2011).  
Antibiotics are a vitally important element in the fight against infectious diseases and 
maintenance of a good quality of life. Natural products provide a wealthy source of 
antimicrobials and research into the production and engineering of novel 
antimicrobials may aid in the fight against, not only drug resistant bacteria, but also a 
whole host of life threatening conditions. Throughout this introduction I will be 
presenting examples of these antimicrobials and the reasoning and strategies behind 
engineering their producers for novel pharmaceutical compound biosynthesis.  
 
1.2 Natural products as antibiotics 
Analysis of the literature and public pharmaceutical documentation has highlighted 
16 natural product derivatives across stages I, II and III of clinical trials (Butler et al., 
2013). Since 2000, over 50% of the drugs released onto the market were either 
natural products, or derived from natural products. From these 12 natural and natural 
based products, 9 are produced by actinomycetes and 3 are produced by fungi, both 
are prolific sources of natural products with pharmaceutical benefits (Butler et al., 
2013; Newman and Cragg, 2012). 
Statistical analysis suggested that typically, pharmaceutical companies are able to 
screen tens of thousands of actinomycetes in one year; however undiscovered 
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antibiotics are likely to occur ≤1 in 107 from randomly screened soil actinomycetes. 
Additionally, only a microscopic percentage of the soil on earth has been screened 
for actinomycetes, which incidentally is not the only environment in which these 
pharmaceutically beneficial compounds are found (Baltz, 2008; Clardy et al., 2006).  
Efforts are being made to discover new antibiotics produced by Nature, identifying 
natural products that have otherwise been inaccessible or missed beforehand. 
Although previously the main source of antibiotics has been from Streptomyces, 
continuation of the traditional culturing methods are still aiding in the discovery of 
new actinomycete strains not only from soil, but also marine sediment (Clardy et al., 
2006; Rocha-Martin et al., 2014). Ribosomal RNA (rRNA) sequencing has been 
exploited for investigating uncultivable bacteria. 16S rRNA is ubiquitous in bacteria 
and contains conserved regions that can be probed and variable regions, which 
enable identification of new bacterial strains. rRNA sequencing has highlighted the 
fact that only a small fraction of bacteria can be cultured using traditional methods 
(Clarridge, 2004; Relman, 1999; Clardy et al., 2006). This indicates that other 
approaches are required to access this untapped resource (Clardy et al., 2006). 
Strategies for discovering new natural products for antibiotics include heterologous 
expression of genes in a culturable host, metagenomics in combination with 
heterologous expression, typically using 16s rRNA, and manipulation of currently 
known producers of natural products, also known as combinatorial biosynthesis 
(Clardy et al., 2006).  
There are three classes of natural products with pharmaceutical benefits of particular 
interest: polyketides (PK), non-ribosomal peptides (NRP), and hybrid PK-NRP 
compounds which will be discussed further. 
1.2.1 Polyketides 
Polyketides are secondary metabolites known to possess a wealth of 
pharmaceutically beneficial activities such as antibacterial, antifungal, antiparasitic, 
antihelminthic and insecticidal properties (Kevin Ii et al., 2009; Dutton et al., 1995). 
The main producers of these biologically active molecules are the actinomycetes 
especially Streptomyces and Saccharopolyspora (Weissman and Leadlay, 2005). 
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Figure 1.2 shows example structures of polyketides (and rifamycin in Figure 1.1) 
illustrating the structural diversity seen across these compounds (Staunton and 
Weissman, 2001).  
 
 
 
 
Polyketides are composed mainly of three basic units; acetate, propionate and 
butyrate, derived from their CoA equivalents. These units are also utilised by fatty 
acid synthases for the synthesis of fatty acids and so are readily available in the cell 
(Figure 1.5) (Staunton and Weissman, 2001; Meier and Burkart, 2009). The 
structural diversity, wealth of stereochemistry and functional groups observed in 
polyketides can partly be attributed to the various starter and extender units that can 
be incorporated (Chan et al., 2009; Smith and Tsai, 2007; Cane et al., 1983). 
Polyketides can be classed by their structure and how they were made, and can be 
divided into unreduced, reduced and unclassified polyketides. Reduced polyketides 
can be further divided into two different classes; the macrocycles which have large 
lactone or lactam rings (such as erythromycin A) or polyether antibiotics, these 
contain between 2 and 5 ether oxygen atoms (for example monensin A) (Figure 1.2) 
(Staunton and Wilkinson, 1997; Oliynyk et al., 2003; Weissman and Leadlay, 2005). 
The biological actions carried out by polyketides vary and are dependent on their 
Figure 1.2- Examples of the secondary metabolites, polyketides. (a) Monensin 
produced by Streptomyces cinnamonensis, is a polyether antibiotic (Oliynyk et al., 
2003). (b) Lovastatin, produced by Aspergillus terreus, is used to treat high 
cholesterol (Alberts et al., 1980). (c) Erythromycin A, a macrolide antibiotic is 
produced by Saccharopolyspora erythraea. The sugar moieties highlighted are added 
by auxiliary enzymes after the release from the PKS (Weber et al., 1990; Labeda, 
1987; Dhillon et al., 1989). 
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structure. Polyether ionophores, such as monensin, have the ability to chelate metal 
ions and disrupt ion balance in order to kill an organism. This involves transporting 
metal ions across a membrane either by: (1) binding to an ion in a polar cavity and 
concealing the charge, ferrying it across the plasma membrane, (2) forming a channel 
allowing ions to flow more freely into the cell, and finally (3) neutral ionophores aid 
in the diffusion of ions into a cell (Pressman, 1976; Pressman and Fahim, 1982). 
Macrolides such as erythromycin, which are constrained by macrocyclisation, work 
by inhibiting protein synthesis by premature chain termination (Menninger and Otto, 
1982; Kohli and Walsh, 2003). 
Total synthesis, a well-studied area, makes use of well-known and studied reactions 
such as the carbon-carbon bond forming aldol reactions to produce fragments of 
polyketide (Ireland et al., 1985; Faul and Huff, 2000; Schetter and Mahrwald, 2006). 
Challenges arise in linking such fragments with the correct stereochemistry thus 
making production of more diverse analogues difficult. Polyketides and specifically 
ladder polyethers become cyclic by epoxide-opening cascades, and, for total 
synthesis, work needs to be done on selective activation for these cascades to occur. 
Additionally efforts need to be made towards facile modifications of epoxide groups 
including being amenable to methyl substitutions (Ireland et al., 1985; Vilotijevic 
and Jamison, 2009; Faul and Huff, 2000). In Nature polyketides are produced by 
giant multimodular proteins termed polyketide synthases (PKS) (Gallimore, 2009; 
Liu et al., 2009). These macromolecular structures have the capacity to synthesise 
polyketides and modify them accordingly to efficiently produce complex structures 
with the correct stereochemistry (Staunton and Weissman, 2001; Weissman and 
Leadlay, 2005) (Section 1.4).  
 
1.2.2 Nonribosomal peptides 
Nonribosomal peptides (NRPs) are another class of natural products produced by 
bacteria, filamentous fungi and more generally actinomycetes (Perlman and 
Bodanszky, 1971). NRPs, as implied by the name, are synthesised independently of 
the ribosome and a nucleic-acid template (Finking and Marahiel, 2004; Grunewald 
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and Marahiel, 2006). As with polyketides, nonribosomal peptides are a group of 
structurally diverse compounds with a large repertoire of activities such as 
antibacterial, immunosuppressive and cytostatic (Schwarzer et al., 2003). 
 
 
 
  
 
NRPs are known to have several different modes of action; polymyxin antibiotics 
(Figure 1.1) target and bind to lipopolysaccharide (LPS) in the outer membrane of 
Gram-negative bacteria, using their hydrophobic tails to disrupt inner and outer 
membranes (Velkov et al., 2010). Gramicidin S (Figure 1.3) is a cationic compound 
and the suggested mode of action is that it is taken up into the cell and disrupts the 
cytoplasmic membrane; polymyxins are also suggested to do this (Katsu et al., 1986; 
Velkov et al., 2010). Vancomycin (Figure 1.1) targets cell wall biosynthesis 
(Watanakunakorn, 1981). Siderophores, such as enterobactin (Figure 1.3), are 
essential for host survival and are released by bacteria in environments where iron is 
scarce as it has a picomolar affinity for the metal ion (Raymond et al., 2003). 
NRPs are formed by oligomerisation through peptide bond formation of between 3 
and 22 proteogenic, non-proteogenic amino acids and aryl acids (Sieber and 
Marahiel, 2003; Schwarzer et al., 2003). NRPs can undergo macrocyclisation such as 
Figure 1.3- Examples of nonribosomal peptides. (a) Gramicidin S, produced by 
Bacillus brevis, has been shown to have antibacterial properties (Gause and 
Brazhnikova, 1944). (b) ACV tripeptide, is the precursor to penicillin and 
cephalosporin antibiotics (Martin et al., 1994; Keeler, 2002). (c) Enterobactin is a 
siderophore which chelates iron, it is found in some Gram-negative bacteria such 
as E. coli (Raymond et al., 2003; Fischbach and Walsh, 2006). 
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gramicidin S, or be formed from multiple copies of identical NRP chains like 
enterobactin (Figure 1.3) (Rusnak et al., 1991; Walsh et al., 1990). The 
macrocyclisation and oxidative cross-linking seen in NRPs aids in their biological 
functions.  NRPs can be further modified by introducing small heterocyclic rings, N-
methylation, N-formylation, glycosylation or by the addition of fatty acids (Walsh et 
al., 2001; Sieber and Marahiel, 2005). These structurally elaborate compounds are 
synthesised by the multimodular enzymes, nonribosomal peptide synthetases (NRPS) 
(Section 1.5). 
 
1.2.3 Polyketide-nonribosomal peptide hybrid products 
Nonribosomal peptides and polyketides are synthesised in a very similar way, by 
multimodular enzymes in an assembly line-like manner utilising an enzyme 
template-directed mechanism (Lipmann, 1980; Hopwood, 1997; Marahiel et al., 
1997). Hybrid polyketide-polypeptide products (Figure 1.4) are composed of a 
combination of monomeric units utilised in both polyketides and nonribosomal 
peptides, again creating structurally diverse biologically active compounds (Du et al., 
2001).   
Nonribosomal peptide-polyketide hybrid products are synthesised by a combination 
of nonribosomal peptide synthetase modules and polyketide synthase modules. These 
products can be synthesised in one of two ways; by individual NRPS and PKS 
modules, coupling the NRP and PK moieties using a ligase, for example coronatine 
biosynthesis (Bender et al., 1999; Rangaswamy et al., 1998) or by a hybrid NRPS-
PKS enzyme, as with epothilone biosynthesis (Molnar et al., 2000). The latter will be 
discussed below.  
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1.3 Polyketide synthases 
There are three classes of polyketide synthases; I, II and III. Type I PKS can be 
subdivided into two types, iterative and modular. Type I modular polyketide 
synthases (PKS) are large multimodular enzymes composed of discrete domains 
covalently linked into modules often on a MDa scale. These enzymes, encoded either 
by a single operon or gene clusters in bacteria, fungi, plants and more infrequently 
animals, are responsible for the production of polyketides as secondary metabolites 
as mentioned previously (1.2.1). In  type I modular PKSs a module describes a group 
of covalently linked discrete domains, with specific roles, responsible for 
incorporation, and in some cases modification, of a single extender unit to a growing 
polyketide chain (Staunton and Weissman, 2001). Iterative type I PKS have a similar 
architecture to a single module in type I modular PKS that is used in continuous 
rounds of elongation. Examples of type I iterative PKS include the PKS responsible 
for lovastatin synthesis (Figure 1.2) (Staunton and Weissman, 2001; Campbell and 
Figure 1.4- Examples of hybrid polyketide-nonribosomal peptides. (a) Epothilone is 
an NRP-PK synthesised by an NRPS/PKS hybrid enzyme produced by Sorangium 
cellulosum (Molnar et al., 2000). (b) Yersiniabactin is also synthesised by an 
NRPS/PKS hybrid enzyme found in Yersinia pestis (Pelludat et al., 1998). (c) 
Rapamycin produced by Streptomyces hygroscopicus where a PK chain is modified by 
nonribosomal synthetase to initiate macrocyclisation creating an NRP-PK hybrid 
product (Molnar et al., 1996; Park et al., 2010; Schwecke et al., 1995). Groups 
highlighted in blue are incorporated by NRPS.   
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Vederas, 2010). Type II PKS are composed mainly of monofunctional proteins i.e. 
two ketosynthase domains (KS) and an acyl carrier protein (ACP), chain elongation 
occurs in iterative cycles producing aromatic polyketides with additional tailoring 
domain such as oxygenases and methyl transferases increasing structural diversity in 
compounds produced. Type II PKS are the source of important pharmaceutical 
compounds such as tetracyclines (Hertweck et al., 2007; McDaniel et al., 2005). 
Type III PKS are composed of a KS homodimer that works in an iterative fashion to 
condense together monomeric units. Type III PKS are usually found in plants and 
produce compounds such as chalcones (Abe and Morita, 2010; Katsuyama and 
Ohnishi, 2012).  
This research is intended to focus solely on the modular nature of proteins and how 
they construct such diverse products, with the hopes of engineering the modular 
enzymes to manufacture novel compounds. Therefore the rest of the introduction 
will focus on type I modular PKS and NRPS (section 1.4).  
 
1.3.1 PKS biosynthetic gene clusters 
In 1990 Peter Leadlay’s group cloned a 10 kb gene fragment from 
Saccharopolyspora erythaea encoding the modular polyketide synthase responsible 
for erythromycin biosynthesis. This was achieved by identifying the gene which 
encoded erythromycin resistance and sequencing from that point using chromosome 
walking, making comparisons with sequences of homologous proteins. The method 
used was based on the fact that the genes which encode the proteins that make up 
bacterial and fungal PKSs are clustered together within the genome, along with 
transcriptional regulators and self-resistance genes (Cortes et al., 1990). At 
approximately the same time Leonard Katz and his group also cloned the DEBS 
biosynthetic gene cluster using the same principles as Leadlay but working from a 
mutation within a gene which disabled erythromycin production (Tuan et al., 1990). 
Figure 1.8 illustrates the biosynthetic gene cluster of 6-deoxyerythronolide synthase 
(DEBS). The catalytic domains of DEBS were determined by comparison with 
homologous domains from FAS with identical activities (Bevitt et al., 1992; Cortes 
et al., 1990; Tuan et al., 1990; Donadio et al., 1991). Characterisation of the 
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biosynthetic gene cluster of DEBS has provided some insight into gene organisation 
in PKS.  
With decreasing costs of genome sequencing and advances in in silico analysis, more 
than 50 PKS gene clusters have been elucidated (Weissman and Leadlay, 2005). 
Currently, common techniques used to identify PKS gene clusters include entire 
genome sequencing and screening cosmid or bacterial artificial chromosome 
libraries with probes based on homologous sequences, such as the KS domain, using 
hybridisation or PCR based methods (Weissman and Leadlay, 2005; Wang et al., 
2011).  
Entire genome sequencing has highlighted an unexpected prevalence of potential 
genes for antibiotic synthesis in bacteria, entire genome sequencing of the Bacillus 
subtilis genome revealed more than 4% is suspected to encode for gene clusters 
responsible for polyketide and bacteriocin synthesis (Kunst et al., 1997). Sequencing 
of certain Streptomyces strains have shown that the abundance of PKS and NRPS 
gene clusters is not unique to B. subtilis (Bentley et al., 2002; Ikeda et al., 2003). 
The elucidation of increasing numbers of PKS gene clusters is providing ever more 
options for engineering to produce novel compounds.  
 
1.3.2 PKS module organisation  
PKSs are composed minimally of three essential domains, an acyltransferase domain 
(AT), responsible for the substrate selected as the extender unit; a ketosynthase 
domain (KS) which catalyses the condensation between the selected extender unit 
and the growing polyketide chain, and an acyl carrier protein (ACP) which houses 
the growing chain (Staunton and Weissman, 2001; Weissman and Leadlay, 2005; 
Menzella et al., 2005; Fischbach and Walsh, 2006). Polyketides are synthesised in an 
assembly line-like fashion with each individual module responsible for incorporating 
a single unit, and the number of modules dictating the number and specificity of 
units incorporated (Chan et al., 2009; Staunton and Weissman, 2001; Fischbach and 
Walsh, 2006). Figure 1.6 illustrates the composition of the minimal module and 
mechanism by which chain elongation occurs.  
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Figure 1.5- Minimal PKS module illustrating the mechanism by which chain elongation 
occurs. (a) The acyltransferase (AT) domain selects an acyl CoA extender unit and 
catalyses its transfer onto the acyl carrier protein (ACP). (b)  Carbon-carbon bond 
formation by decarboxylative condensation then occurs between the extender unit and 
growing polyketide chain catalysed by the ketosynthase (KS) domain (Fischbach and 
Walsh, 2006). 
 
1.3.2.1 Acyltransferase (AT) domain 
The acyltransferase (AT) domain, originally identified due to its homology with the 
malonyl acyltransferase (MAT) in FAS, is responsible for substrate selection and is 
suggested to possess high substrate specificity (Khosla et al., 1999; Walsh, 2008; 
Liou et al., 2003). The reaction catalysed by an AT domain is shown in Figure 1.5. 
The site of acylation is a conserved serine (Dunn and Khosla, 2013). There are two 
types of AT domains known to be utilised by PKS, a cis AT domain which 
associates with a single specific ACP, as illustrated in the DEBS PKS (Figure 1.8) 
(Dunn et al., 2014). Alternatively, there are trans acting AT domains, these domains 
are stand-alone and associate with multiple ACPs for loading of the extender unit as 
occurs with leinamycin biosynthesis (Piel, 2010; Cheng et al., 2003).  
A highly conserved arginine at position 222, or a tryptophan in the DEBS and 
avermectin PKS, has been identified as controlling substrate specificity (Liou et al., 
2003; Rangan and Smith, 1997). Substrate specificity of AT domains within 
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initiating modules varies; in contrast AT domains in the extending modules are more 
substrate specific acting as a gate-keepers, stopping chain elongation in the absence 
of the correct extender unit (Keating and Walsh, 1999; Khosla et al., 1999).  The AT 
domain provides an excellent opportunity for engineering to introduce different 
extender units for novel product biosynthesis. 
 
1.3.2.2 Ketosynthase (KS) domain 
The ketosynthase (KS) domain, approximately 45 kDa in mass, catalyses the 
decarboxylative condensation of the extender unit and growing chain. A conserved 
cysteine in the active site enables the extender unit to be briefly transferred onto the 
KS domain before being added to the growing polyketide chain and contributes to 
the substrate specificity of the module in some way (Fischbach and Walsh, 2006; 
Chen et al., 2006). The KS domain is either inactive or missing completely in the 
initiating modules (Chen et al., 2011). The KS domain has also been pinpointed to 
be responsible for the wealth of stereochemistry observed in polyketides (Lau et al., 
1999).   
 
1.3.2.3 Acyl carrier protein 
Acyl carrier proteins (ACP) are essential non-catalytic domains of less than 100 
amino acids in length. They are the site of chain elongation and are known to interact 
with more than 30 partners (Fischbach and Walsh, 2006; Gully and Bouveret, 2006; 
Gully et al., 2003; Butland et al., 2005). Phosphopantetheinylation of carrier proteins 
is unconditionally required for biosynthesis of not only polyketides, but nonribsomal 
peptides and fatty acids. This post translational modification is mediated by a 
phosphopantetheinyl transferase (PPTase). Each enzyme complex; PKS, NRPS and 
FAS, is associated with a PPTase capable of this modification. 
Phosphopantetheinylation occurs on a conserved serine within the ACP, with the 
phosphopantetheine group from Coenzyme A being covalently attached by a 
phosphodiester link (Figure 1.6). The phosphopantetheine modification creates a 
flexible arm of approximately 20 Å in order to pass the growing chain from one 
module to another (Walsh et al., 1997; Lambalot et al., 1996; Quadri et al., 1998; 
Staunton and Weissman, 2001). 
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Figure 1.6- Mechanism by the ACP becomes phosphopantetheinylated.  The hydroxyl 
group of a conserved serine of an acyl carrier protein (ACP) becomes 
phosphopantetheinylated by a phosphopantetheinyltansferase mediating the formation 
of a phosphodiester link, converting apo-ACP to holo-ACP (Walsh et al., 1997; 
Lambalot et al., 1996; Fischbach and Walsh, 2006).   
 
1.3.2.4 Chain initiation and termination 
As well as individual modules responsible for extender unit incorporation, there are 
two additional features, a loading module composed of an AT domain and ACP 
responsible for initiation and a thioesterase domain responsible for chain 
termination.  
More often than not the module responsible for polyketide chain initiation lacks the 
KS domain. In the initiation module, the AT domain is sufficient for loading the 
ACP with a starter unit before being handed off to the next module, this occurs in the 
DEBS PKS (Figure 1.8) (Keating and Walsh, 1999; Caffrey et al., 1992).  
The thioesterase (TE) domains are responsible for chain termination and are located 
at the C-terminus of the PKS. Chain termination occurs using a Ser-His-Asp 
catalytic triad in an analogous manner to serine proteases. Depending on the nature 
of the TE domain, macrocyclisation can occur of the polyketide product being 
released. If the acyl-bound intermediate is attacked by an external nucleophile a 
linear product will be released, attack by a nucleophile within the polyketide chain 
will lead to a cyclised product (Du and Lou, 2010).  
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1.3.2.5 Linker regions 
Assembly line synthesis by a multimodular protein requires the modules to be 
tethered together in some way, and additionally for loading and catalysing 
condensation between two acyl moieties, so will the globular domains. Therefore 
linker regions between both the individual domains and entire modules exist. Linkers 
between domains are up to 100 residues long and composed mainly of alanine, 
proline and charged residues, the composition of the linkers dictating their flexibility 
and thus the range of motion and interaction with other domains (Staunton and 
Wilkinson, 1997; Bevitt et al., 1992). 
 
1.3.2.6 Accessory domains: KR, DH and ER 
The structural diversity observed in polyketides is also achieved by the addition of 
accessory domains within a module. These domains control the level of reduction of 
the β-keto group of the extender unit added, and are termed a ketoreductase (KR), 
dehydratase (DH) and enoylreductase (ER). Unlike FAS, which have all three 
domains present achieving full reduction of all β-keto groups, PKS modules display 
varying levels of reduction at the β-keto group dependent on which of the accessory 
domains are present. Figure 1.7 illustrates how the β-keto carbon is processed in 
PKS and how it is comparable to FAS.  
 
1.3.2.7 Biosynthetic pathways of polyketide synthases and fatty acid synthases  
The idea of small monomeric units being condensed together by an enzyme 
template-directed mechanism is utilised by multimodular enzymes to produce 
structurally diverse compounds. This mechanism is common to fatty acid synthases 
(FAS), polyketide synthases (PKS) and nonribosomal peptide synthetases (NRPS) 
(Meier and Burkart, 2009).  FAS and PKS utilise the same monomeric units and 
Figure 1.7 illustrates the units used by FAS and PKS and the differences in levels of 
reduction the acyl-CoA units undergo. FAS acyl-CoA monomers undergo reduction, 
dehydration and a second reduction; the acyl and malonyl CoA units are condensed 
together in a head-to-tail manner to create fatty acids. Polyketide acyl-CoA 
monomers in a polyketide chain can undergo varying levels of reduction contributing 
to the structural diversity observed in polyketides, dependent on the presence of the 
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accessory domains within a PKS module (Meier and Burkart, 2009; Staunton and 
Weissman, 2001). 
 
 
 
 
 
 
In fatty acid biosynthesis (Figure 1.7 (2)) (as with PK biosynthesis) the FAS AT 
domain selects the extender unit, and a ketosynthase domain catalyses the carbon-
carbon bond formation between the selected unit and the growing fatty acid. The β-
keto carbon of the malonyl CoA or acetyl CoA unit added then undergoes reduction 
by a ketoreductase (KR) domain to a β-hydroxy group, this is followed by 
dehydration by a dehydratase (DH) yielding an α,β-enoyl product. Finally, a second 
round of reduction is carried out by an enoylreductase (ER) domain, to give a fully 
reduced product. In bacterial and mammalian FAS, more units are added in an 
Figure 1.7- The biosynthetic pathways of FAS and PKS. FAS and PKS acyl-CoA 
monomers are condensed together in an identical manner. An extender unit is 
selected by acyltransferase (AT) domains, which catalyse the transfer onto an acyl 
carrier protein (ACP), the site of chain elongation. The ketosynthase (KS) domain 
then catalyses carbon-carbon bond formation between the extender unit and the 
growing acyl chain. FAS (2) then utilises a ketoreductase (KR), dehydratase (DH) 
and enoyl reductase (ER), to fully reduce the acyl unit added. PKS acyl units undergo 
varying levels of reduction at the β-keto position (3); this is dependent on the 
presence of KR, DH and ER domains present. No reduction results in aromatic 
polyketides being formed (1) (Moore and Hertweck, 2002; Meier and Burkart, 2009). 
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iterative fashion giving full length fatty acids (Meier and Burkart, 2009; Staunton 
and Weissman, 2001). Type II PKS are iterative enzymes which produce aromatic 
PKs (Figure 1.7 (1)), this occurs when the accessory domains are absent (Das and 
Khosla, 2009). In type I modular PKSs differential levels of reduction occur 
dependent on which accessory domains are present. In addition to the essential 
domains within a module, in type I modular PKS, varying levels of accessory 
domains can exist (Figure 1.7 (3). The level of reduction the extender units undergo 
in each round of elongation is dependent within that module and is independent of 
preceding and subsequent modules, producing compounds composed of extender 
units differing at the β-keto position (keto, hydroxyl, enoyl and fully reduced) 
(Staunton and Weissman, 2001; Meier and Burkart, 2009). These domains provide 
another possible dimension for engineering PKS to produce novel compounds. 
Figure 1.8 shows the biosynthetic gene cluster of the PKS DEBS and gives some 
idea as to the arrangement of domains within modules in PKSs, illustrating the 
combinations of accessory domains within different modules (Caffrey et al., 1992; 
Bevitt et al., 1992; Cortes et al., 1990; Tuan et al., 1990).  
 
1.3.2.8 A model system 
Extensive research has been carried out on the PKS responsible for erythromycin 
production, 6-deoxyerythronolide (DEBS). Both structural and mechanistic studies 
have provided great insight into how this PKS works and engineering has provided 
tantalising glimpses into the potential for novel compound production. DEBS has 
been the model system and so the biosynthetic gene cluster is shown in Figure 1.8 
(Bevitt et al., 1992; Cortes et al., 1990; Caffrey et al., 1992; Staunton and 
Weissman, 2001; Staunton et al., 1996; Marsden et al., 1998; Oliynyk et al., 1996; 
Khosla et al., 2007; Khosla et al., 2014). 
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Figure 1.8- Biosynthetic gene cluster of the erythromycin precursor, 6-deoxyerythronalide, producing PKS, DEBS. (a) eryAI, II and III open 
reading frames encode three large polypeptides, DEBS 1, 2 and 3. DEBS 1 is composed of a loading didomain, module 1 and module 2, 
DEBS2 is composed of modules 3 and 4 and finally DEBS3 is composed of modules 5 and 6 and the thioesterase domain. (b) The thioesterase 
domain is not only involved in chain termination but macrocyclisation of the linear polyketide chain. Units incorporated are highlighted in 
bold on the structure on the left (Caffrey et al., 1992). 
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DEBS forms the macrolide intermediate 6-deoxyerythronolide B (6-dEB) (Figure 
1.8). Three open reading frames, eryAI, eryAII and eryAIII, encode for the 
polypeptides DEBSI, DEBSII and DEBSIII respectively. DEBSI contains the 
loading module and two extender modules, DEBS II contains two extender modules 
and DEBS III contains two extender modules and the thioesterase.  The molecular 
mass of this PKS is over 600 kDa (Cortes et al., 1990; Tuan et al., 1990; Kao et al., 
1994; Caffrey et al., 1992). The macrolide intermediate is formed by 6 modules 
responsible for incorporation of ethyl malonyl CoA as extender units, a loading di-
domain which lacks a KS domain and utilises propionyl CoA as the starter unit and 
finally a thioesterase domain which instigates chain release and aids in cyclisation of 
6-dEB (Tuan et al., 1990; Cortes et al., 1990; Caffrey et al., 1992).  
 
1.3.3 Structure determination of PKSs  
The modularity of PKSs makes them an attractive target for combinatorial 
biosynthesis to produce novel compounds. Structural characterisation and 
mechanistic understanding will aid engineering of PKS to produce novel 
compounds.  
There have been significant efforts to structurally characterise the domains within a 
PKS module, including di-domains and docking domains (between modules). 
Several structures exist of KS-AT didomains from DEBS, the KS-AT didomain from 
module 5 (PDB code 2HG4) (Figure 1.9) and the KS-AT didomain from module 3 
(PDB code 2QO3). Structural information revealed well-structured inter- and 
intradomain linkers composed of highly conserved residues and a loop region in the 
KS domain homodimer interface which potentially plays a part in substrate 
specificity. Additionally, an 80 Å distance between the catalytic cysteine in the KS 
domain and the conserved serine in the AT domain was observed indicating that the 
DEBS PKS must undergo structural rearrangement for chain elongation to occur 
(Tang et al., 2007; Tang et al., 2006).  
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Figure 1.9- The structure of the KS-AT didomain of module 5 from DEBS. Structure 
solved to a resolution of 2.7 Å. The KS domain (blue) and AT domain (red) are 
connected by highly structured linker regions (grey). (a) Side view of didomain, 
showing the extension of the N terminal docking domain (grey).  (b) Front view 
illustrating the homodimer interface is mediated by the KS domains and N terminal 
docking domain (Tang et al., 2006). 
 
NMR and crystal structures of DEBS and pikromycin docking domain or linkers 
have been solved. Linkers between modules are structurally well defined and are 
composed of highly conserved residues which not only promote dimerisation of 
domains but create unfavourable interactions with other modules so as to prevent 
misdocking (Broadhurst et al., 2003; Buchholz et al., 2009).  
The ketoreductase, dehydratase and thioesterase domains have been well 
characterised with crystal structures from a number of PKSs (Zheng et al., 2012; 
Keatinge-Clay, 2008; Keatinge-Clay, 2007; Keatinge-Clay and Stroud, 2006; Tsai et 
al., 2001; Akey et al., 2006; Scaglione et al., 2010; Zheng et al., 2010; Zheng and 
Keatinge-Clay, 2011; Gehret et al., 2011; Tsai et al., 2002). Less well characterised, 
the enoyl reductase, has been solved as a di-domain (ER-KR) (Zheng et al., 2012). 
Finally, a structure of an ACP from DEBS has been solved by NMR spectroscopy 
(Alekseyev et al., 2007). Details of the structure of carrier proteins will be covered 
later in this thesis. Even though the structures of individual domains are well 
documented there is no high resolution structure of an entire PKS module.  
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In 1996 Staunton, Leadlay and colleagues proposed an overall model for the DEBS 
PKS referred to as the “Cambridge model” (Figure 1.10) (Staunton et al., 1996). The 
foundations of this model were structural studies utilising limited proteolysis and 
analytical ultracentrifugation (AUC), which showed that KS-AT and TE domains are 
homodimeric whilst those domains involved in reduction are monomeric. In this 
model the PKS forms a “double-helical” structure with proteins intertwined forming 
a homodimer with both chains in the same orientation (“head-to-head”) and the 
essential domains (AT-KS-ACP) forming the core of the complex. The KS domain 
of one module was shown to have a favourable interaction with the ACP of the 
opposite module; however, all domains appear to have access to the ACP. The 
accessory domains then loop out from the main body of the PKS. These models 
satisfy the ability to vary the accessory domains within different modules, and allow 
communication between subunits but prevent cross-talk of ACPs with the incorrect 
domains. This model also supported the seemingly more successful engineering of 
accessory domains. A similar model was outlined two years later by Cane and 
Khosla (Cane et al., 1998).  
Until recently structural studies involving entire PKS modules have been hindered by 
their sheer size and flexibility (Tsai and Ames, 2009; Staunton and Weissman, 
2001). However, in 2008 advances in the field of X-ray crystallography enabled 
elucidation of the crystal structure of the mammalian FAS (mFAS) (PDB code 
2V28). The mFAS displayed an intertwined homodimer in an X orientation with KS, 
DH and ER domains forming the dimer interface (Maier et al., 2008). The bottom 
portion of the X was composed of the essential catalytic domains (KS and MAT) and 
the top was composed of the domains responsible for reduction (KR, DH and ER) 
(Maier et al., 2008). As mentioned previously PKS are homologous to FAS and so 
this gave the best indication of the arrangement of domains within a module until 
recently (Dutta et al., 2014).  
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Figure 1.10- Proposed structure of PKS and mFAS (a) Schematic of modules 5 and 6 of 
DEBS illustrating the “Cambridge model” proposed by Staunton and Leadlay. The 
two chains are twisted together in a “head-to-head” orientation forming a helix. This 
helical conformation allows interactions between the KS domain and ACP from each 
chain. The KR domains loop out between the AT domain and ACP within the same 
monomer (red linkers) (Staunton et al., 1996; Staunton and Weissman, 2001). (b) 
Schematic of the structure of mammalian FAS. This iterative enzyme has a core 
formed of KS, DH and ER homodimers. The bottom of the mFAS is required for chain 
elongation and substrate selection and the top for reduction of the acyl-CoA. The ACP 
and TE domains do not form the body of the enzyme (Maier et al., 2008). 
 
As mentioned previously, there had been no structures of an entire PKS module, 
however, recently electron cryo- microscopy (cryo-EM) was used to elucidate the 
structure of a dimer of module 5 of the pikromycin PKS (PiKAIII). The dimeric 
module was 328 kDa and had a fully functional holo-ACP associated. Figure 1.11 (a) 
shows the solid rendered map of the PKS domain solved to between 7.3 and 9.5 Å. 
The KS dimer is at the top, with the AT domain below supported through a large 
interaction surface area with the KS domain of the other chain. This is followed by 
the KR domains forming the base and interface with the next module. The relative 
orientations of the KS and AT domains observed in the EM structure are different to 
those in the di-domain crystal structures, having a larger interaction surface than 
originally shown, but supporting the “Cambridge model”. Finally the arch shape 
observed provides a “reaction chamber” for the ACP.  (Dutta et al., 2014; Tang et 
al., 2007; Tang et al., 2006; Staunton et al., 1996). Recently, high resolution data has 
been combined with small-angle X-ray scattering (SAXS) to investigate the structure 
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of modules 5 and 6 from DEBS, providing further structural evidence (Edwards et 
al., 2014). 
 
 
Figure 1.11- Structure and chain elongation mechanism of a module of PikAIII (a) 
Cryo-EM structure of module 5 of PiKAIII composed of KS-AT-KR-ACP domains 
with a resolution of 7.3-9.5 Å. The KS forms a dimer at the top, stabilised by AT 
domains from the other monomer chain. The base of the structure is formed by the KR 
domains. (b) Dynamics of the module during chain elongation as observed in EM 
structures. The ACP domain resides within a cavity, then associates with the AT 
domain to be loaded with the extender unit. The ACP then moves to the KS domain 
and chain elongation is catalysed, the ACP then ferries the extended chain to the KR 
domain to undergo reduction. Finally, the ACP then passes the polyketide chain onto 
the KS domain of the following module (Dutta et al., 2014; Whicher et al., 2014). 
 
The elucidation of the structure of module 5 of the pikromycin PKS by EM also 
provided information on how chain elongation occurs (Figure 1.11 (b)). The ACP 
appears to travel to each module for them to carry-out their jobs, specific protein-
protein interactions with the catalytic domains are dependent on the substrate 
attached to the phosphopantetheine arm. There is evidence of domain cross-talk, 
with the KR domain flipping when the ACP interacts with the AT domain, to be in 
place for reduction of the growing chain. Conformational changes of the PKS 
module show the AT domain also restricts side substrate entry in the KS domain, the 
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route of the extending chain. The mechanism indicated by this data shows a cascade 
of conformational changes, dependent on the previous module, in an assembly line-
like fashion (Whicher et al., 2014).  
A combination of structure determination of individual domains, how they dock onto 
one another, and now a structure determination of an entire module and dynamics in 
combination with biochemical characterisation may aid in a more knowledge-based 
reasoning behind engineering PKS, and thus an increased chance in producing 
functional hybrid enzymes to produce novel compounds.  
1.3.4 Engineering of PKSs 
Polyketide derived drugs are said to generate worldwide revenues of £10 billion per 
annum and account for 10% of the top selling drugs (Weissman and Leadlay, 2005). 
Traditionally, polyketide drugs have been isolated from natural sources such as the 
soil or by modifying existing drugs. More recently, the idea of creating novel 
polyketides by engineering polyketide synthases has become an attractive option for 
the production of novel compounds that have pharmaceutical properties (Weissman 
and Leadlay, 2005). It was this idea that has motivated decades of research to 
understanding the structure and function of PKSs.  
Polyketide synthases provide a versatile system for engineering due to their modular 
nature. As described previously, each individual module is composed of domains 
with discrete active sites responsible for extender unit incorporation and catalysing 
chain extension. It was suggested that the structure and organisation of these 
multimodular enzymes would lend themselves to engineering by “cutting and 
pasting” domains and modules, leading to what is now termed “combinatorial 
biosynthesis” (Khosla and Zawada, 1996; Weissman and Leadlay, 2005). 
Combinatorial biosynthesis describes the act of creating novel products by mixing 
features of known structures, and utilising and manipulating the enzymes that 
naturally produce these features (Staunton and Weissman, 2001). 
There are several approaches for engineering PKS to produce novel compounds, 
however engineering of PKS in the natural host is not amenable for a number of 
reasons, and therefore heterologous expression of PKS proteins is often the first 
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obstacle in engineering PKSs. This is discussed in some depth in chapter 3. 
Strategies for engineering PKSs and their successes are covered below. 
There are several strategies that can be considered for PKS engineering, focussing on 
either individual domains, whole modules, using synthetic molecules for 
incorporation and finally alteration of enzymes involved in modification of the final 
polyketide chain. The most practiced strategy of PKS engineering is engineering of 
domains within a PKS biosynthetic gene cluster (Staunton and Weissman, 2001).  
Structural diversity observed in polyketides can, for some part, be attributed to the 
types of starter and extender units incorporated (Moore and Hertweck, 2002; Chan et 
al., 2009). One area of PKS engineering has considered the incorporation of 
alternative starter units. In 1998 Marsden et al. exchanged the promiscuous starter 
module of the avermectin PKS, able to incorporate C2 branched carboxylic acids, 
with the DEBS starter module. The resulting chimeric PKS was able to produce 
novel products. This success highlighted the self-sufficient nature of a PKS module 
and the ability for downstream modules to accept the new polyketide chain (Marsden 
et al., 1998; Dutton et al., 1991). Research into the incorporation of different starter 
units in the DEBS PKS has also included exchanging the DEBS loading di-domain 
with the oleandomycin and tylosin starter modules, creating truncated products with 
acetate or propionate as exclusive starter units (Long et al., 2002).  
Additionally, a strategy called chemobiosynthesis has been used to incorporate novel 
unnatural starter units. To do this the loading KS domain of DEBS was inactivated, 
and the PKS was able to incorporate diketide-S-N-acteyl cysteamine (SNAC) or 
diketide-S-N-proionyl cysteamine (SNPC) to initiate novel product biosynthesis 
(Jacobsen et al., 1998; Frykman et al., 2001; Dutton et al., 1994). The use of SNACs 
and SNPCs is quite costly, however it has been shown that the DEBS can also use 
more cost efficient thioesters, such as methyl thioglycolate, as a means of 
chemobiosynthesis to create novel products (Murli et al., 2005).  
In the same vein, engineering of AT domains within starter and extender modules 
has altered substrate specificity. There are two suggested ways to do this; the more 
commonplace method is AT domain exchange, selecting an AT domain with the 
desired substrate specificity or the less common way, by mutagenesis of amino acids 
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determined to be involved in substrate specificity (Dunn and Khosla, 2013). The AT 
domains of both full length and truncated DEBS have been switched with AT 
domains from the rapamycin PKS, incorporating malonyl CoA as extender units as 
opposed to methylmalonyl CoA extender units, with varying levels of product yields 
observed (Lau et al., 1999; Oliynyk et al., 1996; Ruan et al., 1997). AT domain 
substitution has not been limited to rapamycin, with other PKS AT domains from the 
pikromycin PKS and the FK520 PKS being exchanged (Ruan et al., 1997; Kato et 
al., 2002).  
The biggest pitfall of the production of novel polyketides by altering substrate 
selection by AT domain exchange appears to be the decrease in product titres, 
suggested to be due to the disruption of protein-protein interactions or the inability to 
process the extender chain downstream (Liou and Khosla, 2003; Hans et al., 2003). 
In addition to this there doesn’t appear to be any specific guidelines for successful 
AT domain substitutions, with some domains more difficult to replace, and in some 
cases being dependent on the location of the domain (Reeves et al., 2001; Lau et al., 
1999; Ruan et al., 1997; Dunn and Khosla, 2013). To circumvent the issues related 
to decreased product titres, sections of AT domains responsible for substrate 
selectivity have been switched, creating hybrid AT domains (Lau et al., 1999). 
Mutagenesis of the YASH motif (key to methylmalonyl CoA specificity) to the 
HAFH motif (selective for malonyl CoA) has produced promiscuous DEBS AT 
domains with the ability to also incorporate unnatural extender units (Reeves et al., 
2001; Sundermann et al., 2013; Del Vecchio et al., 2003).  
There are two types of AT domains, cis- and trans- acting. Cis-acting AT domains 
reside within a particular module, trans-acting AT domains are detached single 
enzymes able to load multiple ACP with extender units. It has been suggested that an 
inactivated cis-AT domain could be substituted by a trans-acting AT domain (Piel, 
2010; Dunn et al., 2014). 
Combinatorial biosynthesis has also explored the possibilities of altering the β-keto 
carbon processing, by the introduction or removal/inactivation of the accessory 
domains. The bulk of this research has been carried out with the DEBS and 
rapamycin PKSs (Kao et al., 1997; Kao et al., 1998; McDaniel et al., 1997). 
Exchange of the KR domains has also shown effects on the stereochemistry of the 
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product. The KR domains located in the second and fifth modules of DEBS were 
exchanged with the KR domain from the rapamycin PKS altering the 
stereochemistry observed in the product (Kao et al., 1998). 
The scope of combinatorial biosynthesis is not limited to single domain exchanges, 
McDaniel et al. reportedly substituted multiple AT domains and added the accessory 
β-processing domains in order to generate a novel macrolactone library, they 
otherwise claim would not be possible to create by chemical synthesis (McDaniel et 
al., 1999). Entire modules have been able to be linked together to create novel PKS 
products, this has been shown by fusing a module from the rifamycin PKS at the end 
of a truncated DEBS PKS and replacing module 2 in a full length DEBS PKS 
(Gokhale et al., 1999).  
Functional hybrid PKSs have been expressed using multiplasmid approaches. One 
approach involved cloning native and variant (domain exchanges) DEBS genes into 
compatible vectors. These vectors were introduced into a Streptomyces strain 
consecutively, 70% of the strains containing a full PKS (3 plasmids) yielded 
products (Xue et al., 1999). This approach was repeated using pikromycin, 
erythromycin and oleandomycin PKSs, successfully producing hybrid PKSs (Tang et 
al., 2000). More recently, design of PKS genes for heterologous expression of PKS 
modules in E. coli has shown huge successes, with synthetic genes of 14 modules 
from 8 different PKS able to participate in bi-modular interactions in at least one 
combination (Menzella et al., 2005).  
Engineering PKSs is not without its difficulties. As mentioned previously, PKS 
domains and modules are joined together by linkers and it is well-recognised that 
interference with these linkers can disrupt PK formation or skip the newly introduced 
module (Gokhale et al., 1999; Thomas et al., 2002). A greater understanding of 
linkers between domains and modules could enable design of universal linkers 
allowing any number of PKS domain and module combinations (Weissman, 2004). 
In addition to this, some PKSs, such as DEBS, are composed of multiple 
polypeptides, which need to associate for chain elongation. Highly structured 
docking domains are responsible for this (Broadhurst et al., 2003). Therefore, in 
order to create a hybrid PKS a greater understanding of the docking domains is 
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required. This may enable the design of an “orthogonal” pair of docking domains 
which could be utilised in engineering hybrid PKS (Weissman, 2004). 
The modular nature of polyketide synthases and the applications for creating novel 
pharmaceutical products are mirrored in nonribosomal peptide synthetases described 
below.  
1.4 Nonribosomal peptide synthetases 
Nonribosomal peptide synthetases (NRPS), the producers of non-ribosomal peptides, 
are large multimodular enzymes on the scale of MDa. NRPS construct NRPs in an 
analogous manner to the way PKS produce PKs. Like PKSs, the modules within an 
NRPS are each responsible for the incorporation of a single extender unit, 
constructing a nonribosomal peptide in an assembly line-like fashion utilising the 
same enzyme-template mechanism as PKS and FAS. In an NRPS as module also 
describes a group of domains responsible for incorporation and modification a single 
extender unit to the growing peptidyl chain (Meier and Burkart, 2009). Also, as with 
PKSs, the number, type and order of modules within the NRPS dictates the product 
formed (Schwarzer et al., 2003). NRPS are also known to be able to utilise a vast 
number of substrates (Marahiel et al., 1997).  
1.4.1 NRPS biosynthetic gene clusters 
As with PKS, probing for NRPS biosynthetic gene clusters is carried out in a similar 
manner to PKSs, by exploiting the homologous nature of these multienzymes 
(Marahiel et al., 1997). Figure 1.16 shows the biosynthetic gene cluster of tyrocidine 
biosynthesis, the tyrocidine biosynthetic gene cluster was identified by cloning 
sections of 10-22 kb of B. brevis genomic DNA into a bacteriophage vector and 
screening for homologous DNA using polyclonal antibodies raised against 
Gramicidin S synthetase 2 (GrsB). This led to the discovery of TycA and TycB 
(Mittenhuber et al., 1989).  
Identification of domains within the surfactin synthetase were identified using 
oligonucleotide probes based on highly conserved sequences within the gramicidin 
S, tyrocidine and ACV synthetases and carried out through hybridisation and in situ 
sequencing (Borchert et al., 1992). NRPS operons appear to be between 18 and 45 
kb in length, with the operons containing anywhere between one and six modules, 
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such as TycA and TycC, respectively (Marahiel et al., 1997; Mootz and Marahiel, 
1997). Other genes associated with NRPS are located at either the 5’ or 3’ ends of 
the operons, these proteins show high sequence homology to the type II fatty acid 
thioesterase (Mootz and Marahiel, 1997; Marahiel et al., 1997).  
Comparison of NRPS DNA sequences and heterologous expression of DNA 
fragments revealed how NRPs were formed, with particular proteins involved in 
substrate recognition and activation. It also showed each module was involved in 
incorporation of a single unit and this dictated the length and size of the peptide 
synthetase, and vice versa (Marahiel et al., 1997). The greater the number of 
biosynthetic gene clusters that have been fully characterised could conceivably 
increase the molecular toolbox that could be used for engineering NRPS modules in 
order to produce novel pharmaceutical compounds.  
1.4.2 Biosynthesis of nonribosomal peptides and module organisation 
As with PKS’s, NRPS modules are composed minimally of three core domains, 
responsible for the substrate selection of the extender unit, catalysis and housing the 
growing chain, these are the condensation (C), adenylation (A) and peptidyl carrier 
protein (PCP) or thiolation (T) domains, respectively (Fischbach and Walsh, 2006). 
Figure 1.12 illustrates the domain organisation and chain elongation within a 
minimal module.  
 
 
Figure 1.12- Domain organisation within an NRPS minimal module. The condensation 
domain catalyses the peptide bond formation between the growing peptidyl chain 
housed on the peptidyl carrier protein and an extender unit, covalently attached to the 
PCP domain in the next module (Fischbach and Walsh, 2006; Weber et al., 1990). 
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Synthesis of NRPs are carried out in a number of steps. The A domain is responsible 
for selection and activation of the correct substrate, converting a carboxylic acid to 
an aminoacyl adenylate (Figure 1.13) (Dieckmann et al., 1995). The activated amino 
acid is then transferred onto the terminal thiol of the phosphopantetheine co-factor of 
the PCP domain within the same module (Ehmann et al., 2000a; Stachelhaus et al., 
1996). Formation of the peptide bond then occurs between the electrophilic thioester 
of the aminoacyl-S-PCP (extender unit) and the nucleophilic amine group of the 
upstream peptidyl-S-PCP (growing chain), the C domain catalyses this reaction. This 
continues, with each module adding a single extender unit before reaching the final 
module, which, more often than not contains a thioesterase domain for chain 
termination (Fischbach and Walsh, 2006).   
Another factor contributing to the diversity of non-ribosomal peptides is the presence 
of accessory domains within the module; these can include an epimerase domain, an 
N-methyl transferase or a cyclase domain. The epimerase domain (section 1.4.2.5) 
catalyses the racemisation of the most recently added substrate to the growing 
peptidyl chain. The cyclase domain (section 1.4.2.6) catalyses the formation of small 
heterocyclic rings and N-methylation (section 1.4.2.7), often observed in NRPs 
produced by fungi, is carried out by a methyltransferase domain which uses an S-
adenosylmethionine co-factor to add a methyl group to the N-terminus of the amino 
acids (Fischbach and Walsh, 2006).  
 
1.4.2.1 Adenylation domain 
The adenylation domain initiates the incorporation of a substrate, typically an amino 
acid, by selection and activation. The A domain, sometimes called “The Gatekeeper” 
enzyme, is specific for its cognate amino acid.  A domains are usually approximately 
550 amino acids and activates the amino acid through Mg
2+
-dependent hydrolysis of 
ATP, producing an aminoacyl adenylate and pyrophosphate as a by-product. The 
aminoacyl adenylate can then undergo nucleophilic attack by the free thiol of the 
phosphopantetheine group attached to the PCP (Figure 1.13) (Sieber and Marahiel, 
2005; Hur et al., 2012).   
Introduction 
 
31 
 
 
 
 
Amino acid activation in NRPSs by the adenylation domain is mechanistically 
similar to amino acid activation by aminoacyl-tRNA synthetases however there is 
little or no sequence and structural similarities between the two. Additionally, 
although the adenylation domain has substrate specificity, it is more promiscuous 
than its mechanistically similar counterpart aminoacyl-tRNA synthetases (Sieber and 
Marahiel, 2005).  
A domains show approximately 30-60% sequence identity, and through sequence 
alignments an AMP binding domain has been identified. This site is conserved 
throughout the adenylate forming enzyme superfamily, including in acetyl CoA 
synthetases (Turgay et al., 1992; Starai and Escalante-Semerena, 2004). Sequence 
alignments of the PheA adenylation domain from the gramicidin S synthetase with 
160 other A domains also highlighted 10 residues responsible for substrate 
specificity, in this case for phenylalanine (Stachelhaus et al., 1999).  
Several A domains have been heterologously expressed in E. coli, purified and 
subsequently their activity and substrate specificity have been assayed in vitro by 
ATP-PPi exchange with radiolabelled substrates, for example the EntE and EntF 
adenylation domains from the enterobactin NRPS (Linne and Marahiel, 2004; 
Ehmann et al., 2000a). Several crystal structures of A domains have also been solved 
(section 1.4.3).  
Figure 1.13- Amino acid activation and loading of substrates by adenylation domains in 
NRPS. The selected amino acid is activated by formation of an aminoacyl adenylate in a 
Mg
2+
 dependent manner. This then becomes the substrate for nucleophilic attack of the 
free thiol of the phosphopantetheine arm of the PCP (Sieber and Marahiel, 2005). 
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1.4.2.2 Condensation domain 
Condensation (C) domains catalyse the formation of a peptide bond between the 
newly recruited extender unit and growing peptidyl chain housed on the PCP 
(Stachelhaus et al., 1998). Condensation domains also possess the ability to catalyse 
the formation of a bond between an acyl group from an ACP-bound PK from a PKS 
module and an aminoacyl group bound to a PCP. This occurs in PKS/NRPS hybrid 
enzymes (section 1.5), such as in the rapamycin PKS/NRPS (König et al., 1997; Hur 
et al., 2012). Some C domains also have the ability to catalyse the formation of ester 
bonds, in fact a C domain from an NRPS in S. globisporus is known to be able to do 
both (Lin et al., 2009; Hur et al., 2012). In an analogous manner to some PKSs, the 
domain responsible for catalysis, the condensation domain, is sometimes missing in 
the initiation module in some NRPS, such as in TycA (Figure 1.16) (Fischbach and 
Walsh, 2006; Mootz and Marahiel, 1997). Catalysis in C domains is mediated by 
electrostatic interactions, aided by the structure of the C domain (Keating et al., 
2002; Hur et al., 2012). 
It has been shown that in addition to the substrate specificity of the adenylation 
domain, the condensation domain also displays some level of substrate specificity 
for the aminoacyl adenylate to be added to the growing NRP chain, being selective 
for the D-enantiomer in addition to selectivity observed for particular side chains. 
This selectivity only seems to pertain to the aminoacyl adenylate and not the 
growing chain (Belshaw et al., 1999). This specificity of the C domain for the 
aminoacyl adenylate, once the peptide bond has been formed and the aminoacyl 
adenylate added to the growing chain, is lost and the peptidyl-S-PCP is no longer a 
substrate, this causes release of the growing chain. This mechanism has been 
suggested to prevent accidental initiation in an elongation module. This also explains 
the uni-directional nature of NRPS (Linne and Marahiel, 2000).   
 
1.4.2.3 Peptidyl carrier protein 
The peptidyl carrier protein (PCP) is homologous to the acyl carrier protein (ACP) in 
PKSs (Meier and Burkart, 2009; Crosby and Crump, 2012). As with the ACP, the 
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PCP is a small non-catalytic protein essential for NRP chain elongation. The PCP is 
also phosphopantetheinylated on a conserved serine by an auxiliary 
phosphopantetheinyl transferase (PPTase) (Walsh et al., 1997; Lambalot et al., 
1996). Elongation occurs in a synonymous fashion to PKS as illustrated in Figure 
1.12. The structure of the PCP from module 3 of TycC has been elucidated by NMR 
(Weber et al., 2000), structural aspects of PCP domains will be discussed in depth in 
chapter 5.  
 
1.4.2.4 Chain termination and macrocyclisation 
The thioesterase (TE) domain resides at the C-terminus of the final module within 
the NRPS and is responsible for NRP chain termination (Schneider and Marahiel, 
1998) using an active site serine in a Ser-Asp-His catalytic triad (Kohli and Walsh, 
2003). Chain termination can have one of two outcomes; a linear NRP is observed 
when hydrolysis occurs, as occurs in vancomycin biosynthesis (Hubbard and Walsh, 
2003; Keating and Walsh, 1999). Macrocyclisation occurs when a nucleophile within 
the NRP chain attacks itself, this occurs in daptomycin biosynthesis (Hur et al., 
2012). The main difference between PKS and NRPS TE domains is the PKS TE 
domain is a homodimer, forming a hydrophobic channel, and the NRPS domain is a 
monomer. The NRPS TE domains of surfactin and fengycin have a hydrophobic 
cavity, with a lid region, which can accommodate the NRP chain and allow 
cyclisation (Grunewald and Marahiel, 2006; Bruner et al., 2002; Samel et al., 2006). 
 
1.4.2.5 Epimerase domain 
The structures of NRPs show the presence of D-amino acids to be ubiquitous, 
however in Nature, in the producing organisms, there is a predominant deficiency of 
D-amino acids. In most NRPSs a domain is present responsible for the epimerisation 
of the L-amino acids that are incorporated, residing at the C-terminus of the PCP 
within the same module as the newly added aminoacyl substrate.  Epimerisation of 
amino acids occurs at the α-carbon of the newly added aminoacyl adenylate; in fact 
the amino acid must be tethered to the PCP. Figure 1.14 illustrates epimerisation of 
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an L-amino acid to a D-amino acid by an epimerase domain (Pfeifer et al., 1995; 
Stachelhaus and Walsh, 2000; Hur et al., 2012).  
 
 
 
Studies were performed on modules 4 and 5 of the tyrocidine biosynthetic gene 
cluster (shown in Figure 1.16) to investigate substrate specificity of the C domain 
downstream for the L or D enantiomers. In module 4 of tyrocidine biosynthesis L-
phenylalanine is incorporated into the peptidyl chain and is subsequently converted 
to D-phenylalanine by the E domain located at the C terminus of the PCP, between 
modules 4 and 5. The subsequent C domain (in module 5) is then responsible for the 
condensation of the new peptidyl growing chain and L-asparagine. This study 
showed that the C domain of module 5 is specific for the D-peptidyl growing chain, 
in addition to being specific for the L-aminoacyl adenylate (L-asparagine) to be 
added (Clugston et al., 2003). Although the E domain itself has been known to 
accept alternative substrates (Luo et al., 2001). 
 
1.4.2.6 Cyclisation domain 
Another domain that increases the diversity seen in NRPs is the cyclase (Cy) 
domain. Cy domains catalyse the formation of heterocyclic rings at cysteine, serine 
Figure 1.14- Epimerisation of the peptidyl chain mediated by an epimerase (E) 
domain. The E domain converts the most recently added amino or aryl acid from the 
L-isomer to the D-isomer before the growing peptide chain is passed to the next 
module. Figure adapted from Fischbach and Walsh (2006). 
Introduction 
 
35 
 
and threonine residues creating thiazoline or oxazoline rings (Hur et al., 2012). The 
Cy domains also catalyses the peptide bond formation between the extender unit and 
growing peptidyl chain (Fischbach and Walsh, 2006; Hur et al., 2012). Figure 1.15 
illustrates the formation of the heterocyclic ring. 
 
 
 
During heterocyclisation the thiol/hydroxyl groups of cysteine, serine and threonine 
residues added to the peptidyl chain can attack the peptidyl backbone creating a 
thiazoline or oxazoline ring. The newly formed heterocycle can then undergo further 
oxidation or reduction (Schneider et al., 2003; Reimmann et al., 2001). 
 
Figure 1.15- Mechanism of heterocyclisation within NRPs. The cyclase (Cy) 
domain catalyses the formation of the peptide bond between the extender unit 
and growing peptide chain. The resulting peptide bond then undergoes 
intramolecular nucleophilic attack by the thiol/hydroxyl side chain, this is 
followed by dehydration, forming a thiazoline or oxazoline ring (Hur et al., 
2012). 
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1.4.2.7 Additional NRP chain modifications 
N-methylation often aids in the biological activity of NRPs and is mediated by a 
methyltransferase (MT). The MT catalyses the transfer of a methyl group onto the 
NRP from a (S)-adenosyl methionine (Hur et al., 2012). Methylation occurs when 
the amino acid is loaded onto the carrier protein. There are two types of MT 
domains, cis-MT domains which reside at the C-terminus of the A domains, and 
trans- acting MT domains which can methylate the amino acid extender unit or the 
growing peptidyl chain (Weber et al., 1994; O'Brien et al., 2000; Fischbach and 
Walsh, 2006).  
Other modifications of NRPs can include formylation and halogenation. Formylation 
is mediated by a formylation (F) domain, utilising a N
10
-formyltetrahydrofolate 
cofactor. Formylation is known to occur in the biosynthesis of linear gramicidins. 
This is the least studied accessory domain (Kessler et al., 2004; Schoenafinger et al., 
2006; Hur et al., 2012). Finally, halogenation can occur on the heterocyclic rings 
introduced by Cy domains, this is mediated by a flavin dependent halogenase 
(Dorrestein et al., 2005; Hur et al., 2012).  
 
1.4.2.8 Linking modules in NRPS 
For efficient transfer of the peptide chain between modules, small (15-25 amino 
acid) domains exist between two different NRPS modules. The domains are called 
communication-mediating (COM) domains. COM domains reside at the C terminus 
of upstream module and N terminus of the downstream module; these are a cognate 
pair to ensure the modules are in the correct order for production of the target NRP 
(Hahn and Stachelhaus, 2004).   
 
1.4.2.9 A model system  
Tyrocidine, a cyclic NRP, is produced by B. brevis. Figure 1.16 illustrates the 
biosynthetic gene cluster of tyrocidine.  
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Figure 1.16- Biosynthetic gene cluster of the tyrocidine NRPS. Three polypeptides (TycA, B and C) contain a total of 10 modules. TycA contains 
module 1, the initiation module which incorporates L-Phe which is converted to D-Phe by an epimerase domain. Module 2 then incorporates L-
Pro, followed by L-Phe in module 3. Module 4 then adds L-Phe which is converted to D-Phe. Modules 5 incorporates an L-Asn, followed by L-Gln 
by module 6. Modules 7 and 8 then incorporate L-Tyr and L-Val. Module 9 incoporates the unnatural amino acid ornithine (L-Orn). Finally, 
module 10 incorporates a L-Leu before product termination and cyclisation. The blue circle (*) on the tyrocidine structure indicates the join when 
the decapeptide is cyclised (Mittenhuber et al., 1989; Mootz and Marahiel, 1997). 
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The tyrocidine NRPS is encoded for by three open reading frames, producing three 
polypeptides; TycA, TycB and TycC. TycA is composed of the loading domain 
(module 1), TycB is composed of modules 2, 3 and 4. Finally, TycC, the largest of 
the polypeptides is composed of modules 5-10, modules 1 and 4 exhibit epimerase 
activity and module 9 incorporates the unnatural amino acid ornithine (Orn). 
Tyrocidine is composed of (2) D-Phe, (1) L-Phe, (1) L-Pro, (1) L-Asn, (1) L-Orn, (1) 
L-Gln, (1) L-Tyr, (1) L-Val and (1) L-Leu (Mootz and Marahiel, 1997). Chemical 
synthesis of analogues of tyrocidine, performing single amino acid substitutions has 
yielded analogues with improved antibacterial activities (Marques et al., 2007). It 
was determined that the starter unit D-Phe and L-Orn are required for cyclisation of 
tyrocidine (Kopp and Marahiel, 2007). 
 
1.4.3 Structural and mechanistic studies of NRPSs 
As with PKS, structural studies of entire NRPS modules are severly hindered by size 
and flexibility. However, structural understanding may enable combinatorial 
biosynthesis of these multimodular enzymes. Structure elucidation has been 
successful for individual domains and di-domains which has given insight into 
important structural characteristics, especially when considering engineering 
strategies.  
X-ray crystallographic data shows that the adenylation domain is composed of two 
domains, a larger N-terminal subdomain and a smaller C-terminal subdomain 
(Marahiel and Essen, 2009). Crystal structures of A-domains responsible for 
activating 2, 3-dihydroxyxbenzoate (DhbE) from B. subtilis (May et al., 2002) and L-
phenylalanine (PheA) from B.brevis  (Conti et al., 1997) display highly conserved 
folds (Marahiel and Essen, 2009). In fact, although adenylation domains have really 
low sequence homology they appear to have a conserved, canonical fold (Sieber and 
Marahiel, 2005). Figure 1.17 shows the crystal structure of PheA, with specific 
residues for substrate recognition highlighted (Conti et al., 1997).  
Figure 1.16 shows the crystal structure of the PheA domain. The conserved A 
domain structure is composed of two subdomains, a large N-terminal domain 
contributing 9 out of the 10 residues that compose the hydrophobic binding pocket of 
the substrate, phenylalanine. The C-terminal domain, a smaller domain of 
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approximately 100 residues, contains K527, this residue is important for not only the 
coordination of Phe but also AMP (Conti et al., 1997; Stachelhaus et al., 1999). 
 
 
 
Structural studies of DltA, the D-alanine protein ligase, a member of the adenylate 
activating family, provided some mechanistic insight into the adenylation domain. 
The small C-terminal sub-domain can be in an open state, allowing entry of the 
substrates, followed by a closed state, enabling adenylation of the amino acid and 
transfer onto the PCP (Yonus et al., 2008; Hur et al., 2012).  
 Structural studies of the condensation domain showed that it is also composed of N 
and C-terminal subdomains, forming a ‘V’ shape. Figure 1.17 shows the 
condensation domain VibH from Vibrio cholerae (PDB code 1L5A) (Keating et al., 
2002). The ‘V’ structure of VibH revealed a solvent channel, in which the peptidyl 
growing chain and aminoacyl adenylate approach from each side and peptide bond 
formation catalysed (Keating et al., 2002). 
 
Figure 1.17- Crystal structure of the PheA adenylation domain. N (red) and C (blue) 
subdomain are highlighted, as are the substrates AMP and Phe (sky blue). The 
specificity conferring code of PheA which binds phenylalanine is magnified in the 
inset. This includes residues: D235, A236, W239, T278, I299, A301, A322, I330, C331 
and K517 (Conti et al., 1997; Stachelhaus et al., 1999). 
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The structure of a PCP domain has been elucidated by NMR, highlighting multiple 
conformations in the apo- and holo- states (Weber et al., 2000; Koglin et al., 2006), 
this will be further covered in chapter 5.  
Crystal structures of the TycC5-6 PCP bi-domain (PDB code 2JGP) (Samel et al., 
2007) from the tyrocidine NRPS and termination module from the surfactin NRPS 
(PDB code 2VSQ) have been solved (Tanovic et al., 2008). The bi-domain structure 
however did not show a functional interaction as the phosphopantetheine arm would 
not be able to reach the active site (Samel et al., 2007). The conformation of the PCP 
domain in the termination module however was in an appropriate orientation for an 
interaction with the C domain (Tanovic et al., 2008).   
The overall module structure of mFAS, and more recently the EM structure of a 
PikAIII module showed these multienzymes forming a homodimer to function 
(Dutta et al., 2014; Asturias et al., 2005; Maier et al., 2008). In contrast in NRPSs, 
the TE domain and VibH C domain, suggested that NRPS are actually monomeric 
(Bruner et al., 2002; Tsai et al., 2001; Keating et al., 2002). Gel filtration, chemical 
Figure 1.18- Crystal structure of the condensation domain, VibH. 
The condensation domain is composed of two subdomains, N and  C 
terminal subdomains. These two subdomains form a ‘V’ shape, 
providing a trench where the peptide bond is catalysed between the 
growing peptidyl chain and amino acyl adenylate. His 126 is 
highlighted as the catalytic residue (Keating et al., 2002).   
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cross-linking and AUC showed that the bimodule TycB was monomeric (Sieber et 
al., 2002; Glinski et al., 2002). 
 
1.4.4 Engineering NRPSs     
Engineering of NRPSs has been less extensive than its PKS counterparts. There are 
two approaches for the engineering of NRPS to yield novel products; editing the 
peptidyl chain or adding/removing groups on the peptidyl chain (Giessen and 
Marahiel, 2012). As with PKS however, heterologous expression can assist in easier 
manipulation for engineering novel product biosynthesis (Challis, 2006).  
 A target for NRPS engineering is the design of a hybrid NRPS, selecting modules 
depending on the desired product. This has been achieved with a two module system, 
creating a hybrid NRPS with a module from surfactin, selecting an aspartate residue 
and a second module from the tyrocidine NRPS which incorporates a phenylalanine. 
In addition to this, a termination module was present, this produced a functional 
NRPS (Doekel and Marahiel, 2000). 
Originally, exchanges of A-PCP domains were made to alter the substrates 
incorporated; novel analogues of surfactin were made by exchanging the A-PCP 
didomain of module 7 with fungal A-PCP didomains, creating a hybrid NRPS. 
However, this yielded low product titres, potentially due to the substrate specificity 
of the downstream C domains (Stachelhaus et al., 1995; Belshaw et al., 1999; 
Ehmann et al., 2000b). The reduced product titres have also been suggested to be 
due to disruption of the COM domains, generating an orthogonal pair of COM 
domains may in fact aid in the creation of hybrid NRPS enzyme (Weissman, 2004). 
Identification of linkers more tolerant to forming new interactions between A and 
PCP domains has aided in construction of new hybrid PKS (Doekel and Marahiel, 
2000).   
The most promising aspect of NRPS engineering has been targeting specific residues 
within the active site of an adenylation domain, known as the specificity conferring 
code. This was originally carried out with the adenylation domain of L-Phe from the 
gramicidin NRPS, where mutagenesis of the PheA adenylation code led to the 
incorporation of L-leucine. This has also been done in the surfactin PKS, altering the 
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substrate specificity from L-Glu to L-Gln and L-Asp to L-Asn (Eppelmann et al., 
2002). Genetic engineering of the adenylation domain in this way does seem to have 
some limitations, shape, size and hydrophobicity of the active site appears to control 
substrate specificity and thus the extent of engineering (Villiers and Hollfelder, 
2009).  
NRPS thioesterase modules could also be used to initiate macrocyclisation. 
Experiments carried out with the tyrocidine and surfactin TE domains showed that 
they were able to initiate cyclisation of synthetic peptides equivalent to the native 
peptides they cyclise (Tseng et al., 2002; Kohli et al., 2001; Trauger et al., 2000). 
The tyrocidine TE showed broad substrate tolerance, only really requiring the same 
N and C terminal residues in the peptidyl chain (Trauger et al., 2000) 
The modular nature of these enzymes provides many aspects to engineer to produce 
novel compounds, some of these engineering strategies, such as the use of a 
thioesterase domain to initiate macrocyclisation can be used in conjunction with 
chemical synthesis to produce novel compounds (Sieber and Marahiel, 2003).  
 
1.5 NRPS-PKS hybrid enzymes 
Hybrid NRP/PK products can be found in Nature. There are two ways in which 
NRP/PK hybrid products are synthesised, either they are synthesised by separate 
enzymes and joined or they are synthesised by NRPS/PKS hybrid enzymes (Du et 
al., 2003).  
Both NRPSs and PKSs work in an assembly line like fashion; NRPS and PKS 
modules are also found together in complexes in Nature, producing hybrid synthases. 
There are several well-characterised NRPS-PKS hybrids such as those the produce 
rapamycin and epothilone. The compounds that NRPS/PKS hybrid enzymes 
produce, just as with NRPS and PKS, can be predicted from the domains present. 
Hybrid assembly lines do not have to have a set ratio of NRPS to PKS modules 
(Schwarzer et al., 2003; Fischbach and Walsh, 2006). As usual growing chains are 
transferred between NRPS modules and PKS modules, switching from carbon-
carbon bond formation to amide bond formation (Fischbach and Walsh, 2006; 
Schwarzer et al., 2003; Walsh et al., 2006). As mentioned previously, C domains in 
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NRPS are shown to perform both types of catalysis for bond formation (Hur et al., 
2012).  
Structurally, the dimeric nature of PKS modules, and the heavily implied monomeric 
structure of NRPS modules suggests that while the PKS portion of the enzyme 
dimerises, the NRPS portion remains a monomer (Sieber and Marahiel, 2005). 
However, investigation into the docking domains between NRPS and PKS modules 
suggests that NRPS potentially self-associate to aid in the interaction with their 
dimeric PKS partners (Sieber and Marahiel, 2005; Hur et al., 2012). Understanding 
the interactions between NRPS and PKS modules will theoretically increase the 
options when engineering NRPS and PKS modules.  
 
1.5.1 The hybrid NRP/PK indanomycin 
In Nature, pyrrole groups fulfil a number of roles, forming of hydrogen bonds, 
coordination of metal ions and taking part in stacking interactions (Walsh et al., 
2006). Indanomycin is a pyrroloketoindane produced by an NRPS/PKS hybrid 
enzyme found in Streptomyces antibioticus NRRL 8167 (Li et al., 2009). 
Indanomycin displays a number of beneficial properties these include insecticidal, 
anti-protozoal and antibacterial properties (Liu et al., 1979; Zhang et al., 1997; Li et 
al., 2009) and works by complexing monovalent or divalent metal ions, using the 
carboxylic acid and ether oxygen to transport them across a cell membrane and 
disrupt ion balance (Roege and Kelly, 2009). Of the known pyrroloketoindanes, 
indanomycin is the only one whose biosynthetic gene cluster has been characterised.  
 
1.5.1.1 Biosynthetic gene cluster and structure of indanomycin 
Indanomycin is produced by an NRPS/PKS hybrid enzyme; this multimodular 
enzyme is composed of one NRPS module at the beginning of the biosynthetic gene 
cluster, followed by 11 PKS modules. Figure 1.19 illustrates the composition of 
indanomycin, composed of pyrrole-2-carboxylate, formed from the conversion of L-
proline, six malonyl-CoA units, two methylmalonyl-CoA units and two 
ethylmalonyl-CoA units (Li et al., 2009; Roege and Kelly, 2009).  
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The biosynthetic gene cluster of indanomycin was discovered and characterised by 
the Kelly Group (Li et al., 2009). As with other NRPs and PKs, identification of the 
biosynthetic gene cluster involved probing for the presence of a gene suspected to be 
present. Knowing that indanomycin requires the incorporation of L-proline, primers 
were designed to probe for a proline adenylyltransferase (Li et al., 2009).  
Interestingly, other NRPS such as those for tyrocidine biosynthesis (Figure 1.16) or 
vancomycin biosynthesis have adenylation domains which incorporate unnatural 
amino acids such as ornithine or β-hydroxytyrosine (Mootz and Marahiel, 1997; 
Smith et al., 1975) the NRPS module of indanomycin incorporates L-proline, and 
modifies when it is attached to the carrier protein as with biosynthesis of 
aminocoumarins (Garneau et al., 2005).  
 
1.5.1.2 Starter unit biosynthesis 
As mentioned previously, indanomycin is formed by an NRPS/PKS hybrid enzyme. 
The first module, the NRPS module, is responsible for the formation of the starter 
unit pyrrole-2-carboxylate instigating NRP/PK chain initiation. In starter unit 
biosynthesis L-Proline is activated and covalently attached to the phosphopantetheine 
arm of the carrier protein by the adenylyltransferase. The proline is then oxidised to 
a pyrrole by the flavin dependent prolyl-S-dehydrogenase to pyrrole-2-carboxylate. 
idmI encodes the dehydrogenase (IdmI), idmJ encodes the free standing 
adenylyltransferase (IdmJ), the activation domain, and idmK encodes the carrier 
protein (IdmK). The starter unit is synthesised then passed off into idmL, the first 
module of the PKS part of the NRPS/PKS (Li et al., 2009).  
Figure 1.19- Structure of Indanomycin. Indanomycin is composed of 
six malonyl CoA units (green), two methylmalonyl CoA (red) units 
and two ethylmalonyl CoA units (blue). Initiation of indanomycin 
biosynthesis is mediated by a pyrrole (pink) (Roege and Kelly, 2009). 
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It is interesting to note that the selection and activation of L-proline and the 
dehydrogenation to pyrrole-2-carboxylate are also observed in other biosynthetic 
clusters such as in aminocoumerin biosynthesis (Garneau et al., 2005). Proteins 
within the clorobiocin and coumermycin biosynthetic gene clusters have been shown 
to form pyrrole-2-carboxylate in the same manner as indanomycin, however 
adenylation and dehydrogenase proteins show lower sequence similarity (60-61%) to 
those found in indanomycin biosynthesis compared to between themselves (91-92%) 
(Garneau et al., 2005; Walsh et al., 2006). Genes responsible for the formation of the 
pyrrole group in clorobiocin and coumermycin biosynthetic gene cluster have been 
cloned and expressed in E. coli. ATP[
32
P]PPi experiments were used to probe the 
substrate specificity of the adenylation domains, comparing L-proline to proline 
analogues and L-pipecolinic acid. This showed the adenylation domain already had 
the ability to accept alternative substrates (Garneau et al., 2005).  
The aims of this project were to make some progress towards engineering modular 
enzymes to produce novel compounds with potential pharmaceutical benefits. The 
studies with the clorobiocin and coumermycin pyrrole forming enzymes indicated 
the potential for heterologous expression and expanding the substrate specificity of 
an L-proline activating adenylation domain.  
 
Figure 1.20- NRPS initiation module in indanomycin biosynthesis. IdmJ, the 
adenylyltransferase selects L-proline as the starter unit and activates and loads it 
onto IdmK, the carrier protein. The prolyl-S-dehydrogenase then oxidises the 
proline to pyrrole-2-carboxylate (Li et al., 2009).   
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1.6 Project outlines 
This thesis describes the experiments carried out to structurally and biochemically 
characterise proteins responsible for starter unit formation in indanomycin 
biosynthesis with the future aim to engineer these proteins as a source of novel 
polyketide/nonribosomal peptide production. The proposed work had three main 
goals: 
 Cloning and recombinant expression of proteins required for the 
conversion of L-proline in starter unit biosynthesis of indanomycin. This 
involves cloning of the genes encoding for the adenylyltransferase (IdmJ), 
dehydrogenase (IdmI) and carrier protein (IdmK) into an appropriate expression 
vector and expression to be carried out in E. coli. Approaches for cloning and soluble 
protein expression are discussed in chapters 3 and 4.  
 
 Purification and biochemical characterisation of IdmJ, IdmI and IdmK. 
Successful cloning and protein expression will be followed by purification by nickel 
affinity chromatography. Biochemical characterisation of the system will require 
phosphopantetheinylated IdmK, therefore investigation into exogenous PPTases with 
ability to modify IdmK may be required. Discussion of the expression of IdmK and 
obtaining a holo-IdmK species can be found in chapter 4. Characterisation of starter 
unit incorporation can be carried out in vitro with homogenous protein samples. 
 
 Structural characterisation of IdmJ, IdmI and IdmK. After establishing a 
protocol to obtain a homogeneous protein sample, structural characterisation of 
individual proteins within the whole module can be carried out. A combination of 
biochemical and structural techniques can be used to investigate protein-protein 
interactions required for a functional NRPS module. Structural characterisation can 
provide insights into a structure function relationship, aiding in structure based 
engineering strategies. Structural characterisation of IdmK is discussed in chapter 5.  
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2. Materials and methods 
2.1 Materials 
2.1.1 Chemicals 
Analytical grade chemicals and reagents were used throughout. Monobasic sodium 
phosphate, dibasic sodium phosphate, methanol, glycerol, glycine, sodium chloride, 
ampicillin, Tris base, glacial acetic acid, ethylenediaminetetraacetic (EDTA), 
isopropanol and ammonium acetate were purchased from Fisher Scientific Ltd. 
(Loughborough, UK). Agar, agarose, dithiothreitol (DTT) and isopropyl-β-D-1-
thiogalactopyranoside were purchased from Melford Laboratories Ltd. (Suffolk, 
UK). Ethanol, bromophenol blue, N,N,N`,N`-tetramethylethylenediamine (TEMED), 
nickel (II) chloride,   acrylamide:N,N′-methylenebisacrylamide 24:1, urea, tryptone 
and yeast extract were obtained from Sigma-Aldrich (Dorest, UK). Phosphate 
buffered saline (PBS) was purchased from Oxoid, part of Fisher Scientific Ltd. 
Hydrochloric acid, 2-mercaptoethanol and imidazole were purchased from Acros 
Organics, also part of Fisher Scientific. Ammonium persulfate was purchased from 
Amersham Biosciences Ltd. (Buckinghamshire, UK). Sodium dodecyl sulphate 
(SDS) was obtained from BDH Chemicals Ltd. (Poole, UK). SYBR® Safe was 
purchased from Invitrogen (Paisley, UK). 6 × Blue/Orange dye was purchased from 
Promega (Southampton, UK). Nickel (II) chloride hexahydrate was obtained from 
Alfa Aesar (Lancashire, UK). Lysozyme was purchased from MP Biomedicals 
(Cambridge, UK). 
15
NH4Cl and D-glucose-
13
C6 were purchased from Cambridge 
Isotope Laboratories, Inc. (Leicestershire, UK). 
 
2.1.2 Bacterial strains and plasmids 
The bacterial strain used in transformations for DNA manipulation was E. coli XL10 
Gold
®
 Ultracompetent cells (Tet
rΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F ́ proAB lacIqZΔM15 Tn10(Tetr) Amy 
Cam
r
]). Protein expression was achieved in the E. coli strain BL21-Gold (DE3) (B F
–
ompT hsdS(rB
–
mB
–
) dcm
+
 Tet
r
 galλ(DE3) endA Hte). The E. coli strains were both 
purchased from Agilent Technologies, Cheshire, UK. 
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Both the pKK223-3 and pETDUET plasmids were provided by Prof. Alan Berry 
(Astbury Centre, University of Leeds, UK). The pMAL
™
 c5X vector was a kind gift 
from Dr James Ross (Astbury Centre, University of Leeds, UK). pET23a vectors 
were either a kind gift from Dr David Brockwell (Astbury Centre, University of 
Leeds, UK) or purchased from Merck chemical Ltd. (Formerly Novagen) 
(Nottingham, UK).   
 
2.1.3 Enzymes 
Restriction enzymes EcoRI-HF
®
, HindIII-HF
®
, KpnI-HF
®
, PstI-HF
®
, SacI-HF
®
, 
SalI-HF
®
, XhoI and NdeI were purchased from New England Biolabs® (Ipswich, 
MA, USA). PfuTurbo
®
 was obtained from Promega (Southampton, UK). 
Deoxyribonuclease I from bovine pancreas was purchased from Sigma Aldrich 
(Dorset, UK).   
 
2.1.4 Antibodies 
The primary antibody used was the Monoclonal Anti-polyHistidine antibody 
produced in mouse at a 1: 3 000 dilution. The secondary antibody used was Anti-
mouse IgG conjugated with horseradish peroxidase in a 1: 20 000 dilution, both were 
purchased from Sigma-Aldrich (Dorset, UK).  
 
2.1.5 Genes 
Gene sequences from Streptomyces antibioticus NRRL 8167 encoding a prolyl-S-
dehydrogenase (idmI), a proline adenylyltransferase (idmJ) and a proline carrier 
protein (idmK) were obtained from GenBank (Accession number FJ545274) (Li et 
al., 2009) and genes were synthesised and purchased from Genscript (New Jersey, 
USA). Synthetic gene DNA and amino acid sequences can be found in the appendix.  
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2.1.6 Oligonucleotides 
Oligonucleotides (primers) were synthesised and purchased from Sigma Aldrich 
(Dorset, UK) or Integrated DNA Technologies (IDT) (Glasgow, UK). Primer 
sequences can be found in the appendix.  
2.1.7 Media 
Bacterial cultures were grown in 2 ×TY medium unless stated otherwise stated. This 
medium contained 16 g tryptone, 10 g of yeast extract and 5 g of NaCl made up to 1 
L with distilled water. Bacterial cultures of IdmJ were grown in LB medium, 
containing 10 g tryptone, 5 g yeast extract and 10 g NaCl made up to 1 L with 
distilled water. TB medium contained 12 g of tryptone, 24 g of yeast extract and 4 
mL glycerol made up to 900 mL, after sterilisation by autoclaving at  121 °C for 20 
min, 100 mL of sterile filtered 0.17 M KH2PO4 0.72 M K2HPO4 was added prior to 
culturing. ZYP-5052 autoinduction medium contained 925 mL ZY (10 g tryptone, 5 
g yeast extract made up to 925 mL with distilled water and 1 mL 1 M NaOH added, 
followed by sterilisation by autoclaving at 121 °C for 20 min), 1 mL 1 M MgSO4 
(filter sterilised), 20 mL 50 × 5052 (25 g glycerol, 73 mL distilled water, 2.5 g 
glucose and 10 g α-lactose filter sterilised) and 50 mL 20 × NPS (90 mL distilled 
water, 6.6 g (NH4)2SO4, 13.6 g KH2PO4 and 14.2 g Na2HPO4 sterile filtered).  Media 
was sterilised by autoclaving at 121 °C for 20 min. 1.5 % (w/v) agar was added to 2 
× TY for solid phase medium.   
Isotopically labelled protein was produced by growing bacterial cultures in minimal 
medium containing 10 g K2HPO4, 10 g KH2PO4, 7.5 g Na2PO4, 9 g K2SO4 and 1 g 
NH4Cl made up to 1 L with distilled water. Before culturing, 100 µL 1 M CaCl2, 2 
mL 1 M MgCl2 and 20 mL 20 % (w/v) glucose were added. CaCl2 was sterilised by 
autoclaving and MgCl2 and glucose were sterile filtered. For 
15
N labelled protein 
NH4Cl was substituted with 
15
NH4Cl. For expression of 
13
C, 
15
N labelled protein the 
glucose was also substituted with 10 mL 20 % (w/v) D-glucose 
13
C6.       
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2.2 Methods 
2.2.1 General methods 
2.2.1.1 pH measurements 
pH measurements were completed using a Jenway 3020 pH meter, calibrated 
according to the Manufacturer’s guidelines 
 
2.2.1.2 Centrifugation 
Centrifugation was performed using an Avanti
®
 J-26 XP centrifuge (Beckman 
Coulter
®
, Buckinghamshire, UK), at 4 °C unless otherwise stated. Samples of 
volumes ≤ 1.5 mL were centrifuged using a SANYO MSE Micro Centaur Centrifuge 
(MSE, London, UK) at room temperature unless otherwise stated.   
 
2.2.1.3 Asceptic technique 
Standard asceptic techniques were employed throughout, media and heat resistant 
materials were sterilised by autoclaving at 121 °C for 20 min. Heat labile materials 
were sterilised by sterile filtering using a 0.22 µm Millex-GP syringe Tip filter 
purchased from EMD Millipore (Hertfordshire, UK) or wiped down with 70% (v/v) 
ethanol.   
 
2.2.1.4 Antibiotic supplements 
Ampicillin was made up as a 50 mg mL
-1
 stock in distilled water, sterile filtered and 
used at a final concentration of 50 µg mL
-1 
in solid phase and solution phase media.  
 
2.2.1.5 Culture growth 
Single colonies were picked from 2 × TY or LB agar plates supplemented with the 
correct antibiotic(s) and used to inoculate 5 mL 2 × TY or LB starter cultures in 50 
mL Falcon tubes. These cultures were incubated for 16 hrs at 37 °C, shaking at 200 
rpm in an orbital shaker. Unless stated otherwise, 50 mL day cultures were 
inoculated with 50 µL of the starter culture and incubated for 9 hrs at 37 °C, shaking 
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at 200 rpm in a 250 mL conical flask. 10 mL of the day culture was then used to 
inoculate 1 L 2 × TY medium in a 2.5 L conical flask. Protein expression was 
induced by the addition of IPTG, giving a final concentration of 0.1 mM unless 
stated otherwise. For optimal protein expression, the optical density (OD) at 600 nm 
was observed and the culture was induced when the cell density reached an OD of 
between 0.6 and 1.0.  
 
2.2.1.6 Glycerol stocks 
Glycerol stocks were used to streak out on 2 × TY or LB agar plates for culture 
growth (see 2.2.1.5). Glycerol stocks were made by adding 0.5 mL of starter culture 
to 0.5 mL sterile glycerol in a Nunc CryoTube™ (Thermo Fisher Scientific, 
Roskide, Denmark), mixed well and stored at -20 °C. 
 
2.2.2 DNA methods 
2.2.2.1 Plasmid purification 
Plasmid DNA was purified from 5 mL cultures using Wizard
®
 Plus SV Minipreps 
DNA purification system (Promega, Southampton, UK) as instructed in the protocol 
provided. Plasmid DNA was purified from 50 mL cultures using HiSpeed
®
 Plasmid 
Midi Kits (QIAGEN, West Sussex, UK) as per manufacturer’s guidelines.  
 
2.2.2.2 Agarose gel electrophoresis 
Unless stated otherwise agarose gels contained 0.7 % (w/v) agarose dissolved in 1 × 
TAE buffer and carried out according to Sambrook et al. (1989). A 1 kb ladder was 
used for determining the size of DNA fragments >2 kb, a 100 bp ladder was used for 
determining the size of DNA fragments <2 kb, DNA ladders were purchased from 
Promega (Southampton, UK).  
10 × TAE buffer: 
10 mM EDTA 
200 mM Glacial acetic acid (17.5 M) 
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400 mM Tris base 
 
2.2.2.3 Extraction of DNA from an agarose gel 
DNA was purified from agarose gels by excising the bands and subsequently using a 
QIAquick
®
 gel extraction kit (West Sussex, UK) according to the manufacturer’s 
guidelines.   
 
2.2.2.4 Polymerase chain reaction (PCR) amplification of DNA 
Different PCR extension times were used depending on the target DNA to be 
amplified. However, PfuTurbo Polymerase was used consistently. All reactions were 
carried out in thin walled PCR tubes. The reaction mixture was as follows: 
 
 
5 µL of 10 µM forward oligo
 
5 µL of 10 µM reverse oligo 
5 µL of 0.1-50 ng/µL template DNA 
5 µL of 2 mM dNTPs 
5 µL of 10 × Cloned Pfu DNA polymerase reaction buffer   
25 µL of sterile water 
 
The reactions were then incubated at 95 °C for 5 mins, 0.5 µL of PfuTurbo 
Polymerase (2.5 U µL
-1
) was added to the reaction and the following cycling 
conditions were adjusted and used dependent on the length of the target DNA. A list 
of relevant primers and sequences can be found in the appendix. 
Generally, the PCR program after the addition of PfuTurbo polymerase used was as 
follows: 
92 °C, 2 mins 
92 °C, 30 secs 
55-65 °C, 30 secs
*
 
72 °C, 1 min per kb of target 
 
72 °C, 10 mins 
30 × 
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*
The annealing temperature was determined by subtracting 5 °C off of the primer 
melting temperature (Tm). The Tm of the primer was calculated using the equation 
2.1 below: 
𝑇𝑚 = 64.9°𝐶 + 41.0°𝐶 × (𝐺 + 𝐶 − 16.4)/𝑁 
Equation 2.1- Equation to calculate the Tm of the binding region of primers used in 
PCR amplification of DNA. Where G + C are the number of G and C bases and N is 
primer length.  
The concentration of DNA used in the reactions ranged from 0.1 to 10 ng µL
-1
. To 
assess the success of PCR amplification 5 µL of the reaction was run on an agarose 
gel (section 2.2.2.2).  
 
2.2.2.5 PCR product purification 
PCR products were purified using a QIAquick® PCR purification kit (West Sussex, 
UK) as per manufacturers guidelines, however sterile water was used to elute the 
DNA.  
2.2.2.6 DNA quantification 
DNA was quantified either spectrophotometrically at a wavelength of 260 nm, or by 
running a 0.7 % (w/v) agarose gel. To quantify DNA on an agarose gel densitometry 
was used. The intensity of the 500 bp band in the 100 bp ladder (Promega, 
Southampton, UK) which contains 150 ng per 5 µL of sample was compared to the 
target DNA band. This can be done using the GeneTools software from Syngene 
(Cambridge, UK).  
 
2.2.2.7 DNA digests 
DNA digests were performed on a 20 µL scale unless stated otherwise, incubated for 
between 2 and 16 hrs at 37 °C. The reaction set up was as follows: 
2 µL compatible reaction buffer supplied 
4-7 µL DNA (up to 50 ng) 
1 µL of restriction enzyme 1 (20 units) 
1 µL of restriction enzyme 2 (20 units) 
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The reaction was made up to 20 µL with sterile deionised water. For single digests, 
one restriction enzyme was used and water adjusted accordingly. Where possible 
High-Fidelity (HF
™
) restriction enzymes were used.  
 
2.2.2.8 Ligation reactions 
DNA ligations were completed between a gene, termed the insert, and a target 
vector. Reactions were performed in thin-walled PCR tubes in a 10 µL reaction 
volume. Insert and vector DNA were incubated together in a molar ratio of 3:1 at 4 
°C for 16 hrs in a reation containg 1 µL T4 DNA ligase and 1 µL of 10 × T4 DNA 
ligase buffer. Between 2 and 4.5 µL of the reaction was then transformed into XL10 
Gold
®
 Ultracompetent cells (section 2.2.2.11).  
 
2.2.2.9 Ligation independent cloning 
Ligation independent cloning was carried out using the FastCloning method as 
described in Li et al. (2011). Primers were designed to amplify the target insert 
(gene) and vector creating complimentary 5’ and 3’ ends of DNA fragments 
(2.2.2.4). An agarose gel was used to confirm the presence of the PCR products 
(2.2.2.2), which were then mixed in a 1:1 volumetric ratio. The reactions were 
digested with DpnI for 1 hr and subsequently transformed into XL10 Gold
®
 
Ultracomptetent cells (2.2.2.10). Figure 3.28 in section 3.3.6 illustrates the 
FastCloning strategy.   
 
2.2.2.10 Site directed mutagenesis 
Site-directed mutagenesis was performed using a QuikChange
®
 Site-directed 
mutagenesis kit (Stratagene, Cambridge, UK) as per the manufacturer’s instructions. 
Primers were designed as recommended by the manufacturer. Site-directed 
mutagenesis primers can be found in the appendix.    
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2.2.2.11 Transformation into E. coli cells 
Plasmid DNA was transformed into E. coli XL10 Gold
® 
Ultracompetent cells and/or 
E. coli BL21-Gold (DE3) cells (Section 1.1.2) using the heat shock method 
according to the manufacturer’s guidelines. 
 
2.2.2.12 DNA sequencing 
DNA sequencing was carried out by Beckman Coulter Genomics (Essex, UK). 
Sequencing primers used can be found in the appendix. 
 
2.2.3 Protein methods 
2.2.3.1 Small scale protein expression trials 
Small scale protein expression was performed on a 5 mL scale. Glycerol stocks of E. 
coli BL21-Gold (DE3) cells containing the target plasmid were plated onto 2 × TY 
agar plates supplemented with ampicillin at a final concentration of 50 µg mL
-1 
(section 2.2.1.4), plates were incubated at 37 °C for 16 hrs. A single colony was then 
used to inoculate 5 mL 2 × TY starter culture supplemented with ampicillin (section 
2.2.1.4), this was incubated at 37 °C for 16 hrs. 5 µL of the starter culture was then 
used to inoculate a 5 mL culture of TB, 2 × TY, LB or autoinduction medium 
containing ampicillin (section 2.2.1.4). TB, 2 × TY and LB cultures were incubated 
at 37 °C until the optical density of the culture at 600 nm reached between 0.6 and 
1.0, cells were then induced by the addition of IPTG giving a final concentration of 
60 μM. Cultures were then incubated for 16 hr at 37, 21 or 18 °C. Cells were then 
harvested for analysis of protein expression.  
 
2.2.3.2 Sample preparation for analysis of protein expression 
Cells were harvested from 5 mL expression cultures by centrifugation of 1.5 mL of 
the culture in the microfuge at 13 300 × g for 5 min. Harvested cells were then 
resuspended and incubated with 400 μL of CelLytic™ B lysis reagent for 10 min, 
followed by centrifugation at 13 300 × g for 5 min to separate the soluble and 
insoluble cellular components. Insoluble cellular components were resuspended in 
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100 μL of PBS. Samples were then prepared for analysis by SDS-PAGE and 
N-terminal His6-tag detection by blotting with an anti-polyHistidine antibody 
(sections 2.2.3.3 and 2.2.3.6). Samples for SDS-PAGE were diluted 1:4 with sterile 
H2O, samples for His6-tag detection were not diluted.  
 
2.2.3.3 Detection of the N-terminal His6-tag  
Detection of the N-terminal His6-tag was carried out by blotting 2 μL of soluble or 
insoluble cellular samples onto a nitrocellulose membrane. The blotted membrane 
was left to dry for 20 mins, then incubated for 1 hr at room temperature in blocking 
buffer. The blocking buffer was then removed and the membrane incubated with 10 
mL of primary antibody solution for 1 hr. The membrane was then washed with 
PBS-T for 10 mins; this was repeated 2 more times. The membrane was then 
incubated with 10 mL of secondary antibody solution for 45 mins at room 
temperature. The membrane was washed with PBS-T for 10 mins (3 times), followed 
by a 10 min wash in PBS. The membrane was then visualised by incubation with 
ECL Prime Western blotting detection reagent (VWR International Ltd, 
Leicestershire, UK) for 1 min, with increasing levels of exposure using a 
GeneGnome
5
 system (Syngene, Cambridge, UK).  
For detection of the N-terminal His6-tag by western blot an SDS-PAGE gel was run 
as described in section 2.2.3.6. The SDS-PAGE gel was then placed in transfer 
buffer for 15 mins. Transfer of proteins from the SDS-PAGE gel to a nitrocellulose 
membrane was performed using a Mini Trans-Blot
®
 Electrophoretic Transfer Cell 
(Bio-Rad, Hertfordshire, UK). The transfer stack was assembled as instructed by the 
manufacturer, transfer was carried out at 100 V for 1 hr. Blocking was performed as 
described above, however the blocking was carried out at 4 °C and the blocking 
buffer contained 3 % BSA as opposed to 5 % skimmed dried milk powder. The 
antibody solution incubations, washing and visualisation was carried out as 
described above.   
PBS-T: 
1 × PBS 
0.05 % (v/v) Tween-20  
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Blocking buffer: 
PBS-T 
5 % skimmed dried milk powder or 3 % BSA   
 
Antibody solution: 
Blocking buffer  
Antibody at appropriate dilution (section 2.1.4) 
 
Transfer Buffer: 
24 mM Tris base 
194 mM Glycine 
20 % (v/v) methanol 
 
2.2.3.4 Nickel affinity purification of His6-tagged proteins 
E. coli cells were cultured, as described in section 2.2.1.5, containing the plasmid 
with the target gene for protein expression. Protein purification was performed in 
batch using Chelating Sepharose
™
 fast flow resin chelated with nickel ions. E. coli 
cells were harvested by centrifugation (2.2.1.2) at 12 000 g for 20 mins. The 
supernatant was discarded and the pellet re-suspended using a homogeniser in 
washing buffer, 10 g of cells in 50 mL buffer. The cells were then lysed using a cell 
disrupter from Constant Systems Ltd (Northamptonshire, UK) at 20 KPSI. The 
insoluble cell debris was then removed by centrifugation at 40 000 g for 45 mins. 
The supernatant containing the soluble target protein was then subjected to 
purification by nickel affinity chromatography. 
The supernatant was incubated with the 5 mL of nickel resin in a 50 mL Falcon tube 
for 30 mins with mild agitation at 4 °C. The resin was then centrifuged at 4 000 g for 
10 mins, the supernatant was discarded. The resin was then washed by the addition 
of washing buffer to a final volume of 50 mL, re-suspended thoroughly, then 
centrifuged at 4 000 g for 10 mins and the supernatant removed. This wash step was 
repeated 4 times. Bound protein was eluted by the addition of 15 mL of elution 
buffer to the resin and incubated for 1 hr at 4 °C with mild agitation; the resin was 
centrifuged at 4 000 g for 10 mins and the supernatant, containing the protein, was 
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collected. The eluate was then dialysed into 50 mM Tris.HCl pH 7.4 as described in 
section 2.2.3.5. After dialysis protein was sterile filtered using 0.22 µm Millex-GP 
syringe tip filters and stored at 4 °C. Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (2.2.3.6) and mass spectrometry (2.2.3.7) was used to confirm the 
presence of the correct protein. 
Protein purification washing buffer: 
50 mM Tris.HCl pH 7.5  
20 mM Imidazole  
0.5 M NaCl 
 
Protein purification elution Buffer:  
50 mM Tris.HCl pH 7.5  
0.5 M Imidazole  
0.5 M NaCl 
 
2.2.3.5 Dialysis 
Dialysis was performed at 4 °C in volumes 50-100 times larger than the sample, with 
mild stirring. For proteins smaller than 14 000 Da dialysis tubing with a molecular 
weight cut off of 3 000 Da was used, otherwise tubing with a molecular weight cut 
off of 14 000 Da was used. Dialysis tubing was purchased from Fisher Scientific 
Ltd. (Loughborough, UK). Briefly, samples for dialysis were placed in dialysis bags 
in the dialysis buffer. Samples were left to equilibrate for 4 hrs, and then the dialysis 
bag was transferred to freshly made dialysis buffer and again left for 4 hrs to 
equilibrate. After equilibration, the sample was sterile filtered using 0.22 µm Millex-
GP syringe tip filters. 
 
2.2.3.6 Reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis  
Reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
was carried out using the standard method (Laemmli, 1970). For approximate 
molecular weight determination the Prestained Protein Marker, Broad Range (7-175 
kDa) ladder was used (NEB, Ipswich, MA, USA). These contain the protein 
Materials and methods 
59 
 
markers: E. coli MBP-β-galactosidase (175 kDa), E. coli MBP-paramyosin (80 kDa), 
E. coli MBP-CBD (58 kDa), E. coli CBD-Mxe Intein-2CBD (46 kDa), E. coli 
CBD-Mxe Intein (30 kDa), E. coli CBD-BmFKBP3 (25 kDa), chicken egg white 
lysozyme (17 kDa) and bovine lung aprotinin (7 kDa). SDS-polyacrylamide gel 
electrophoresis was carried out as described in Sambrook et al. (2001) using a 15% 
acrylamide resolving gel and 3.75% acrylamide stacking gel (recipe listed below). 
Ammonium persulfate (APS) was made up freshly for usage. The two 
polymerisation initiation components, APS and TEMED, were added to the gel 
solutions last. Gels were set between two glass plates as per manufacturer’s 
guidelines. The resolving gel was poured immediately followed by an isopropanol 
layer and allowed to set. The isopropanol was removed and the stacking gel poured 
and a comb inserted. Once the stacking gel was set, gels could be used immediately 
or wrapped in damp laboratory roll and covered in cling film. Wrapped gels could be 
stored at 4 °C for up to 1 week.  
Resolving gel: 
7.5 mL 30 % (w/v) acrylamide  
3.75 mL 1.5 M Tris.HCl pH 8.8 
3.5 mL H2O 
150 µL 10 % (w/v) SDS 
50 µL 25 % (w/v) APS 
5 µL TEMED 
Stacking gel: 
625 µL 30 % (w/v) acrylamide 
625 µL 1 M Tris.HCl pH 6.9 
3.65 mL H2O 
50 µL 10 % (w/v) SDS 
50 µL 25 % (w/v) APS 
5 µL TEMED 
2 × loading buffer: 
154 mg DTT 
2 mL 10 % (w/v) SDS 
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1 mL glycerol 
170 µL 1 M Tris.HCl pH 6.9 
163 µL H2O 
200 µL 0.2 % (w/v) bromophenol blue in ethanol 
Running buffer: 
3 g Tris Base 
14.4 g glycine 
1 g SDS 
140 µL β-mercaptoethanol 
Made up to 1 L with H2O 
Protein samples were prepared by adding 2 × loading buffer in a 1:1 ratio and boiled 
at 100 °C for 5 mins. Electrophoresis was performed at 30-60 mA for approximately 
1-2 hrs. SDS-PAGE gels were then stained in a methanol/ acetic acid/ water (5/1/1; 
v/v/v) solution containing 0.1 % (w/v) Coomassie Brilliant Blue for 2 hrs and 
subsequently destained using a methanol/acetic acid/water (5/1/1; v/v/v) solution. 
Alternatively, for rapid determination of results, gels were stained using InstantBlue 
(Expedeon, Cambridgeshire, UK) or Quick Blue Coomassie Stain (Triple Red, 
Buckinghamshire, UK). InstantBlue was used for in-gel tryptic digests (section 
2.2.3.10).  
2.2.3.7 Determination of protein concentration 
Protein concentration was determined spectrophotometrically at 280 nm and 
calculated using the Beer-Lambert law (Equation 2.2). 
𝑨 =  𝜺𝒄𝒍 
Equation 2.2- Beer-Lambert law, where A is the absorbance, ɛ is the molar extinction 
coefficient, c is the concentration of the protein and l is the path length. 
The molar extinction co efficient for each protein was calculated using their amino 
acid sequence and the ExPASy ProtParam tool. The calculated molar extinction 
coefficient was used throughout this research. The molar extinction coefficient 
calculated by ExPASy ProtParam for IdmJ was 51130 M
-1
 cm
-1
, for IdmI was 25940 
M
-1 
cm
-1
 and for IdmK was 5500 M
-1
 cm
-1
.     
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2.2.3.8 Increasing protein concentration 
Protein samples required to be at a higher concentration were concentrated by 
centrifugation through using a centrifugal concentrator. For sample volumes larger 
than 0.5 mL Sartorius Stedium Vivaspin
®
 6 or 20 centrifugal concentrators with a 
molecular weight cut-off of either 3 kDa or 10 kDa depending on the proteins’ 
molecular weight. For samples smaller than 0.5 mL Sartorius Stedium Vivaspin
®
 
500 centrifugal concentrators were used, with a molecular weight cut-off of 5 kDa 
(Goettingen, Germany). Concentrators were used in accordance with the 
manufacturer’s guidelines.   
 
2.2.3.9 Sample preparation for mass spectrometry 
Buffer exchange or desalting of protein samples was carried out using either Zeba
™
 
Spin Desalting Columns purchased from Thermo Fisher Scientific (Loughborough, 
UK) or Bio-Spin Exclusion Columns from Bio-Rad (Hertfordshire, UK) according to 
the manufacturer’s guidelines. For analysis by mass spectrometry, protein samples 
were exchanged into 50 mM ammonium acetate pH 7.4.  
 
2.2.3.10 In-gel tryptic digestion and analysis by LC-MS/MS 
In-gel tryptic digestion and analysis LC-MS/MS was carried out by Dr James Ault 
(Astbury Centre, University of Leeds, UK). Proteins to be analysed by in-gel tryptic 
digestion were run on a 15 % acrylamide gel as described in section 2.2.3.6. The gel 
was stained with InstantBlue (Expedeon, Cambridge, UK) to identify the target band. 
The band/s were excised and split into ~ 1 mm pieces. To remove the InstantBlue 
stain, gel pieces were immersed in 30 % ethanol in a 0.5 mL Eppendorf tube then 
incubated at 60 °C for 30 mins with shaking. Gel pieces were incubated in 100 % 
acetonitrile for 5 mins, followed by 40 µL 20 mM DTT in 25 mM ammonium 
bicarbonate at 56 °C for 1 hr with shaking. The supernatant was removed, substituted 
with 40 µL of 55 mM iodoacetamide in 25 mM ammonium bicarbonate, which was 
then incubated 37 °C for 45 min shaking, in the dark. The supernatant was removed 
and gel slices washed with 25 mM ammonium bicarbonate for 10 mins at room 
temperature, this was followed by a 5 min incubation in 100 % acetonitrile. Gel 
slices were then removed from the acetonitrile and left to dry completely for 1 hr 
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under a laminar flow hood. Once the gel pieces were dry they were cooled on ice and 
subsequently incubated with an ice-cold solution of 20 ng/µL trypsin in 25 mM 
ammonium bicarbonate for 10 mins, on ice. The supernatant was removed and 40 µL 
of 25 mM ammonium bicarbonate added to the rehydrated gel slices. The gel slices 
were briefly vortexed and centrifuged then incubated at 37 °C for 18 hrs. The 
digested peptides were recovered by vortexing and centrifugation of the solution, 
incubated for 18 hrs and the supernatant transferred to a fresh 0.5 mL Eppendorf 
tube. 5 µL of wash solution (acetonitrile/water/formic acid (60/35/5; v/v)) was added 
to the peptide solution. Additional peptide recovery from the gel pieces was 
performed by incubation of the gel slices with 40 µL of wash solution for 10 mins at 
37 °C, the resulting supernatant was combined with the original peptide recovery 
solution; this was repeated a second time. The peptide solution was then dried by 
vacuum centrifugation. In preparation for separation by liquid chromatography (LC) 
and analysis by MS/MS, the dried peptides were resuspended in 20 µL acetonitrile/ 
water/ formic acid (2/97.9/0.1; v/v/v).   
In order to separate the peptides, LC was carried out on the peptide mixture using an 
Ultimate 3000 nano LC system (Dionex, Amsterdam, Netherlands). 2 µL of the 
peptide mixture was loaded onto a C18 guard column. The column was then washed 
with 2 % acetonitrile/ 0.1 % formic acid for 5 min at 25 µL min
-1
.  The peptides were 
then separated by performing a gradient of 2-40% of 0.1% formic acid in acetonitrile 
with 0.1% formic acid in water over 60 min at 0.35 µL min
-1
, on a PepMap C18, 100 
µm i.d. x 15 cm analytical column (Dionex, Amsterdam, NL). 
The peptides separated on the column were then analysed directly by a quadrupole-
ion mobility - orthogonal time of flight mass spectrometer (Synapt G2-S, Waters 
UK, Manchester, UK) via Nano Flow electrospray ionisation (ESI). The mass 
spectrometer (MS) was operated in positive mode time of flight (TOF), using a 
capillary voltage of 3.8 kV and a sampling cone voltage of 20 V,  source offset of 15 
V and a trap bias of 5 V and backing pressure of 8.47 mbar. The buffer gas utilised 
was argon at a pressure of 5.0 × 10
-4
 mbar in both the trap and transfer regions. The 
source temperature was 80°C.  Mass calibration was carried out through a separate 
injection of sodium iodide (2 µg/µL). A 1 µM solution of the peptide mass standard 
Glu-1- Fibronopeptide B (Glu-Fib) in acetonitrile/water/formic acid (50/49/1; v/v/v) 
was introduced as the lock mass calibrant at a flow rate of 1 µL min
-1
 with a one sec 
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lock-spray scan collected every 30 sec during data acquisition. To determine the lock 
mass calibration correction factor ten scans were averaged. Data acquisition was 
carried out using a data dependent analysis. A one sec MS over m/z 350-2000 was 
collected followed by three one sec MS/MS performed over m/z 100-2000 of the 
three most abundant ions in the MS spectrum. Capillary electrophoresis applied to 
the ion was dependent on its charge state and mass. For increased sequence coverage 
dynamic exclusion (60 sec) was used.  
Data was processed using the MassLynx v4.1 suite of software supplied with the 
mass spectrometer. Peptide MS and MS/MS data were processed with ProteinLynx 
Global Server v3.0.2 software (Waters UK, Manchester, UK) and searched against 
reviewed entries of the UniProtKB/SwissProt database (release 2014_03), the 
database was modified to include the amino acid sequence of the synthetic IdmJ 
protein (amino acid sequence located in the appendix). 
 
2.2.3.11 Cysteine alkylation 
Alkylation of cysteines was performed using a 20-30 µM protein sample in 50 mM 
Tris.HCl pH 7.4 containing 8 M urea on a 500 µL scale. To reduce samples, DTT 
was added to a final concentration of 5 mM from a 0.5 M stock and incubate at 55 
°C for 25-45 mins. The protein was allowed to cool to room temperature. 500 mM 
iodoacetamide was then added to a final concentration of 14 mM and incubated for 
30 mins at room temperature in the dark. The reaction was then quenched by either 
adding DTT to give a final concentration of 10 mM or by preparing the samples for 
analysis by mass spectrometry by exchanging the buffer (2.2.3.9).    
 
2.2.3.12 Mass spectrometry 
Samples to be analysed by mass spectrometry were desalted into 50 mM ammonium 
acetate as described in section 2.2.3.9. Samples were then analysed by nano-ESI-MS 
by a quadrupole-ion mobility spectrometry-orthogonal TOF MS (Synapt, HDMS 
Waters UK Ltd., Manchester, UK) operating in positive TOF ‘V’ mode. Samples 
were analysed in acetonitrile : 1% aqueous formic acid (50:50; v/v). The MS was 
operated with a capillary voltage of 1.2 kV and a cone voltage of 50 V, the 
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nanoelectrospray nitrogen pressure was was set to 0.1 mbar with a backing pressure 
of 1.78 mbar. Nitrogen was used as a buffer gas at a pressure of 8.0 × 10
-3
 mbar in 
the trap and transfer regions and 3.6 × 10
-4
 in the ion mobility cell. The source 
temperature was 80 °C and desolvation temperature 150 °C. Mass calibration was 
carried out through a separate injection of sodium iodide (2 µg/µL) in 50:50 (v/v) 
water: acetonitrile. Data was processed using the MassLynx v4.1 suite of software 
supplied with the mass spectrometer. Analysis of protein samples by mass 
spectrometry were carried out by Dr James Ault (Astbury Centre, University of 
Leeds, UK).   
 
2.2.3.13 Protein purification by size exclusion chromatography 
For increased homogeneity, protein samples purified by nickel affinity 
chromatography (section 2.2.3.4) were subject to further purification by size 
exclusion chromatography. This was performed using an ÄKTA Prime Purifier 
System and a HiLoad
™
 Superdex
™
 S75 prep grade column (GE Healthcare Life 
Sciences, Buckinghamshire, UK). The column was equilibrated with a selected 
buffer which had been filtered and degassed. 3 mL of protein purified by nickel 
affinity chromatography at a concentration of 8 mg/mL was loaded onto the column 
using a 5 mL sample loop (GE Healthcare Life Sciences). The column was run at a 
flow rate of 2.0 mL/min. 2 mL fractions were collected and analysed by SDS-PAGE 
(2.2.3.3), fractions containing the purified protein were pooled and concentrated 
(2.2.3.5).  
2.2.4 Crystallographic methods 
2.2.4.1 Sample preparation 
A homogeneous protein sample was prepared through purification by nickel affinity 
chromatography (2.2.3.4) and subsequent size exclusion chromatography (2.2.3.13). 
The protein sample was sterile filtered using 0.22 µm  Millex-GP syringe tip filters 
purchased from EMD Millipore (Hertfordshire, UK) and concentrated (2.2.3.8) to 12 
mg/mL.  
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2.2.4.2 Screening conditions and crystal trays 
Crystallisation condition screens were carried out using 96 well CrystalQuick
™ 
RW 
sitting drop trays purchased from Greiner Bio-One (Gloucestershire, UK) with a 10 
mg/mL protein sample. The commercially available screens used were Crystal 
screen 1 and 2, Index 1 and 2, Salt RX (Hampton Research, Califronia, USA) and 
Wizard 3 and 4 (Emerald BioStructure, Washington, USA). 
Crystallisation conditions identified for the prolyl carrier protein were pH 8.2, 0.056 
M sodium phosphate monobasic monohydrate, 1.344 M potassium phosphate 
dibasic. Crystals were grown in 24 well plates by hanging drop vapour diffusion. 
Drops were dispensed in a 1:1, 2:1 and 1:2 crystallisation buffer to protein ratio. 
Protein samples were of a concentration 10 mg/mL.   
 
2.2.4.3 Data acquisition and processing 
Data acquisition and processing was carried out by Dr Chi Trinh (Astbury Centre, 
University of Leeds, UK). For data acquisition crystals were prepared by immersing 
in 25% (v/v) glycerol as a cryo-protectant, prior to flash cooling in liquid nitrogen. 
High resolution diffraction data was collected at 100 K on the I04 beamline 
Diamond Light Source Ltd (DLS) (Oxfordshire, UK). The data were reduced using 
the automated processing suit Xia2 at DLS (Winter, 2010). Phasing by molecular 
replacement was attempted using both Molrep (Vagin and Teplyakov, 1997) and 
Phaser (Mccoy et al., 2007) with different homologous carrier proteins as the initial 
search model (PDB codes: 2FAE (Roujeinikova et al., 2007), 2LIU (Busche et al., 
2012), 2LKI (Srisailam et al., 2006), 2XZ1 (Guy et al., 2011), 3GZL (Gallagher and 
Prigge, 2010), 2LPK (Ramelot et al., 2012), 1X3O (unpublished, Riken Structural 
Genomics/Proteomics), 2EHT (unpublished, Riken Structural 
Genomics/Proteomics), 2QNW  (unpublished, Structural Genomics Consortium) and 
2L4B (unpublished, Seattle Structural Genomics Center for Infectious Disease). 
SWISS-MODELLER (Arnold et al., 2006; Biasini et al., 2014; Guex et al., 2009; 
Kiefer et al., 2009) and ITASSER (Roy et al., 2010; Zhang, 2008) were also used to 
generate models from the IdmK amino acid sequence.  
 
Materials and methods 
66 
 
2.2.5 Nuclear magnetic resonance (NMR) spectroscopy methods 
2.2.5.1 Sample preparation 
Uniformly [
15
N] and [
13
C, 
15
N] labelled protein was prepared by growing the 
bacterial cultures in minimal medium (2.1.7) using 
13
C6 glucose and 
15
NH4Cl as the 
sole carbon and nitrogen sources. Labelled protein was expressed and purified as 
described in sections 2.2.1.5, 2.2.3.4 and 2.2.3.13. Mass spectrometry (section 
2.2.3.12) was used to determine the extent of isotopic labelling. Protein samples 
were dialysed into 50 mM Tris.HCl pH 7.4, 0.02% (w/v) sodium azide (section 
2.2.3.5). Samples to be used for NMR spectroscopy were concentrated to 0.5 mM 
and 10% (v/v) D2O was added. Shegemi NMR tubes were used for data acquisition 
with samples containing 300 µL of the protein sample.  
 
2.2.5.2 Data acquisition 
2D and 3D NMR experiments were carried out at 25°C on Varian INOVA 
spectrometers (Varian Inc., California, USA) at 500 or 600 MHz equipped with 
room temperature probes or at 750 MHz with a cryogenically cooled probe. Table 
2.1 shows the experimental details used to collect each spectrum. 
 
2.2.5.3 Data processing and analysis 
All data collected was processed with NMRPipe software (Delaglio et al., 1995). 
Typical data processing included multiplication by a cosine bell, followed by zero 
filling to increase the number of points at least by a factor of 2 followed by rounding. 
Fourier transformation was performed in all dimensions. In the case of the final 
15
N 
or 
13
C dimension, to double the number of data points, mirror image linear prediction 
was carried out. Phase corrections in the direct dimension were manually adjusted 
using NMRDraw and NMRPipe (Delaglio et al., 1995).  In most cases phase 
corrections were not required in the indirect dimension due to use of an optimal 
initial delay time, however, when required they were adjusted in the same manner as 
the direct dimension.  Data were converted to NMRView format by NMRPipe for 
use with CCPNmr analysis (Vranken et al., 2005).  
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An initial 
1
H-
15
N heteronuclear single quantum coherence spectrum (HSQC) was 
collected to assess the suitability of NMR for structural determination and further 
HSQC spectra were collected for sample quality control before or after collection of 
datasets. Backbone assignments were completed using the following spectra: HNCA, 
HNcoCA, HNcaCO, HNCO, HNCACB and HNcoCACB. Aromatic residue 
assignments were completed using 2D aromatic filtered 
1
H-
13
C-NOESY-HSQC and 
2D hbCBcgcdHDceHE spectra (Marion et al., 1989a; Marion et al., 1989b; 
Zuiderweg and Fesik, 1989; Yamazaki et al., 1993; Kalverda et al., 2009). A 2D 
aromatic filtered 
1
H-
13
C-NOESY-HSQC spectrum was acquired by using a standard 
1
H-
13
C NOESY-HSQC pulse sequence (Biopack) with no increments for 
13
C and the 
1
H-
13
C one-bond transfer time as 14.5 ms. Assignments of aliphatic amino acid side 
chain were completed using 
1
H-
13
C HSQC, HcCH-TOCSY and hCCH TOCSY 
spectra. Finally distance restraints were measured using
 15
N-NOESY-HSQC and 
13
C-
NOESY-HSQC spectra.  
Backbone assignments were completed by a semi-automated method using MARS 
(Jung and Zweckstetter, 2004) and checked manually using strip plots. Secondary 
structure predictions for use with MARS were calculated using the PSIPRED server 
at http://bioinf.cs.ac.uk/psipred (Buchan et al., 2013; Jones, 1999). TALOS was used 
to predict Φ and Ψ torsion angles and assigned from 1Hα, 13Cα, 13Cβ, CO and 15N 
nuclei from backbone assignments to assign secondary structural preferences (Shen 
et al., 2009a). 
Chemical shift referencing was derived from the chemical shift of the water line 
assuming a temperature of 25°C and a pH of 7.4 (Cavanagh et al., 2007). Following 
backbone assignment the chemical shift referencing was further validated using the 
program CheckShift (Ginzinger et al., 2007). Chemical shift referencing with the 
referencing compound DSS is still required.  
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Experiment  Spectral 
frequency 
(
1
H) MHz 
SW (Hz) 
 
Number of 
(complex) data 
points 
nt tmix 
(s) 
1
H 
13
C 
15
N 
1
H 
13
C 
15
N 
1
H-
15
N HSQC 500 8000 - 1800 2048 - 256 16 - 
HNCO 600 7620 2170 1940 2048 32 32 4 - 
HNcaCO 600 7620 2170 1940 2048 32 32 16 - 
HNCA 600 7620 4530 1940 2048 32 32 4 - 
HNcoCA 600 7620 4530 1940 2048 32 32 8 - 
HNCACB 600 7620 12100 1940 2048 32 32 32 - 
CBCAcoNH 600 7620 12100 1940 2048 48 32 8 - 
1
H-
13
C HSQC 750 10480 15000 - 2048 400 - 8 - 
1
H-
13
C HSQC 
(aromatic)
 
750 10480 15000 - 2048 92 - 64 - 
HcCH-TOCSY 750 10480 8000 15700 1024 128 54 4 - 
hCCH-TOCSY 750 10500 13000 13000 2048 56 72 8 0.14 
hbCBcgcdHDceHE 500 8000 3770 - 1024 28 - 2592 - 
HccoNH 600 7600 5400 1940 1024 64 32 16 - 
HBHAcoNH 600 9620 4750 1940 2048 62 32 16 - 
1
H-
15
N  J 
modulated HSQC 
600 7620 -  1990 1616 - 128 32 - 
      
Experiment  Spectral 
frequency 
(
1
H) MHz 
SW (Hz) 
 
Number of 
(complex) data 
points 
nt tmix 
(s) 
13
C/
15
N 
1
H 
1
H 
13
C/
15
N 
1
H 
1
H 
15
N-NOESY-
HSQC
 
600 12000 8200 2050 2048 144 40 8 0.12 
13
C-NOESY-
HSQC (aromatic) 
750 10500 8250 5800 2048 300 0 256 0.15 
13
C-NOESY-
HSQC (aliphatic) 
600 9620 6900 6190 2048 182 62 4 0.1 
Table 2.1- Experimental parameters of spectra acquired on the Varian INOVA 
spectrometer (Varian Inc., California, USA). SW-spectral width, nt- number of 
transients and tmix-mixing time (s). 
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2.2.5.4 Structure generation 
Structure determination by CS-ROSETTA was aided by Dr Gary Thompson. An 
initial structure ensemble was generated using CS-ROSETTA 3.2 (Shen et al., 2008; 
Shen et al., 2009b), using H, HN, CA, CB and CO chemical shifts from the 
backbone assignments and the amino acid sequence of IdmK. A total of 5000 
structures were calculated on a cluster of 7-14 CPU processors. Residual dipolar 
coupling (RDC) Q factor and combined chemical shift and ROSETTA energy scores 
were used to score the ensemble of structures.  RDC Q values were calculated using 
PALES as described in section 2.2.5.5 and 5.3. Further validation was carried by 
comparison with known canonical acyl carrier protein folds (PDB codes: 1HY8, 
1T8K, 1VKU, 2AVA, 2CGQ, 2GDW, 2KOO, 2KWL and 2L0Q) (Xu et al., 2001; 
Qiu and Janson, 2004; Zornetzer et al., 2006; Koglin et al., 2006; Ploskon et al., 
2010; Barnwal et al., 2011; Chan et al., 2010) and structure homology searches were 
completed using the Dali server (http://ekhidna.biocenter.helsinki.fi/dali_server/) 
(Holm and Rosenstrom, 2010).  
To validate the ROSETTA fold and generate a high resolution NOE (nuclear 
Overhauser effect) derived structure of IdmK, refinement of an ensemble of 
structures from the ROSETTA calculation was carried out using ARIA/CNS 
(Rieping et al., 2007). The structure ensemble was selected by taking the structure 
with the best fit for secondary structure elements to the measured 
1
H-
15
N RDC data 
as measured by the RDC Q factor. A set of 20 structures were selected with the 
lowest RMSD for the backbone secondary structure elements when compared to this 
structure. ROSETTA structures were regularised using the xplor-nih script 
(AddAtoms.py) (Schwieters et al., 2006) with all backbone atoms fixed during 
minimisation (Schwieters et al., 2003; Schwieters et al., 2006).  
ARIA structure calculations were carried out by Dr Gary Thompson. ARIA 
structures were calculated using the best fitting ROSETTA structures as a seed for 
structure calculation, replacing those generated by ARIA in the first of eight rounds 
of calculations (it0). The hot and cooling/annealing phases in the ARIA structure 
calculation were extended by a factor of 4 in length (Fossi et al., 2005b). The final 
structures were refined in a box of water. Chemical shift restraints were included as 
Φ and Ψ dihedral restraints for regions of secondary structure showing consistent 
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TALOS predictions (Rieping et al., 2007). RDC Q values were calculated using 
Equation 2.3 (Cornilescu et al., 1998).  
𝑄 =  √
∑ (𝑅𝐷𝐶𝑖
𝑜𝑏𝑠 − 𝑅𝐷𝐶𝑖
𝑐𝑎𝑙𝑐)
2
𝑖
∑ (𝑅𝐷𝐶𝑖
𝑜𝑏𝑠)2𝑖
 
Equation 2.3 - Equation to calculate the agreement between experimental and 
calculated RDCs (Q factor), where i is the residue (Zweckstetter, 2000).   
 
2.2.5.5 RDC alignment media and measurements  
Residual dipolar couplings were measured in two different liquid crystalline 
alignment media, PF1 filamentous bacteriophage and an alkyl-poly (ethylene-
glycol)/n-alkyl alcohol mixture.  
For alignment of IdmK in Pf1 bacteriophage (ASLA Biotech, Estonia), an initial 
1
H-
15
N HSQC was collected (isotropic) then Pf1 bacteriophage was added to a final 
concentration of 8 mg/mL. A 
1
H-
15
N HSQC was collected and processed as 
described in section 2.2.5.3. This spectrum was used to determine the suitability of 
Pf1 bacteriophage as an alignment medium. 
 A second alignment medium was trialled. The alkyl-poly (ethylene-glycol)/n-alkyl 
alcohol mixture was used. Hexanol, the n-alkyl alcohol selected, and C12E6 alkyl-
poly (ethylene-glycol)  (PEG) alignment medium was made at a (2x concentration) 
by titrating hexanol into a solution of 10% C12E6 using 5μL and  0.5 μL 
MicroVolume syringes (SGE Analytical Science, Milton Keynes, UK). The 
magnitude of alignment of the dipolar coupling medium was monitored using the 
quadrupolar splitting of HDO peak in the D
2
 (deuterium) NMR spectrum from the 
D2O lock solvent. For the Hexanol/PEG medium the quality of the alignment was 
followed by monitoring the lineshape in the sample, which showed a clean doublet 
with a splitting of 29 Hz when complete alignment was achieved at a PEG 
concentration of 10%. Final samples were prepared by adding 50% of the 
hexanol/PEG solution to the NMR sample. After alignment of the protein the 
deuterium splitting was checked again and adjustments to achieve a clean spectrum 
with a deuterium splitting of ~25Hz were made with hexanol or PEG solution. The 
quality of the data and deterioration of the spectral quality due to over alignment and 
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increases in the rotational correlation time from the aligned samples was also 
monitored using 
1
H-
15
N HSQC spectra and 
1
H coupled 
1
H-
15
N HSQC spectra. RDC 
Measurements were made using 
1
H-
15
N J modulated HSQC spectra (Tjandra et al., 
1996) with 
1
JHN evolution delays (∆) of 0.001 (×2), 0.003, 0.005, 0.007, 0.009, 
0.011, 0.013, 0.015 (×2), 0.017, 0.019, 0.021 and 0.023s. Data were processed with 
NMRpipe and peak intensities were measured using NMRView 5.2. Fitting of peak 
intensity data was achieved using the in house python script  fitR_bs (Dr Gary S 
Thompson and Dr Christopher MacRaild) which carries out non-linear least squares 
fitting starting with initial fitting parameters estimated using a number of heuristics. 
Statistical error analysis was carried out via 1000 rounds of Monte-Carlo 
simulations, with noise derived from differences in peak intensities from the 2 data 
sets measured with duplicate delays. The data was fitted to the equation 2.3.  
I2∆ = I0[−A + cos(2𝜋
1JNH∆)] exp (−
2∆
T2
∗) 
Equation 2.4- With I0 being the initial peak amplitude, Δ(t) the time delay (s), A the 
unmodulated component of the peak intensity, 
1
JNH the measured one-bond coupling 
(with or without the dipolar component) and T2* the effective transverse relaxation 
rate (Tjandra et al., 1996).  
 
Tensor frames, predicted RDCs, magnitude of alignment (Da), rhombicity (R) and 
quality of fit (Q) for RDCs were calculated using PALES (Zweckstetter and Bax, 
2000). PALES fits the observed dipolar couplings to the alignment tensor frame, Da 
and R; values from which predicted dipolar couplings can be back calculated using 
the Equation 2.4. 
D = Da [(3 cos
2 𝜃 − 1) +
3
2
𝑅 sin2 𝜃 cos(2𝜑)] 
Equation 2.5-Where θ and φ are polar angles with respect to the alignment tensor 
frame (Da and R) (Schwieters et al., 2003; Schwieters et al., 2006).  
 
2.2.5.6 Initial structural investigations of holo-IdmK 
To investigate structural differences of holo-IdmK and apo-IdmK experiments were 
run using 
15
N holo-IdmK. To ensure monomeric-labelled holo-IdmK was present 
experiments were run in the presence of 1 mM DTT. An initial 
1
H-
15
N HSQC was 
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collected of 
15
N holo-IdmK. Conservative chemical shift perturbation mapping was 
used in order to identify sites of interaction of the post-translational modification 
without assignment of the holo state (Williamson et al., 1997). Combined 
1
H, 
15
N 
chemical shift differences were calculated Equation 2.5. 
∆= [(𝛿15N𝑎𝑝𝑜/ℎ𝑜𝑙𝑜)
1/2
+ (5 × 𝛿1H𝑎𝑝𝑜/ℎ𝑜𝑙𝑜)
2]
1/2
 
Equation 2.6- Calculation of the differences in chemical shift from the 
1
H-
15
N HSQC 
spectra of holo- and apo- IdmK (Williamson et al., 1997).  
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3. Cloning and recombinant protein expression of 
nonribosomal peptide synthetase proteins required for 
starter unit biosynthesis of the polyether ionophore 
indanomycin 
The native producers of natural products such as nonribosomal peptides and 
polyketides include organisms like gram-positive bacteria and fungi (Stachelhaus 
and Marahiel, 1995). In this thesis the target compound, indanomycin, is produced 
by a strain of Streptomyces, Streptomyces antibioticus NRRL 8167 (Liu et al., 1979). 
Over-expression of NRPS proteins, required for structural and biochemical 
characterisation, is problematic in Streptomyces. Issues which prevent the over-
expression of proteins in the native system include slow bacterial growth during 
incubation and low product titres (Fujii, 2009; Peirú et al., 2010). An additional 
disadvantage is the genetic limitations of such an organism, including the occurrence 
of native PKS/NRPS gene clusters which may contaminate target protein PKS/NRPS 
expression and purification, the complexity of DNA manipulation with slow growing 
bacteria, and a lack of tools for genetic engineering (Fujii et al., 2009; Peirú et al., 
2010; Cane et al., 1998; Weissman and Leadlay, 2005).  
Over-expression of NRPS and PKS proteins has been carried out in some 
Streptomyces strains. Expression of these multimodular enzymes has been preferable 
due to the already existing abilities of these organisms to produce such 
macromolecules and the substrates required (Weissman and Leadlay, 2005). 
Expression is usually carried out in strains that are fully sequenced such as 
S. coelicolor A3 (2) (Bentley et al., 2002) or S. avermilitis (Ikeda et al., 2003).  
Alternative strategies explored for the expression of NRPS or PKS proteins in 
Streptomyces includes genetic engineering to reduce contamination by native 
PKS/NRPS gene clusters, by targeted deletion of the native NRPS/PKS gene cluster 
(such as the deletion of the actinorhodin gene cluster in its producing strain, 
S. coelicolor CH999) (McDaniel et al., 1993). Another approach to reduce the 
background genetic noise was to perform systematic deletions of the genome to 
create a genome-minimised bacterial strain. A genome minimised S. avermilitis 
bacterial strain was used to produce the antibiotic streptomycin, at levels above those 
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found in the native host S. griseus (Komatsu et al., 2010; Waksman et al., 2010). 
However more recently E. coli has become a popular choice of host system for 
recombinant protein expression due to its rapid life cycle, well characterised 
metabolic pathways, culture times, cost and ease of DNA manipulation (Fujii et al., 
1999; Rosano and Ceccarelli, 2014).  
Recombinant protein expression of NRPS and PKS modules in E. coli is not without 
its pitfalls, one particular difficulty being the expression of post-translationally 
modified proteins, which is required for the expression of the PKS/NRPS carrier 
protein. This issue was addressed by genetic engineering of E. coli to introduce the 
gene encoding the B. subtilis phosphopantetheinyl transferase, Sfp, to enable 
production of functional 6-deoxyerythronolide B synthase modules (Pfeifer et al., 
2001).  
In principle, producing recombinant PKS and NRPS proteins only involves a few, 
seemingly simple, steps; obtain the gene of interest, clone into a target vector under 
the control of an inducible promoter, express the target protein in a suitable host 
followed by protein purification (which can be aided by introduction of an affinity 
tag when obtaining the target gene). As expected there are a number of viable 
options at each stage of recombinant protein expression in order to attempt to 
produce soluble protein, including host, vector, promoter and affinity tag and this is 
another advantage as multiple combinations of these things can be trialled in E. coli 
(Rosano and Ceccarelli, 2014). The target host selected for recombinant gene 
expression in this case was E. coli. This chapter reviews work carried out to clone 
the indanomycin NRPS genes, idmJ and idmI and express soluble proteins. 
The initial aim of the project was to clone the genes involved in conversion of L-
proline to pyrrole-2-carboxylate (Figures 1.20 and 3.1), the starter unit for the 
polyether ionophore antibiotic indanomycin, into E. coli for recombinant gene 
expression. 
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Prior to this work a number of NRPS proteins have been expressed in E. coli, 
including other NRPS proteins that convert L-proline to pyrrole-2-carboxylate in 
aminocoumarin biosynthesis (Garneau et al., 2005); however those required for 
indanomycin starter unit biosynthesis; IdmI, IdmJ and IdmK, had not. In order to 
characterise these proteins and their enzymatic mechanism for starter unit 
biosynthesis, and to enable protein engineering experiments, recombinant protein 
expression was essential.  
 
3.1 Design of synthetic genes for recombinant protein expression 
in E. coli 
To express the S. antibioticus enzymes responsible for indanomycin starter unit 
biosynthesis in E. coli, genes were designed and subsequently synthesised and 
purchased from Genscript (New Jersey, USA). Design and purchase of a synthetic 
gene is now an attractive and accessible option for obtaining the target gene, and 
preferable to obtaining the gene by PCR from the genomic DNA, since the cost of 
gene synthesis has significantly decreased (Mueller et al., 2009). Additionally, genes 
can be designed to contain, or omit, certain features and characteristics such as the 
inclusion of an affinity tag or codon optimisation for recombinant expression. Amino 
acid sequences for the adenylyltransferase (idmJ), prolyl dehydrogenase (idmI) and 
Figure 3.1- Indanomycin starter unit biosynthesis. idmJ encodes a proline 
adenylyltransferase which activates L-proline and loads it onto a prolyl carrier 
protein encoded by idmK. The proline is then converted to pyrrole-2-
carboxylate by a prolyl-S-dehydrogenase encoded by idmI (Li et al., 2009). 
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prolyl carrier protein (idmK) were obtained from GenBank (accession number 
FJ545274) (Li et al., 2009). Genes were designed so they could be cloned and 
expressed individually or as a synthetic operon. 
 
 
 
 
 
As illustrated in Figure 3.2, all genes were designed with unique restriction sites at 
their 5’ and 3’ ends and the selected restriction sites did not occur within any of the 
genes. All genes contained ribosome binding sites to permit expression in any 
vector, and a His6-tag was included at the N-terminus of each protein to allow 
protein purification by nickel affinity chromatography. Additional features included 
a glutamate residue following the initiating methionine in order to prevent cleavage 
of the methionine therefore preventing premature protein degradation (Tobias et al., 
1991; Hirel et al., 1989). A double amber stop codon at the 3’ end of the gene was 
included to prevent a stop codon read-through. As these genes are usually expressed 
in Streptomyces, a bacterial strain whose genome has a high GC content (Muto and 
Osawa, 1987), genes were designed to be codon optimised for expression of the 
Figure 3.2- Schematic of the design for synthetic genes. (a) Synthetic idmJ, idmI 
and idmK were designed with unique restriction sites at the 5’ and 3’ ends to be 
cloned into pET23a individually or altogether. BamHI and EcoRI restriction sites 
were at the 5’ and 3’ termini of the idmI gene. SacI and SalI restriction sites were 
at the 5’ and 3’ termini of the idmJ gene respectively, and HindIII and XhoI 
restriction sites were at the 5’ and 3’ termini of the idmK gene. (b) Synthetic genes 
contained a ribosome binding site, initiating methionine residue followed by a 
glutamate, a His6-tag at the 5’ terminus of the gene and a double amber stop codon 
at the 3’ terminus of the gene. These features are flanked by the selected restriction 
sites. 
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protein in E. coli. Synthesised genes were supplied in pUC57, an appropriate cloning 
vector.  
 
3.1.1 Initial cloning strategy for NRPS starter module domains 
The initial strategy was to clone the genes individually into pET23a for protein 
expression. Figure 3.3 illustrates the standard “cut and paste” strategy used for 
cloning idmJ, idmI and idmK into pET23a. Vector and insert DNA were amplified 
by growth in E. coli XL10 Gold Ultracompetent cells. Once amplified, insert and 
vector DNA was prepared by restriction digestion creating complimentary “sticky 
ends” for ligation. The resulting construct(s) were transformed into E. coli XL10 
Gold Ultracompetent cells. Successful pETidmI/J/K constructs were indicated by 
growth on 2 × TY agar plates containing ampicillin and resulting constructs were 
screened with relevant restriction enzymes, and success was confirmed by DNA 
sequencing. The correct construct could then be transformed into an E. coli 
expression strain.  
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3.1.2 Amplification of vector and target gene plasmids 
The pET23a vector DNA was purchased from Merck4Biosciences (Nottingham, 
UK) (kindly gifted from Dr David Brockwell, Astbury Centre, University of Leeds, 
UK). The empty vector was transformed into E. coli XL10 Gold Ultracompetent 
cells (Section 2.2.2.11). A single colony was used to inoculate a 5 mL 2 × TY starter 
culture, 0.5 mL of this was subsequently used to make a glycerol stock of E. coli 
XL10 Gold ultracompetent cells containing the empty pET23a vector (Section 
2.2.1.6).  
 
Figure 3.3-“Cut and paste” cloning strategy for cloning idmI, idmJ and idmK. Genes 
were to be cloned individually into pET23a from pUC57 vector yielding pETidmI, 
pETidmJ and pETidmK expression vectors. Both the synthetic gene plasmids and the 
pET23a vector are amplified by growth in E. coli XL10 Gold Ultracompetent cells. 
Both are digested with the appropriate restriction enzymes and a ligation performed 
between the insert and vector DNA. Resulting constructs are transformed into E. coli 
XL10 Gold Ultracompetent cells, cells containing the correct constructs will grow in 
colonies on the agar plates containing ampicillin. Plasmids from the cells can then be 
purified and screened by restriction digests to identify correct constructs. 
Results one 
79 
 
pUC57 plasmids containing the individual genes arrived in the form of lyophilised 
DNA and were resuspended in sterile water as per the guidelines of the supplier of 
the synthetic genes. The three pUC57 plasmids containing the adenylyltransferase, 
dehydrogenase and carrier protein were designated pUCidmJ, pUCidmI and 
pUCidmK, respectively. Plasmid DNA was then transformed into Agilent 
Technologies E. coli XL10 Gold Ultracompetent cells (Section 2.2.2.11). Glycerol 
stocks were made of XL10 Gold cells containing pUCidmI/J/K plasmids for storage 
and DNA production (Section 1.2.1.6). Initial restriction digests of pUCidmJ with 
SacI and SalI, pUCidmI with BamHI and EcoRI and pUCidmK with HindIII and 
XhoI were performed for each plasmid for a preliminary product check and digested 
DNA was run on a 0.7 % (w/v) agarose gel as described in Sections 2.2.2.2 and 
2.2.2.7. 
 
Figure 3.4-0.7 % (w/v) agarose gel of a restriction digest of pUC57-gene constructs (a) 
pUCidmJ digested with SacI and SalI yielding a band at 1540 bp corresponding to the 
idmJ gene (b) pUCidmI digested with BamHI and EcoRI yielding a band at 1180 bp 
corresponding to the idmI gene and (c) pUCidmK digested with HindIII and XhoI 
yielding a band at 325 bp corresponding to the idmK gene. All agarose gels contain a 
band at 2790 bp corresponding to the pUC57 vector. All gels indicate the presence of 
the correct plasmids after transformation into XL10 Gold Ultracompetent cells. 
 
Once the preliminary digest was analysed the genes were sub-cloned for protein 
expression as described below.  
 
3.2 The adenylyltransferase (IdmJ) 
Conversion of L-proline to pyrrole-2-carboxylate requires the activation of the amino 
acid for loading onto the prolyl carrier protein (IdmK). The adenylyltransferase 
(IdmJ) is responsible for selection of the correct substrate, in this case L-proline, and 
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its activation. The adenylyltransferase (IdmJ) is required to load the carrier protein 
with L-proline (Li et al., 2009), or any other substrate in an enzyme dependent 
manner, for future engineering studies.  
 
3.2.1 Cloning the adenylyltransferase (idmJ) into pET23a 
Originally individual genes were to be sub-cloned into pET23a. pET vectors contain 
T7 promoters for induction by IPTG (Studier et al., 1990) and a range of restriction 
sites for cloning. To obtain the target gene idmJ (the insert) the glycerol stock of E. 
coli XL10 Gold Ultracompetent cells containing the pUCidmJ plasmid was used to 
inoculate 5 mL starter culture in 2 × TY medium supplemented with ampicillin. This 
in turn was used to inoculate a 50 mL culture of 2 × TY medium (Section 2.2.1.5). 
Plasmid DNA was then purified using a QIAGEN Plasmid Midi kit (Section 
2.2.2.1). Vector DNA was produced in a similar manner. The pUCidmJ and pET23a 
vector were then digested with the restriction enzymes SacI-HF
®
 and SalI-HF
®
; high 
fidelity (HF
™
) enzymes were used due to reduced star activity (Kamps-Hughes et al., 
2013). Restriction digests were performed as described in section 2.2.2.7 and run on 
a 0.7 % (w/v) agarose gel. Insert and vector DNA bands were then cut out of the 
agarose gel and a gel extraction performed (section 2.2.2.3). A ligation reaction was 
performed between pET23a and idmJ (2.2.2.8), 4 μL of the ligation reaction was 
subsequently transformed into E. coli XL10 Gold Ultracompetent cells (2.2.2.11).  
Successful plasmid ligation was screened for by antibiotic selection: bacterial 
colonies that grew on the 2 × TY agar plates containing ampicillin indicated the 
presence of a pETidmJ construct. To confirm the presence of the pETidmJ construct 
10 colonies were picked and used to inoculate 10 individual 5 mL starter cultures. 
Plasmid DNA from selected colonies was purified using the Promega Wizard
®
 SV 
Minipreps Purification kit (section 2.2.2.1) and restriction digests using SacI-HF
®
 
and SalI-HF
®
 were performed to screen for the correct plasmid. Figure 3.5 shows 
digested plasmid DNA from 10 colonies screened for the pETidmJ plasmid. The 
expected sizes of the DNA bands for a restriction digest using SacI-HF
®
 and 
SalI-HF
®
 of the pETidmJ construct are approximately 3.7 kb (3666 bp) and 1.5 kb 
(1540 bp) corresponding to the vector and insert respectively. 
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Figure 3.5- 0.7 % (w/v) agarose gel of the isolated plasmid DNA from the 10 
colonies after digestion with SacI-HF
®
 and SalI-HF
®
 restriction enzymes. The 
grey arrow indicates the expected size of the vector DNA and the red arrow 
indicates the expected size of idmJ. Lanes 1 and 2 appear to be undigested 
plasmid DNA, plasmids in lanes 3-6, 9 and 10 appear to have yielded two DNA 
fragments, one at approximately 3700 bp corresponding to the pET23a vector 
and the second approximately 2000 bp in size, this is too large to be idmJ. The 
plasmid in lane 7 contains a DNA fragment at 1500 bp corresponding to idmJ 
the vector is 2700 bp in size, corresponding to pUC57. Finally the digested 
plasmid in lane 8 contains only one DNA fragment at the approximate size for 
pET23a. 
 
Figure 3.5 indicates that the ligation reaction between pET23a and idmJ was 
unsuccessful. Plasmids 1 and 2 do not appear to be digested by SacI-HF
®
 and 
SalI-HF
®
 (lanes 1 and 2), Plasmids 3, 4, 5, 6, 9 and 10 are digested by SacI-HF
®
 and 
SalI-HF
®
 yielding a DNA fragment corresponding to pET23a and an unidentified 
insert too large to be idmJ (lanes 3-6, 9 and 10). Plasmid 7 (lane 7), when digested 
by SacI-HF
®
 and SalI-HF
®
 produced two DNA fragments, one corresponding to 
idmJ and the other pUC57 indicating pUCidmJ contamination during insert 
preparation. Finally, digestion of plasmid 8 (lane 8) yielded one DNA fragment 
corresponding to empty pET23a; this indicates incomplete digestion of pET23a in 
vector preparations.  
Several attempts at cloning idmJ into pET23a were made. The restriction enzyme 
stocks were replaced with new enzymes, as well as new vector DNA purchased from 
Merck4Biosciences (Nottingham, UK), however this strategy was not successful. 
Inefficient digestion during vector and insert preparations using SacI-HF
®
 and SalI-
HF
®
 resulted in plasmids that are incompletely digested which are able to simply 
“snap shut” in the presence of T4 DNA ligase and will transform efficiently, 
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contaminating the transformation plates with the incorrect plasmid. Although digests 
were performed for extended periods of time there may have been incompatibility 
with the two restriction sites selected. In addition to this, sites selected may have 
been in too close a proximity to one another in the vector, decreasing the efficiency 
of activity of the restriction enzyme. 
 
3.2.2 Cloning the adenylyltransferase (idmJ) into pKK223-3 
The next approach to sub-clone idmJ was to select an alternative vector. The vector 
selected was pKK223-3 (Pharmacia). This was obtained in the form of pKnanA 
(Timms et al., 2013) from Prof. A. Berry (Astbury Centre, University of Leeds, UK). 
Figure 3.6 illustrates the planned cloning strategy. The idmJ gene was amplified by 
culturing cells containing the pUCidmJ plasmid, the plasmid purified and insert cut 
out of the pUC57 vector using EcoRI-HF
®
 and HindIII-HF
®
 restriction enzymes. 
The pKnanA plasmid was propagated by culturing of E. coli XL10 Gold 
Ultracompetent cells containing the pKnanA plasmid, purifying the plasmid DNA, 
performing a restriction digest using EcoRI-HF
®
 and HindIII-HF
®
 restriction 
enzymes to cut out the nanA gene and create complimentary sticky ends to the idmJ 
insert. The insert and vector will be ligated together and transformed into E. coli 
XL10 Gold Ultracompetent cells. A successful ligation between pKK223-3 and idmJ 
will be indicated by colony growth on 2 × TY agar plates supplemented with 
ampicillin. Restriction digests with EcoRI-HF
®
 and HindIII-HF
®
 will be used to 
screen resulting plasmids from the ligation. Confirmation of the ligation between 
idmJ and pKK223-3 can then be confirmed by sequencing and the resulting construct 
designated pKidmJ. This strategy exploits the removal of a gene from the target 
vector to confirm the double digest of the vector has been successful. 
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Insert and vector DNA were prepared as previously described, using the restriction 
enzymes EcoRI-HF
®
 and HindIII-HF
® 
(3.2.1). Figure 3.7 shows the nanA gene has 
been successfully cut out of the pKK223-3 plasmid using the EcoRI and HindIII 
sites.  
 
 
 
 
Figure 3.6- Schematic for the method used to clone idmJ into pKK223-3. idmJ will 
be cut out of the pUC57 plasmid using EcoRI and HindIII sites that reside in the 
pUC57 multiple cloning site. The pKnanA plasmid will be digested with the same 
restriction enzymes, removing the nanA gene creating complimentary sticky ends to 
the insert. A ligation reaction can then be performed between the two DNA 
fragments. Resulting plasmids from the ligation can be transformed into E. coli 
XL10 Gold cells and the pKidmJ plasmid screened for. 
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The ligation reaction and subsequent transformation were also performed as before 
(section 3.2.1). 10 colonies were screened for the correct plasmid by restriction 
digestion with EcoRI-HF
®
 and HindIII-HF
®
; results are presented in Figure 3.8. The 
pKidmJ construct digested with EcoRI-HF
®
 and HindIII-HF
®
 should yield two DNA 
fragments, one at 4600 bp and the other at 1500 bp. 
 
 
 
 
 
 
Figure 3.7-0.7 %  (w/v) agarose gel of restriction digest of the pKnanA 
construct using EcoRI-HF
®
 and HindIII-HF
®.
-The nanA gene (~900 bp) 
was successfully cut out of the pKnanA plasmid (~4.6 kb). The vector DNA 
was then purified from the agarose gel using a Qiagen gel extraction kit 
(2.2.2.1). 
Figure 3.8-0.7 % (w/v) agarose gel of restriction digests of the 10 isolated 
plasmids from a ligation reaction between pKK223-3 and idmJ. Lanes 1 
and 3 appear to contain two bands at 4600 and 900 bp corresponding to 
pKK223-3 and the nanA gene respectively. Lane 2 shows only one band 
at the correct size for the vector however no insert can be observed. Lane 
4 shows DNA fragments corresponding to pUC57 (2.7 kb) and idmJ. 
Lanes 5-9 shows DNA fragments corresponding to the pUC57 plasmid 
and an unknown insert of approximately 500 bp. Plasmid purification for 
colony 10 (lane 10) appears to have been unsuccessful. 
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The agarose gel in Figure 3.8 indicates that the ligation between pKK223-3 and idmJ 
was unsuccessful. Restriction digests with EcoRI-HF
®
 and HindIII-HF
®
 of plasmids 
1 and 3 (lanes 1 and 3) yielded two DNA fragments, one at 4600 bp and a second at 
900 bp corresponding to pKK223-3 and the nanA gene respectively. Lane 2 shows a 
DNA band at 4600 bp corresponding to linearised pKK223-3 with no insert present. 
Restriction digestion of plasmid 4 (lane 4) yielded two bands, one at 2700 bp and a 
second at 1500 bp corresponding to pUC57 and idmJ. Lanes 5-9 show two bands, 
one at 2700 bp corresponding to the expected size of pUC57 and an unknown DNA 
fragment approximately 500 bp in length. Finally, there is no DNA present in lane 
10 suggesting plasmid purification was unsuccessful. Again, contamination from 
insert and vector preparations were observed (lanes 1-4) in addition to contamination 
by an unknown insert (lanes 5-9). This approach did not yield any positive results 
and was repeated without any success.  
 
3.2.3 Cloning the adenylyltransferase (idmJ) into pETDUET 
After the unsuccessful attempts at cloning idmJ into pET23a and pKK223-3 a third 
vector was trialled for sub-cloning, pETDUET. pETDUET is a vector that contains 
two multiple cloning sites. idmJ was to be cloned into the first multiple cloning site 
using the SacI and SalI restriction sites. The SacI and SalI sites are separated by a 
few more base pairs in pETDUET vector than pET23a. The empty pETDUET vector 
was transformed into E. coli XL10 Gold Ultracompetent cells and a glycerol stock 
made (sections 2.2.2.11 and 2.2.1.6). Vector and insert DNA were prepared as 
described in section 3.2.1, using SacI-HF
®
 and SalI-HF
®
 restriction enzymes. A 
ligation reaction was performed between pETDUET and idmJ, to create a plasmid 
designated pET(2)idmJ, followed by a transformation. Six colonies were picked from 
the transformation plate and used to inoculate six 5 mL cultures of 2 × TY medium. 
Plasmid DNA was purified from 4.5 mL of the culture and the pET(2)idmJ plasmid 
screened for by restriction digests with SacI-HF
®
 and SalI-HF
®
. Figure 3.9 shows 
the results from the restriction digests. 
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Figure 3.9-0.7 % agarose gel showing restriction digests with SacI-HF
®
 and SalI-HF
®
 
of plasmids isolated from a ligation between pETDUET and idmJ. Lanes 1-6 all show 
two DNA fragments after digestions with SacI-HF
®
 and SalI-HF
®
, one band at 5500 bp 
and a second at 1550 bp corresponding to the expected sizes of pETDUET (5420 bp) 
and idmJ (1540 bp). 
 
Initial screening from the ligation reaction indicates the presence of the pET(2)idmJ 
plasmid. DNA fragments in lanes 1-6 all showed a band at 5500 bp and another at 
1540 bp, corresponding to the correct sizes for vector and insert, respectively. This 
suggested that all plasmids screened were pET(2)idmJ. Plasmid 1 was selected for 
sequencing. A glycerol stock was made of E. coli XL10 Gold Ultracompetent cells 
containing plasmid 1. Purified plasmid DNA from this stock was subjected to DNA 
sequencing using the primers “pET UPSTREAM” and “DuetDOWN1” (see 
Appendix) (section 2.2.2.12). The sequencing revealed that pETDUET contained the 
correct sequence for the idmJ gene. 
The purified plasmid DNA of the pET(2)idmJ plasmid was then transformed into 
E.coli BL21 (DE3) Gold cells, a single colony was picked and used to inoculate 5 
mL of 2 × TY medium. 0.5 mL of this culture was used to make a glycerol stock, 
which was used for subsequent protein expression trials.  
 
3.2.4 Recombinant protein expression of the adenylyltransferase (IdmJ) 
Protein expression of IdmJ was attempted in E.coli BL21 (DE3) Gold cells 
containing the pET(2)idmJ plasmid. Initial small scale protein expression was 
attempted in 2 × TY medium as described in section 2.2.3.1. To determine if IdmJ 
had been expressed as a soluble protein, cells from 1.5 mL of the culture were 
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harvested, lysed and soluble and insoluble fractions separated for analysis by SDS-
PAGE (sections 2.2.3.3 and 2.2.3.6). 
 
 
 
The expected mass of IdmJ, as calculated from the amino acid sequence of the 
synthetic gene, is 53 522 Da. From the SDS-PAGE gel in Figure 3.10 it was unclear 
as to whether IdmJ was expressed as a soluble or insoluble protein, if expressed at 
all.  
There are a number of properties in protein expression that can be adjusted in order 
to produce soluble protein; one aspect is changing the growth medium. Changing the 
growth medium may help with solubility as different media permit differential cell 
growth patterns, for example LB medium, promotes cell growth at an early log 
phase, however prevents high cell densities (Sezonov et al., 2007; Rosano and 
Ceccarelli, 2014). Other media, such as TB, encourage high cell densities which 
could mean increased expression; however more cells means less oxygen, which will 
prompt expression of a large number of proteins creating a metabolic burden, 
perhaps inhibiting soluble protein expression (Rosano and Ceccarelli, 2014; Unden 
et al., 1995). For this reason a range of media of varying degrees of richness were 
trialled. In addition to 2 × TY (the current growth medium), protein expression was 
Figure 3.10- Reducing SDS-PAGE gel showing initial overexpression of IdmJ.  
Lane 1 is the insoluble fraction of induced E. coli BL21 (DE3) Gold cells 
containing the pET(2)idmJ plasmid. Lane 2 shows the soluble fraction. The red 
arrow indicates where IdmJ would be expected to appear on an SDS-PAGE gel. 
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tested in LB, TB and autoinduction media (section 2.1.7). Autoinduction medium 
supplies glucose as a nutrition source for E. coli, protein expression is suppressed in 
the presence of glucose. When glucose is no longer present protein expression is 
initiated. Another easily adaptable variable is the temperature at which the induced 
cells are grown. The temperature can be reduced in an attempt to improve protein 
solubility. Therefore induced cells will be grown at 37°C, 21°C (room temperature) 
or 18°C. In order to reduce the rate of protein expression, allowing more time for 
accurate protein folding, the concentration of IPTG was reduced, giving a final 
concentration of 60 μM (Tolia and Joshua-Tor, 2006).  
Expression trials were carried out on a 5 mL scale. The glycerol stock of E. coli 
BL21 (DE3) Gold cells containing the pET(2)idmJ plasmid was used to inoculate a 5 
mL overnight starter culture, which in turn was used to inoculate 5 mL day cultures 
of TB, 2 × TY and LB media which were incubated at 37°C. Once the OD600 of cell 
cultures reached between 0.6-1.0 the cells were induced with IPTG to a final 
concentration of 60 μM. Upon induction the temperature of incubation was either 
kept at 37°C or reduced to 21°C or 18°C. This method for cell growth and induction 
was utilised for all media trialled, excluding autoinduction medium. In autoinduction 
medium, cells were incubated at the same temperature throughout the experiment: 
due to the slow cell growth at lower temperatures (21 and 18°C) these cultures were 
incubated for approximately 28 hours in total. Each medium was trialled at all three 
temperatures. Samples were taken from the soluble cell fraction and analysed by 
SDS-PAGE (Figure 3.11). 
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Analysis of the SDS-PAGE gel of the soluble cell fractions in Figure 3.11 and 
comparison with untransformed E. coli BL21 (DE3) Gold cells (see appendix) 
suggests that IdmJ was not being expressed as a soluble protein due to a lack of a 
protein band at the expected mass (indicated by the red arrow). To check for low 
levels of soluble protein expression an anti His6-tag antibody was used to detect 
His6-tagged protein as a more sensitive method of detection. This was carried out by 
blotting 2 µL of the soluble fraction or 2 µL of the insoluble fraction resuspended in 
PBS on a nitrocellulose membrane and the His6-tag detected as described in section 
2.2.3.2. Figure 3.12 below shows the results of His6-tag detection in samples taken 
from the pET(2)idmJ expression trial.  
 
 
 
Figure 3.11- pET(2)idmJ expression trials. Reducing SDS-PAGE gel of the 
soluble cell fractions from the IdmJ expression trial. Expression of IdmJ 
was carried out by growing E. coli BL21 (DE3) Gold cells containing the 
pET(2)idmJ plasmid in four different media at three different temperatures. 
Lanes 1-3 shows the results of protein expression in TB medium at 37 °C, 21 
°C (room temperature) and 18 °C respectively. Lanes 4-6 show the results of 
expressing protein in 2 × TY at 37 °C, 21 ° C and 18 °C respectively. Lanes 
7-9 show the results of expressing IdmJ in LB medium at 37 °C, 21 °C and 
18 °C respectively. Finally lanes 10-12 show the results of expressing IdmJ 
in autoinduction medium at 37 °C, room 21 °C and 18 °C respectively. IdmJ 
is approximately 53 kDa, the red arrows indicate where a band is expected if 
soluble protein is expressed. 
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Detection of the His6-tag utilising an anti-polyHistidine tag antibody identified a 
number of expression conditions which produced soluble protein. Figure 3.12 shows 
that His6-tagged protein was detected in the insoluble fractions of cells grown at 
37°C when cells were cultured in LB and autoinduction medium (outlined in red), 
and no protein expression detected in TB or 2 × TY medium. When the temperature 
of the cultures were reduced to 21 °C after induction, soluble protein was detected in 
LB, 2 × TY and autoinduction medium (green). Low levels of His6-tagged protein 
were also detected in the insoluble fractions of cells. When cells were incubated at 
18°C after induction soluble protein was detected in TB, 2 × TY and LB medium, 
lower levels of His6-tagged protein were detected in the insoluble fraction. At lower 
incubation temperatures, cell growth was slow in autoinduction medium with low 
levels of protein expression; this therefore suggested that this medium was 
unsuitable for the expression of IdmJ. The results show that expression of IdmJ is 
somewhat temperature dependent, with soluble protein being expressed at lower 
temperature. Although the gene was codon optimised for expression in E. coli, 
fermentation of S. antibioticus, the native host, is at 28°C for 72 hours (Li et al., 
2009). The most consistent medium for expression of soluble IdmJ was LB medium, 
Figure 3.12- N-terminal His6-tag detection in IdmJ expression trials.  Soluble (top 
row) and insoluble (bottom row) cellular fractions were blotted onto a 
nitrocellulose membrane and an anti His6-tag antibody used for detection of a 
His6-tag to probe for protein expression. Blots are of E. coli BL21 (DE3) Gold cells 
grown in four different media and expression induced at three different 
temperatures. At 37 °C His6-tagged protein was detected in the insoluble fractions 
of cells grown in LB or autoinduction medium. There does not appear to be any 
soluble His6-tagged protein expressed. At 21 °C His6-tagged protein was detected 
in the soluble fractions of cells grown in 2 × TY and LB medium. Much lower 
levels of His6-tagged protein were detected in the insoluble fraction of cells grown 
in LB and autoinduction medium. At 18 °C although His6-tagged protein was 
detected in the insoluble fractions of cells grown in TB, 2 × TY and LB medium 
increased levels were detected in the soluble cell fraction. No His6-tagged protein 
was detected in cells grown in autoinduction medium at 18 °C. This is a negative 
display of the image for clarity. 
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with soluble protein being detected at 21°C and 18°C. The next stage was to attempt 
protein expression on a larger, 1 L scale, followed by subsequent protein 
purification.  
 
3.2.5 Purification of IdmJ and analysis 
After establishing an expression protocol, the next step was to purify IdmJ for 
analysis by SDS-PAGE and mass spectrometry. When the genes were synthesised 
they were designed to contain an N-terminal His6-tag to enable purification by nickel 
affinity chromatography. Briefly, for large-scale expression, a glycerol stock of 
E.coli BL21 (DE3) cells containing the pET(2)idmJ plasmid was used to inoculate a 
5 mL starter culture of 2 × TY medium. The starter culture was then used to 
inoculate 500 mL of LB medium in a 2 L flask. The cell OD was monitored at 600 
nm, when cell growth reached an OD of 0.6 the temperature was reduced to 18°C 
and protein expression induced by the addition of IPTG at a final concentration of 
60 μM. The cultures were then incubated for a further 16 hr at 18°C. IdmJ was 
subsequently purified using batch nickel affinity chromatography as described in 
section 2.2.3.4. Samples were taken at each stage of the purification and subjected to 
analysis by SDS-PAGE.  
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Analysis of nickel affinity purification of IdmJ by SDS-PAGE (Figure 3.13) 
revealed two bands in lane 8, suggesting two His6-tagged protein species were 
purified. The approximate molecular masses of these protein species appear to be 
approximately 58 and 53 kDa. Approximately 15 mg of protein was purified from 
1 L of culture. For a more in-depth and accurate analysis of the molecular mass, a 70 
μL sample of eluted protein was desalted into 50 mM ammonium acetate pH 7.4 
(section 2.2.3.9) and analysed by ESI-MS (section 2.2.3.12). Figure 3.14 shows the 
mass spectrum of the eluted proteins.  
Figure 3.13- Reducing SDS-PAGE gel showing stages of the nickel affinity 
purification of IdmJ. Broad range pre-stained protein markers are in lane (M). 
Lane 1 shows the whole cell lysate of induced BL21 (DE3) Gold cells containing the 
pETidmJ construct expressed in LB media at 18 °C, cells were harvested by 
centrifugation and lysed, the soluble (lane 2) and insoluble fractions (lane 3) were 
then separated by centrifugation.  The soluble fraction was then incubated with 
resin chelated with nickel chloride for 1 hour then the post-load supernatant (lane 
4) was discarded. The resin was washed with a low imidazole washing buffer (5, 6 
and 7) to remove non-specifically bound proteins. Lane 8 shows purified protein 
after elution with a high imidazole buffer. There appears to be two protein species 
eluted from the resin, these species are present in the whole cell lysate (1) soluble 
fraction (2) and in post-load (4), there are lower levels in the insoluble fraction (3). 
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Figure 3.14- ESI-MS of eluted protein from the purification of IdmJ. (a) mass 
spectrum raw data (b) deconvoluted mass spectrum of raw data identifying two species 
with masses of  55 953 Da and 56 131 Da. The expected mass for IdmJ is 53 522 Da. 
 
The mass calculated from the amino acid sequence encoded by the synthetic gene for 
IdmJ is 53 522 Da. Although SDS-PAGE analysis (Figure 3.13) showed two protein 
species eluted from the resin with approximate masses of 58 and 53 kDa, the mass 
spectrum above shows the mass of two protein species at 55 953 Da and 56 131 Da. 
The smaller of these masses (55 953 Da) shows a difference from the expected mass 
of IdmJ of 2 431 Da and is clearly outside the error margin for mass spectrometry, 
this protein will be denoted as IdmJ†. There is a second peak at 56 131 Da, 178 Da 
larger than that of IdmJ†. After considering known post-translational modifications 
and their masses a suggested source of this additional mass could be due to a 
spontaneous post-translational modification of the His6-tag, 
alpha-N-6-phosphogluconylation (Geoghegan et al., 1999), although no further 
evidence for this modification was obtained.  
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3.2.6 Characterisation of IdmJ† 
In order to identify the root of the additional mass the first aspect examined was the 
DNA sequence. Plasmid DNA was purified from the E.coli BL21 (DE3) Gold cell 
glycerol stock used for expression of IdmJ and transformed back into E. coli XL10 
Gold Ultracompetent cells for DNA sequencing using the sequencing primers “pET 
UPSTREAM” and “DuetDOWN1” (see Appendix) (section 2.2.2.12). Sequencing 
results showed no change in the original plasmid, the gene or vector, indicating that 
IdmJ should have the expected amino acid sequence and thus the correct mass. 
The next step was to eliminate the possibility that additions or changes to the amino 
acid sequence had occurred, to do this LC-MS/MS was utilised to evaluate peptide 
fragments generated from an in-gel tryptic digest for protein identification (section 
2.2.3.10) this was carried out by Dr James Ault (Astbury Centre, University of 
Leeds, UK). The schematic in Figure 3.15 below illustrates the in-gel tryptic digest 
method.  
 
  
 
 
 
 
Figure 3.15- Schematic of method for an in-gel tryptic digest followed by LC-MS/MS 
for protein identification. A sample of eluted protein from the IdmJ purification was 
run on an SDS-PAGE gel, after staining the gel, protein bands were excised. The 
protein was reduced and alkylated followed by a digest using trypsin. Peptides were 
separated by high performance liquid chromatography (HPLC). Identical pools of 
peptides were subject to ESI-MS. Peptides were then sequenced by collision-
activated dissociation followed by MS/MS. Peptide fragments were identified using a 
database edited to contain the synthetic IdmJ amino acid sequence (Henkin et al., 
2004; Fujii, 2009). 
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The in-gel tryptic digest followed by LC-MS/MS was carried out for both eluted 
species seen in lane 8 of the SDS-PAGE gel in figure 3.13. Both bands were 
separately excised from the SDS-PAGE gel, reduced and alkylated and digested with 
trypsin. Subsequently peptides were separated by high performance liquid 
chromatography (HPLC) (2.2.3.10). Trypsin cleaves on the C-terminus of either 
arginine or lysine residues, therefore the fragments produced from a known amino 
acid sequence can be predicted. Figure 3.16 shows the HPLC traces of both proteins 
that were purified in the adenylyltransferase purification (Figure 3.13, lane 8) 
digested with trypsin. 
  
 
 
 
 
 
Figure 3.16 shows the HPLC traces of peptide fragments from the two protein 
species eluted during purification of IdmJ. Both the top band of approximately 58 
kDa (top trace) and bottom band of approximately 53 kDa (bottom trace) in Figure 
3.13 display identical HPLC traces in Figure 3.16. As mentioned previously trypsin 
will cleave the amino acid sequence on the C-terminal side of arginine and lysine 
residues. This will create a pool of peptides, which can be predicted from the amino 
acid sequence alone. Identical HPLC traces therefore indicate that the protein species 
in the top and bottom bands of the SDS-PAGE gel are composed of the same 
peptides suggesting they are identical proteins. 
Figure 3.16- HPLC trace of purified IdmJ† digested with trypsin. A comparison 
of peptides present of bands excised from lane 8 of the SDS-PAGE gel in figure 
3.13. The top trace shows peptide fragments present in the protein species in the 
top band on the SDS-PAGE gel. The bottom trace shows the peptide fragments 
present in the protein species in the bottom band of the SDS-PAGE. 
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 Collision induced dissociation (CID) of peptides caused further fragmentation of the 
peptides. This enables sequencing of individual populations of peptides. The 
peptides that were identified from the tryptic digest and sequenced accounts for 
approximately 75 % of the amino acid sequence of IdmJ; sequence coverage is 
illustrated in Figure 3.17. 
 
 
 
 
 
 
 
Purification by nickel affinity chromatography followed by an in-gel tryptic digest 
and LC-MS/MS identified peptide fragments that were expected from a tryptic digest 
of IdmJ. This suggests that both bands in lane 8 of Figure 3.13 were modifications of 
IdmJ. Identification of the C-terminal peptide fragment indicated the additional mass 
does not come from a stop codon read-through and purification by the His6-tag 
indicated that the N-terminus of IdmJ is correct. Additionally, peptide fragmentation 
can also highlight any amino acids that have been post-translationally modified. 
During sample preparation, prior to the tryptic digest, the cysteine residues were 
alkylated to prevent disulphide bond formation as it may reduce peptide yields and 
hinder identification. Aside from cysteine alkylation, and other modifications such as 
oxidation that are caused by the method, the identity of the remaining post-
translational modification could not be determined. 
DNA sequencing and the in-gel tryptic digest followed by analysis using LC-MS/MS 
has indicated that the source of the additional mass observed for IdmJ† is not due to 
changes in the DNA or amino acid sequences. Peptide sequencing by MS/MS was 
also unable to identify the post-translational modification. Reduction and alkylation 
Figure 3.17- Summary of the peptide coverage of the IdmJ synthetic gene 
amino acid sequence from the tryptic digest. An in-gel tryptic digest generated 
pre-defined peptide fragments, LC-MS/MS was then used to identify the 
peptide fragments using databases of known protein sequences. The amino 
acid sequence of the synthetic IdmJ gene was added to the database. 
Approximately 75 % of the peptides were identified within the IdmJ amino 
acid sequence. 
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of cysteine residues prior to the tryptic digest could remove a covalent post-
translational modification at one or more cysteine residues, therefore removing the 
source of the additional mass. 
To investigate if the cysteine residues were playing a role in acquiring the additional 
2 431 Da observed for IdmJ†, the cysteine residues were alkylated and the protein 
mass obtained by analysis using ESI-MS. 25 μM of IdmJ†, purified by nickel 
affinity chromatography, was unfolded by 8 M urea. The protein was reduced by the 
addition of DTT and the cysteine residues alkylated by the addition of iodoacetamide 
(section 2.2.3.11). The reaction was incubated in the dark for 30 min, and then 
quenched by buffer exchange into 50 mM ammonium acetate pH 7.4 for analysis by 
ESI-MS  (section 2.2.3.12). Figure 3.18 below shows the mass spectrum of alkylated 
IdmJ†.  
 
Figure 3.18- ESI-MS analysis of alkylated IdmJ. 25 μM of purified IdmJ was unfolded 
by the addition of urea to a final concentration of 8 M. The protein was then reduced 
with DTT and alkylated by the addition of iodoacetamide. (Top) mass spectrum raw 
data (bottom) deconvoluted mass spectrum of raw data above. 3 peaks are can be seen 
in the spectrum, at 53 753 Da, 56 186 and 56 368 Da. 
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There are four cysteine residues in the amino acid sequence of IdmJ at positions 104, 
127, 169 and 308, therefore the potential for alkylation at four positions. Alkylation 
with iodoacetamide introduces a carbaminomethyl group onto the cysteine residue, 
increasing the mass of the protein by 57 Da per group added. Table 3.1 below shows 
and compares the expected and observed masses for the alkylation of IdmJ and 
IdmJ†. 
Sample Expected mass (Da) Observed mass (Da) 
IdmJ (Figure 3.14) 53 522 55 953 (IdmJ†) 
Fully alkylated IdmJ  53 753 53754 
Fully alkylated IdmJ† 56 181 56 186 
56 365 
Table 3.1- Table showing the expected masses for full alkylation of all 
cysteine residues in both IdmJ and IdmJ† compared to the masses observed 
by ESI-MS. 
 
The mass spectrum in Figure 3.18 shows the alkylation of IdmJ† yielded three 
protein species; 53574 Da, 56 186 Da and 56 365 Da. Table 3.1 shows the 
comparison of expected masses for fully alkylated IdmJ and IdmJ†, i.e. alkylation of 
all four cysteine residues. Table 3.1 shows IdmJ of the correct mass (53 522 Da) 
with all four cysteine residues alkylated has an expected mass of 53 753. The mass 
spectrum in Figure 3.18 shows a peak at 53 754, corresponding to IdmJ with the 
addition of four carbamidomethyl groups. The expected mass of IdmJ† with all four 
cysteine residues alkylated is 56 181 Da, a protein species was observed with as 
mass of 56 186 Da, this is indicative of IdmJ† alkylated on all four cysteine residues. 
Finally, the peak at 56 368 Da indicates the presence of 7 carbamidomethyl groups, 
suggesting IdmJ† has been alkylated at 7 positions. Although excess iodoacetamide 
can eventually cause non-specific alkylation of other groups such as the amine group 
of lysine residues, the thioester of methionine residues, imidazole groups of 
histadines and carboxylate groups of aspartate or glutamate (Yang and Attygalle, 
2007), the source of the extra three carbamidomethyl groups in IdmJ† is unlikely to 
be a non-specific alkylation. If this were the case more alkylated species would be 
observed e.g. +5, +6, +7 carbamidomethyl group etc. This could indicate that the 
source of the additional mass in IdmJ† contains four thiol groups that are being 
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alkylated. These results show when IdmJ† is unfolded, reduced and the cysteine 
residues alkylated the expected mass of IdmJ with four cysteine residues alkylated is 
observed. This provides further evidence of the involvement of the cysteine residues 
in acquiring the additional mass.   
To further investigate the role of the cysteine residues in the observed increase in 
mass, to potentially deduce the contributions of each cysteine residue, and in an 
attempt to express a protein of the expected mass, individual cysteine to alanine 
mutations were made at all four positions. The pET(2)idmJ plasmid DNA was 
purified from E. coli XL10 Gold Ultracompetent cells and site-directed mutagenesis 
carried out using primers designated “C104A For”, “C104A Rev”, “C127A For”, 
“C127A Rev”, “C169A For”, “C169A Rev”, “C308A For” and “C308A Rev” 
designed to mutate the cysteine residues to alanine (sequences can be found in the 
appendix). Mutagenesis was carried out using the QuikChange
™
 Lightning 
Site-Directed Mutagenesis kit as described in section 2.2.2.10. 3 colonies were 
picked from the transformation plates of the mutagenesis reaction and plasmid DNA 
purified. DNA sequencing was carried out using the sequencing primers “pET 
UPSTREAM” and “DuetDOWN1”. This confirmed the presence of the correct point 
mutations within the idmJ gene. Plasmids containing the genes with the single point 
mutations C104A, C127A, C169A and C308A were transformed into E. coli BL21 
(DE3) Gold cells for protein expression. 
Protein was expressed using the same method for wild-type IdmJ. Protein expression 
was carried out on a 5 mL scale and IdmJ variants were purified by nickel affinity 
chromatography. A 70 µL sample of each variant was desalted into 50 mM 
ammonium acetate pH 7.4 for analysis by ESI-MS (sections 2.2.3.9 and 2.2.3.12). 
Figure 3.19 below shows the deconvoluted mass spectra of IdmJ C104A, IdmJ 
C127A, IdmJ C169A and IdmJ C308A. 
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Sample Expected mass  
IdmJ (C104A, C127A, C169A and 
C308A) 
53 492 Da 
IdmJ† (C104A, C127A, C169A and 
C308A) 
55 923 Da 
Table 3.2-Expected masses for IdmJ and IdmJ† containing the cysteine to 
alanine mutation. 
Figure 3.19- ESI-MS analysis of IdmJ variants. From top to bottom 
deconvoluted mass spectra of IdmJ C104A, IdmJ C127A, IdmJ C169A and 
IdmJ C308A. A number of protein species can be observed in each spectrum. 
Peaks suggested to be due to the same species are highlighted in the same 
colour. Table 3.2 shows the expected masses of IdmJ and IdmJ† containing 
the cysteine to alanine mutation. 
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Analysis of IdmJ variants by mass spectrometry (Figure 3.19) identified potential, 
consistent, degradation products seen in the four variants (masses ~ 43 200, 28 947 
and 26 971 Da (purple, green and yellow)). Analysis indicated that when C104A, 
C169A and C308A were expressed both IdmJ and IdmJ† were present (red and blue 
highlighted peaks). MS analysis of these three species also show the ~178 Da adduct 
seen in Figure 3.14 present (light green). Expression, purification and MS analysis of 
C127A shows a peak at 53 944 Da (pink), this is a mass difference of 452 Da, 
compared to IdmJ; this does not correspond to any known particular modification. 
C127A is the only variant where the larger species, IdmJ†, is not observed. This may 
indicate that the source of the additional mass may be modification at position C127. 
Figure 3.20 illustrates what may be occurring in expression of IdmJ in E. coli.  
Figure 3.20 summarises the results of the cysteine alkylation and mutagenesis 
experiments and a suggested theory behind what may be occurring. During 
alkylation (Figure 3.20 (b)) of the cysteine residues IdmJ is fully alkylated (four 
positions). IdmJ† is still present, however it has been alkylated four and seven times. 
This may indicate that the post-translational modification is occurring at one position 
and contains one thiol group and three slightly less reactive groups (marked x) that 
are able to be alkylated, accounting for the extra masses. Identification of the 
cysteine residue being post-translationally modified was carried out by creating 
alanine variants C104A, C127A, C169A and C308A (Figure 3.20 (c)). Expression of 
C104A, C169A and C308A showed the continued presence of the post-translational 
modification, as opposed to C127A suggesting this as the residue that becomes 
modified, potentially during expression. Removal of the modification may create an 
active enzyme and the additional mass (452 Da) seen in the MS of C127A could be 
attributed to phosphopantetheine loaded with proline (452 Da) catalysed by IdmJ.     
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3.2.7 Summary and conclusions 
Original difficulties in cloning idmJ into pET23a may have arisen from the two 
restriction sites selected for cloning idmJ, SacI and SalI, being too close in proximity 
to one another in the multiple cloning site (11 bp). Attempts at cloning idmJ into 
pKK223-3 were also unsuccessful. idmJ was finally successfully cloned into 
Figure 3.20- Schematic of the expression of IdmJ/IdmJ†. (a) Expression and 
purification of IdmJ yielded two species. Analysis by ESI-MS showed a protein 
species which was 2 431 Da larger than expected designated IdmJ†. (b) Alkylation of 
the cysteine residues yielded three species, one corresponding to IdmJ alkylated in 
four positions (53 754 Da), the second IdmJ† alkylated in four positions (56 186 Da) 
and finally IdmJ alkylated in seven positions (56 365 Da). Alkylation of IdmJ† at 
seven positions could indicate that the post-translational modification contains a 
thiol able to be alkylated as readily as the other cysteine residues and three 
additional groups in the post-translational modification able to also be alkylated, 
but at a slower rate. Systematic mutagenesis of each individual cysteine residue 
showed that in three variants the modification was still present. However in C127A 
the 2 431 Da modification was absent indicating this may be the site of modification. 
The mass of the protein species observed was 452 Da larger than expected for IdmJ, 
this corresponds to phosphopantetheine loaded with proline.   
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pETDUET. Expression trials of the pET(2)idmJ plasmid was carried out in E. coli 
BL21 (DE3) Gold cells. Soluble protein was not expressed at 37°C. Soluble protein 
expression was however seen at 25°C and 18°C in TB, LB and autoinduction 
medium (Figure 3.12). Soluble protein expression was then carried out at 18°C and 
in LB medium.  
Protein purification was carried out using nickel affinity chromatography. Analysis 
by SDS-PAGE (Figure 3.13) showed purification of two protein species, and 
analysis by MS (Figure 3.14) showed the protein purified was 2431 Da larger than 
the expected mass of IdmJ believed to be a post-translational modification, this 
protein was designated IdmJ†.  DNA sequencing and an in-gel tryptic digest 
indicated that the protein purified was IdmJ (Figure 3.17).  
To probe whether a post-translational modification was occurring at one of the 
cysteine residues the protein was treated with iodoacetamide in order to alkylate the 
cysteine residues. Mass spectrometry results (Figure 3.18) showed masses equivalent 
to IdmJ being alkylated four times, equivalent to the number of cysteine residues in 
the protein, and IdmJ† alkylated four and seven times. Figure 3.20 shows a possible 
explanation behind how IdmJ† is alkylated in four and seven positions. Potentially, 
the modification of IdmJ† contains groups that can react with iodoacetamide.  
Finally, in order to identify the site at which a potential modification could occur, the 
cysteine residues in IdmJ were mutated to alanine residues, the variants were then 
expressed, purified and analysed by MS (Figure 3.19). Purification of C104A, 
C169A and C308A and analysis by MS showed peaks corresponding to IdmJ and 
IdmJ† containing the cysteine to alanine mutation. Purification and MS analysis of 
C127A showed a peak at 53 944 Da, 452 Da larger than expected for IdmJ, while 
IdmJ† was absent. These results suggest C127 is the site of a 2431 Da modification.  
 
3.3 The prolyl dehydrogenase (IdmI) 
The formation of the starter unit, pyrrole-2-carboxylate, requires an enzyme to 
oxidise the prolyl group (Figure 3.1); this is the role of the prolyl dehydrogenase, 
IdmI. IdmI carries out the oxidisation of the prolyl group in a flavin-dependent 
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manner. To successfully reconstitute this system in E. coli cloning and expression of 
IdmI was required.  
 
3.3.1 Cloning the prolyl dehydrogenase (idmI) into pET23a  
As mentioned previously, the original strategy was to clone each individual gene into 
the expression vector pET23a. The idmI gene was engineered to have BamHI and 
EcoRI sites at the 5’ and 3’ ends of the DNA respectively. The cut and paste method 
illustrated in Figure 3.3 was the initial method selected for sub-cloning idmI from 
pUCidmI into pET23a, creating a pETidmI plasmid. Insert and vector DNA were 
prepared by digesting the pUCidmI plasmid and pET23a vector with BamHI-HF
®
 
and EcoRI-HF
®
 restriction enzymes for 16 hr. The restriction digests were run on a 
0.7 % (w/v) agarose gel and the insert and vector DNA were purified from the 
agarose gel (section 2.2.2.3). Insert and vector DNA were ligated as described in 
section 2.2.2.8. Ligated DNA was transformed into E. coli XL10 Gold 
Ultracompetent cells and plated onto 2 × TY agar plates containing ampicillin to 
select for the pETidmI contruct. Plasmid DNA was purified from 10 individual 
colonies and restriction digests performed using BamHI-HF
®
 and EcoRI-HF
®
 
restriction enzymes to screen for the correct construct. When digested with BamHI 
and EcoRI the correct construct should yield bands at approximately 3.6 kb (3666 
bp) and 1.2 kb (1180 bp) corresponding to the vector and insert respectively. 
 
Figure 3.21-0.7 % (w/v) agarose gel of plasmid DNA purified from colonies to screen 
for the pETidmI plasmid. Purified plasmid DNA digested with BamHI-HF
®
 and EcoRI-
HF
®
. Plasmid DNA in lane 1 was undigested; lane 2 shows a single DNA band at 
approximately 3000 bp. Digests of plasmids in lanes 3 and 4 yielded two DNA 
fragments, one at 2700 bp corresponding to pUC57 and the other an unidentified band 
at approximately 300 bp. Digestion of plasmid DNA in lanes 5-10 yielded two DNA 
fragments, one 2700 bp in length and a second 1180 bp this corresponds to pUC57 and 
idmI respectively. 
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Figure 3.21 indicates that the ligation between pET23a and idmI was unsuccessful. 
Plasmid 1 does not appear to have been digested with BamHI-HF
®
 and EcoRI-HF
®
. 
There is a single DNA band in lane 2 of approximately 3000 bp, there was no insert 
of 1180 bp corresponding to idmI. Plasmid DNA in lanes 3 and 4 yielded two DNA 
fragments when digested with BamHI-HF
®
 and EcoRI-HF
®
, one 2700 bp in length 
and a second 300 bp in length, corresponding to pUC57 and an unidentified insert. 
Plasmid DNA in lanes 5-10 yielded two DNA fragments when digested with 
BamHI-HF
®
 and EcoRI-HF
®
, one 2700 bp in length and the other 1180 bp in length 
corresponding to pUC57 and idmI. These results indicated that the ligation reaction 
was contaminated by the pUCidmI plasmid, as well as other unknown contaminants. 
The preparation of insert and vector DNA was repeated as was the ligation, with no 
success. Potentially, as with the pET23a digest for idmJ, the proximity of the two 
restriction sites being utilised in pET23a may have prevented efficient digestion, 
even with an extended incubation period. Additionally incomplete digestion of the 
pUCidmI plasmid was contaminating the transformation reaction. An alternative 
approach of cloning idmI into pKK223-3 was then taken. 
 
3.3.2 Cloning the prolyl dehydrogenase (idmI) into pKK223-3  
In order to clone idmI into pKK223-3, creating the plasmid pKidmI plasmid, a 
similar strategy was used as illustrated in Figure 3.6. However, PCR had to be 
utilised to alter the restriction sites at the 5’ and 3’ ends amplifying the insert idmI. 
idmI was originally designed to have an BamHI site at the 5’ end of the gene and 
EcoRI site at the 3’ end of the gene, however to use the pKK223-3 vector from the 
pKnanA precursor the nanA gene must be cut out using an EcoRI site at the 5’ end 
and PstI site at the 3’ end of the nanA gene.  
Primers designated “IdmI EcoRI For” and “IdmI PstI Rev” were designed to change 
the 5’ BamHI site to an EcoRI site and the 3’ EcoRI site to a PstI site (Sequences can 
be found in the appendix). A PCR reaction was performed using Pfu Turbo DNA 
polymerase (section 2.2.2.4). Figure 3.22 shows samples taken from PCR reactions 
set-up to contain 0.1, 1 and 10 ng of template DNA.  
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Insert DNA from the 10 ng template PCR reaction (Figure 3.22, lane 3) was purified 
using a QIAquick
®
 PCR purification kit (section 2.2.2.5) and digested with 
EcoRI-HF
®
 and PstI-HF
®
. The subsequent product, the insert, was purified in the 
same manner as the PCR product. A ligation reaction was then performed between 
the insert and the pKnanA vector digested with EcoRI-HF
®
 and PstI-HF
®
. 
Subsequent constructs from the ligation reaction were transformed into E.coli XL10 
Gold cells and the correct plasmid screened for by restriction digests using 
EcoRI-HF
®
 and PstI-HF
®
. Figure 3.23 shows purified plasmid DNA from the 
pKK223-3 ligation with idmI digested with EcoRI-HF
®
 and PstI-HF
®
.  
 
 
 
Figure 3.22- 0.7 % (w/v) agarose gel of the PCR reaction to amplify the idmI gene. 
PCR reactions were set up with (1) 0.1 ng (2) 1 ng and (3) 10 ng template DNA. idmI 
was amplified from the pUCidmI using primers to change the 5’ and 3’ restriction 
sites to EcoRI and PstI respectively. 
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A pKidmI plasmid digested with EcoRI-HF
®
 and PstI-HF
®
 should yield two bands, 
one at approximately 4.6 kb (4586 bp) and a second at 1.2 Kb (1180 bp). Plasmid 
DNA in lanes 2, 4, 5 and 10 show bands at 2700 bp corresponding to pUC57 and an 
unknown DNA fragment 300 bp in length. Plasmid DNA in lanes 3 and 6 digested 
with EcoRI-HF
®
 and PstI-HF
®
 yielded one DNA fragment approximately 4.6 kb 
corresponding to pKK223-3, without an insert present. Digestion of plasmids 7 and 9 
(lane 7 and 9) yielded two DNA fragments, 2700 bp and 1500 bp corresponding to 
pUC57 and an unknown insert respectively. Finally, plasmid DNA in lanes 1 and 8 
digested with EcoRI-HF
®
 and PstI-HF
®
  yielded two DNA fragments, one 4.6 kb in 
length and a second 1.2 kb indicating that plasmids 1 and 8 are the pKidmI construct. 
Subsequent DNA sequencing of plasmid 1 from Figure 3.22 provided further 
confirmation of obtaining the correct construct, pKidmI plasmid (section 2.2.2.12). 
The pKidmI plasmid was transformed into E. coli XL10 Gold cells and a glycerol 
stock made (section 2.2.1.6 and 2.2.2.11).  
3.3.3 Recombinant protein expression of the prolyl dehydrogenase (IdmI) 
After successful sub-cloning of idmI into pKK223-3, the pKidmI construct was 
transformed into E. coli BL21 (DE3) Gold cells for protein expression and a glycerol 
stock made. Small-scale protein expression trials were attempted on a 5 mL culture 
Figure 3.23-0.7 % (w/v) agarose gel of plasmid DNA purified ten colonies from 
the ligation between idmI and pKK223-3 after being digested with EcoRI-HF
®
 
and PstI-HF
®
. A pKidmI plasmid digested with EcoRI and PstI should yield two 
DNA fragments, one at 4.6 kb and the other at 1.2 kb. Plasmid in lanes 2, 4, 5 and 
10 show two DNA fragments, one  fragment 2700 bp in length corresponding the 
correct length of pUC57, and a second unknown DNA fragment approximately 
300 bp. Plasmid DNA in lanes 3 and 6 show a single band at approximately 4.6 kb 
corresponding to pKK223-3. Plasmid DNA in lanes 7 and 9 yielded two bands, 
one at 2.7 kb corresponding to pUC57 and the second unknown DNA fragment 
approximately 1.5 kb in length. Plasmid DNA digested in lanes 1 and 8 has 
yielded two fragments, one at 4.6 kb and the other at 1.2 kb corresponding to 
pKK223-3 and idmI respectively. 
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scale in TB, 2 × TY, LB and autoinduction medium at 37 °C, 21 °C and 18 °C as 
described for the pETidmJ plasmid (section 3.2.4). The soluble cellular components 
were subject to analysis by SDS-PAGE in order to identify protein expression. The 
expected mass for IdmI as calculated from the amino acid sequence of the synthetic 
gene is 41 191 Da. The blue arrow in Figure 3.24 indicates the expected mass of 
IdmI.  
 
Figure 3.24- Reducing SDS-PAGE analysis of soluble protein produced in the 
expression conditions trialled for pKidmI. Expression conditions for pKidmI. Lanes 1-3 
is soluble protein expressed in TB medium at 37 °C, room temperature and 18 °C 
respectively. Lanes 4-6 is soluble protein expressed in 2 × TY medium 37 °C, room 
temperature and 18 °C respectively. Lanes 7-9 is soluble protein expressed in LB 
medium at 37 °C, room temperature and 18 °C respectively. Finally lanes 10-12 is 
soluble protein expressed in autoinduction medium at 37 °C, room temperature and 
18 °C respectively. The blue arrow indicates where a protein band for IdmI would 
occur.  
The SDS-PAGE gel in Figure 3.24 shows the soluble protein expressed in E.coli 
BL21 (DE3) Gold cells containing the pKidmI plasmid in TB, 2 × TY, LB and 
autoinduction medium at 37°C, 21°C and 18°C. There does not appear to be a 
protein band at the expected mass for IdmI in the SDS-PAGE gel. This suggests that 
IdmI was not expressed as a soluble protein, therefore as with the pET(2)idmJ 
plasmid, an anti polyHistidine antibody was used as a more sensitive probe for 
Results one 
109 
 
protein expression in the soluble and insoluble cell fractions.  Figure 3.25 shows the 
results for probing for the His6-tag of IdmI in the soluble and insoluble fractions.  
 
 
 
 
 
 
 
 
In order to identify expression conditions that produced soluble protein an anti 
polyHistidine antibody was used to detect the N terminal His6-tag of IdmI from the 
soluble and insoluble fractions of the expression trial. Figure 3.25 shows no 
reactivity patches indicating there was too little or no His6-tagged protein present. 
Expression of IdmI from the pKidmI plasmid in E. coli BL21 (DE3) Gold cells was 
unsuccessful in TB, 2 × TY, LB and autoinduction medium at 37°C, 21°C and 18°C. 
This therefore led to exploring alternative methods for protein expression.  
 
3.3.4 Cloning the prolyl dehydrogenase (idmI) into pMAL-c5X 
Since soluble and insoluble IdmI was not expressed from the pKidmI plasmid, it was 
decided to clone IdmI into a pMAL vector, creating pMALidmI. Cloning IdmI into a 
pMAL vector will create a fusion protein with a maltose binding protein (MBP) tag. 
Although a clear explanation of why MBP helps with protein solubility does not 
exist, it has been hypothesised that a large soluble affinity tag will encourage the 
otherwise insoluble protein to be more soluble (Rosano and Ceccarelli, 2014). 
To create an MBP-IdmI fusion protein the restriction sites for idmI were changed to 
NdeI and EcoRI restriction sites at the 5’ and 3’ of the gene respectively using the 
Figure 3.25- N-terminal His6-tag detection in IdmI expression trials. Soluble (top 
row) and insoluble (bottom row) fractions were blotted onto nitrocellulose 
membrane and an anti His6-tag antibody was used to detect the N terminal His6-
tag of IdmI, probing for protein expression. Blots are of E. coli BL21 (DE3) Gold 
cells containing the pKidmI plasmid grown in TB, 2 × TY, LB and autoinduction 
media at 37°C, 21°C and 18°C. The blot indicates that there was little, if any His6-
tagged protein expressed from the pKidmI construct. This is a negative display 
image for clarity. 
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“IdmI NdeI For” and “IdmI EcoRI Rev” in a similar manner to the pKidmI plasmid, 
using the same PCR conditions (section 3.3.2) (primer sequences are located in the 
appendix). The pMAL vector, pMAL-c5X, was purchased from New England 
Biolabs
®
 (Ipswich, MA, USA) (kindly gifted by Dr James Ross, Astbury Centre, 
University of Leeds). The insert and vector DNA were prepared by digesting with 
NdeI and EcoRI-HF
®
 and a ligation reaction performed as described previously for 
the pKidmI construct (section 3.3.2). Plasmid DNA was purified from 8 individual 
colonies selected from the pMAL-C5X and idmI ligation transformation plate and 
the pMALidmI plasmid screened for by restriction digest with NdeI and EcoRI-HF
®
. 
Figure 3.26 below shows the results from the restriction digest. 
 
Figure 3.26-0.7 % agarose gel of restriction digests with NdeI and EcoRI restriction 
enzymes of purified plasmid DNA from the pMAL-C5X vector and idmI ligation. 
When digested with NdeI and EcoRI a pMALidmI construct would yield two DNA 
fragments, one 5.6 kb in length (vector) and the other 1.2 kb in length (idmI).  Plasmid 
DNA in lanes 1-3 and 5, when digested with NdeI and EcoRI, yielded a single band at 
approximately 5.6 kb corresponding to pMAL-C5X. Restriction digests of Plasmid 
DNA in lanes 4 and 8 shows two bands, one corresponding to the vector (5.6 kb), the 
other approximately 2 kb in length, too large to be idmI. Finally, plasmid DNA in lanes 
6 and 7 shows two bands, one at 5.6 kb corresponding to the vector pMAL-C5X and 
the other the correct length for idmI (1.2 kb). 
 
Lanes 6 and 7 in Figure 3.26 suggests the successful sub-cloning of idmI into the 
pMAL-c5X. Plasmid 6 (lane 6) was transformed into E. coli XL10 Gold cells and 
was confirmed to be the pMALidmI construct by DNA sequencing (section 
2.2.2.12). The pMALidmI plasmid was also transformed into E. coli BL21 (DE3) 
Gold cells for protein expression and a glycerol stock made of these cells containing 
this plasmid too. 
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3.3.5 Expression of the MBP/prolyl dehydrogenase fusion protein 
A small scale protein expression trial of E. coli BL21 (DE3) Gold cells containing 
the pMALidmI plasmid was carried out as previously described for the pKidmI 
construct, screening TB, 2 × TY, LB and autoinduction medium at 37 °C, room 
temperature and 18 °C. The soluble cellular components were analysed by 
SDS-PAGE. As mentioned previously, the expected mass for IdmI is 41 191 Da, 
however the MBP-IdmI fusion protein will have a total mass of approximately 83 
kDa indicated by the blue arrow in Figure 3.27.  
 
    
  
 
 
 
 
 
The expected mass for the MBP-IdmI fusion protein is approximately 83 kDa. There 
is no clear overexpression of soluble MBP-IdmI in TB, 2 × TY, LB or autoinduction 
Figure 3.27- Reducing SDS-PAGE analysis of expression trials of the pMALidmI 
fusion protein. Protein expression trials of MBP-IdmI were carried out with E.coli 
BL21 (DE3) Gold cells containing the plasmid pMALidmI being grown and induced in 
TB, 2 × TY, LB and autoinduction media at 37 °C, room temperature and 18 °C. 
Lanes 1-3 is soluble protein expressed in TB media at 37 °C, room temperature and 
18 °C respectively. Lanes 4-6 is soluble protein expressed in 2 × TY media 37 °C, room 
temperature and 18 °C respectively. Lanes 7-9 is soluble protein expressed in LB 
medium at 37 °C, room temperature and 18 °C respectively. Finally lanes 10-12 is 
soluble protein expressed in autoinduction medium at 37 °C, room temperature and 
18 °C respectively. The blue arrow indicates where a protein band for MBP-IdmI 
fusion protein would be expected to occur, at approximately 83 kDa in mass.  
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media in the range of temperatures trialled as illustrated in the SDS-PAGE gel in 
Figure 3.27 by comparison with uninduced E. coli BL21 (DE3) Gold cells (see 
appendix). In order to determine if the MBP-IdmI fusion protein was being 
expressed as a soluble or insoluble protein, blotting for the His6-tag using an anti 
polyHistidine antibody was performed on both the soluble and insoluble cellular 
components as carried out for the pET(2)idmJ and pKidmI constructs (sections 3.2.4 
and 3.3.3). Figure 3.28 below shows results when blotting for the His6-tag in soluble 
and insoluble fractions of the expression of pMALidmI in TB, 2 × TY, LB and 
autoinduction media at 37°C, 21°C and 18°C. 
 
Figure 3.28- Detection of the N-terminal His6-tag MBP-IdmI fusion protein. Soluble 
(top row) and insoluble (bottom row) fractions from E. coli BL21 (DE3) Gold cells 
containing the pMALidmI construct being expressed in TB, 2 × TY, LB and 
autoinduction medium at three different temperatures. The His6-tag was detected using 
an anti His6-tag antibody. The blot above indicates that extremely low levels of MBP-
IdmI fusion protein were in the insoluble fractions of cells grown at 21ºC and 37 ºC. 
This is a negative display image for clarity. 
 
The MBP-IdmI fusion protein was mainly expressed as an insoluble protein, 
extremely low levels of His6-tagged protein is present in the insoluble fractions of 
cells grown in 2 × TY, LB and autoinduction medium at 37°C and 21°C as 
illustrated by Figure 3.28 (red boxes). Soluble expression of the MBP-IdmI fusion 
protein was not achieved.  
Thus far the expression of soluble IdmI had been unsuccessful, expressing the 
protein individually and as a fusion protein, however there were still a number of 
avenues to explore. The next strategy was to clone all three genes into the same 
vector and express them together. In the natural host all three proteins would be 
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expressed together and expression of IdmI may dependent upon expression of the 
other proteins within the same module (Figure 3.1).  
 
3.3.6 Cloning genes responsible for starter unit biosynthesis into pETDUET 
In an effort to express the prolyl dehydrogenase (IdmI) as a soluble protein all three 
protein were to be cloned into the same vector and expressed simultaneously. Figure 
3.29 illustrates the strategy for cloning the adenylyltransferase (IdmJ) and proline 
carrier protein (IdmK) into the same vector as IdmI creating a plasmid designated 
pET(2)idmJ/idmK/idmI. 
Results one 
114 
 
  
 
 
Figure 3.29- Proposed strategy for cloning idmJ, idmI and idmK into pETDUET. (a) 
Step one involves cloning idmI into multiple cloning site 2 in pETDUET. PCR 
amplification will be used to amplify idmI from the pUCidmI plasmid altering the 5’ 
and 5’ restriction sites to NdeI and XhoI. pETDUET will be amplified by growth of the 
plasmid in E. coli XL10 Gold cells. Both the insert and vector will be digested with 
NdeI and XhoI restriction enzymes, and are subsequently ligated together. The 
resulting constructs will be transformed into E. coli XL10 Gold cells and a potential 
pET(2)idmI plasmid screened for by restriction digests with NdeI and XhoI. 
Sequencing will confirm the pET(2)idmI plasmid. (b) The next step is to clone idmJ into 
multiple cloning site 1 of pETDUET. The pET(2)idmI plasmid and pUCidmJ plasmid 
were amplified by growth in E. coli XL10 Gold cells. Both the vector and insert DNA 
were prepared by digestion with SacI and SalI. A ligation reaction between the insert 
and vector DNA followed by subsequent transformation into E. coli XL10 Gold cells 
will be carried out. Resulting constructs will be screened by restriction digestion with 
SacI and SalI, the resulting plasmid pET(2)idmJ/idmI will be confirmed by sequencing. 
(c) The final step, cloning idmK into pET(2)idmJ/idmI, was to be cloned in a ligation 
independent manner between idmJ and idmI. PCR primers with complimentary ends 
to each other are to be used to amplify both the insert and vector. Insert and vector 
DNA can then be digested by DpnI in a 1:1 vector to insert (v:v) ratio and then 
transformed into E. coli XL10 Gold cells. Subsequent constructs can be screened by 
restriction digestion and DNA sequencing used to confirm construction of the 
pET(2)idmJ/idmK/idmI plasmid. 
 
The first step to create the pET(2)idmJ/idmK/idmI is to clone idmI into the multiple 
cloning site 2 of pETDUET. To do this, PCR primers were designed to alter the 5’ 
and 3’ restriction sites to NdeI and XhoI. Insert DNA was amplified by PCR which 
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simultaneously changed the 5’ and 3’ end restriction sites, pETDUET was amplified 
by growth of E. coli XL10 Gold cells containing the pETDUET plasmid. Both insert 
and vector DNA were digested with NdeI and XhoI and subsequently ligated 
together. A transformation was performed of resulting constructs, colony growth on 
2 × TY agar plates containing ampicillin indicated the presence of the pET(2)idmI 
plasmid. The plasmid was screened for by digestion with NdeI and XhoI restriction 
enzymes. Figure 3.30 (a) shows an agarose gel of the PCR reaction carried out to 
amplify idmI from the pUCidmI using “NdeI IdmI For” and “XhoI IdmI Rev” 
primers (primer sequences located in the appendix). Figure 3.30 (b) shows the 
agarose gel of four individual plasmids purified from four individual colonies picked 
from the transformation plates of resulting constructs from the ligation between 
pETDUET and idmI, creating a pET(2)idmI plasmid.  
 
 
 
 
 
 
 
 
 
 
The PCR amplification of idmI was successful (Figure 3.30 (a)). A positive 
pET(2)idmI clone would yield two bands on an agarose gel, one at approximately 5.5 
kb (5420 bp) corresponding to pETDUET, a second 1.2 kb (1180 bp) corresponding 
to idmI. Lanes 1 and 2 in the agarose gel in Figure 3.30 (b) show DNA bands at 
these expected sizes, suggesting the ligation between pETDUET and idmI was 
successful. Plasmid DNA in lane 1 was subsequently transformed into E. coli XL10 
Figure 3.30-0.7 % agarose gels displaying the results of steps taken to clone idmI 
into pETDUET. (a) idmI was amplified by PCR using “NdeI IdmI For” and “XhoI 
IdmI Rev” primers, the PCR reaction was carried out with 10 ng of template 
DNA. The Blue arrow indicates the size amplified idmI was expected at. (b) Four 
individual colonies were picked from the transformation plates of the ligation 
reaction between idmI and pETDUET, plasmid DNA was purified and digested 
with NdeI and XhoI. Plasmids in Lanes 1 and 2 show DNA fragments at 5.5 kb 
corresponding to pETDUET and a second fragment at approximately 1.2 kb 
corresponding to the idmI gene. Plasmid DNA in lanes 3 and 4 digested with NdeI 
and XhoI yielded a single unknown DNA fragment approximately 8 kb in length.  
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Gold cells (section 2.2.2.11), a glycerol stock made and subject to DNA sequencing 
to confirm this plasmid was the pET(2)idmI construct (section 2.2.1.6 and 2.2.2.12). 
The next stage was to clone idmJ into multiple cloning site one of the pET(2)idmI 
plasmid. Figure 3.29 (b) illustrates the strategy to be used to create the 
pET(2)idmJ/idmI plasmid. In brief, the standard cut and paste method was used to 
cut idmJ out of the pUCidmJ plasmid using the SacI and SalI sites and ligated into 
the pET(2)idmI plasmid, also digested with SacI-HF
®
 and SalI-HF
®
 restriction 
enzymes. A ligation reaction was carried out as described in section 2.2.2.8. 8 
colonies were picked from the transformation plate from the ligation reaction 
between pET(2)idmI and idmJ and the pET(2)idmJ/idmI plasmid screened for by 
digestion with SacI-HF
®
 and SalI-HF
®
 restriction enzymes. A pET(2)idmJ/idmI 
plasmid digested with SacI-HF
®
 and SalI-HF
®
 would yield two DNA fragments, one 
at approximately 6.7 kb corresponding to pETDUET (5420 bp) and idmI (1180 bp) 
and a second DNA fragment at 1.5 kb corresponding to idmJ (1540 bp).  
 
 
 
 
 
 
 
 
 
 
Figure 3.31-0.7% agarose gel of restriction digests with SacI-HF
®
 and SalI-HF
® 
of 
plasmid DNA from 8 colonies screening for the pET(2)idmJ/idmI plasmid. 8 individual 
colonies were selected from the resulting constructs from the pET(2)idmI and idmJ 
ligation transformation. Digestion of plasmid DNA in lane 1 yielded two DNA 
fragments, both unknown fragments, one fragment >10 kb and the second 
approximately 4.5 kb. Digestion of plasmid DNA in lanes 2, 7 and 8 yielded two DNA 
fragments, one at approximately 6.7 kb and a second at 1.5 kb corresponding to 
pET(2)idmI and idmJ respectively. Plasmid DNA in lane 3, digested with SacI-HF
®
 
and SalI-HF
®
 yielded at single band at approximately 5.5 kb, corresponding to the 
pET(2)idmI plasmid. Plasmid DNA in lanes 4 and 6 also yielded a single band when 
digested with SacI-HF
®
 and SalI-HF
®
, this time an unknown DNA fragment at 
approximately at 8 kb. Finally restriction digestion of plasmid DNA in lane 5 yielded 
two DNA fragments one at ~5 kb and a second at 2 kb from an unknown origin. 
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To create the pET(2)idmJ/idmI plasmid, idmJ had to be cloned into the first multiple 
cloning site of pETDUET using the SacI and SalI restriction sites. Figure 3.31 is the 
agarose gel of the resulting constructs from a ligation between pET(2)idmI and idmJ 
digested with SacI-HF
®
 and SalI-HF
®
. Plasmid DNA in lanes 1, 4, 5 and 6 yielded 
DNA fragments of varying sizes that were unidentified. Plasmid DNA in lane 3 
corresponded to the pET(2)idmI plasmid, idmJ was not present. Although the 
plasmid in lane 8 appears to display bands corresponding to pET(2)idmI and idmJ 
there are additional bands above the band corresponding to pET(2)idmI, therefore 
indicating the presence of DNA fragments of unknown origin. Plasmid DNA in lanes 
2 and 7 however did yield two DNA fragments, one at 6.7 kb and a second at 1.5 kb 
corresponding to pET(2)idmI and idmJ respectively. This indicates that the 
pET(2)idmJ/idmI construct has been made. Plasmid DNA from lane 2 was 
transformed into E. coli XL10 Gold cells, a glycerol stock made. DNA sequencing 
with sequencing primers “pET UPSTREAM” and “DUETDOWN1” was used to 
confirm that idmJ was cloned into multiple cloning site one of pETDUET (primer 
sequences are located in the appendix).  
The final stage in creating the pET(2)idmJ/idmK/idmI clone was to utilise a ligation 
independent cloning method called FastCloning (Li et al., 2011) to sub-clone idmK 
into the pET(2)idmJ/idmI plasmid to express all three proteins together. Figure 3.28 
(c) illustrates the FastCloning strategy to be used. In short, insert DNA from 
pUCidmK was amplified using primers designated “IdmK Triple Clone For” and 
“IdmK Triple Clone Rev”. The PCR primers used to amplify the pET(2)idmJ/idmI 
plasmid were designated “pET(2)idmJ/idmI Triple Clone For” and “pET(2)idmJ/idmI 
Triple Clone Rev”. Amplification with these primers created overlapping 
complimentary ends between “IdmK Triple Clone For” and “pET(2)idmJ/idmI Triple 
Clone Rev” and between “IdmK Triple Clone Rev” and “pET(2)idmJ/idmI Triple 
Clone For” (primer sequences are located in the appendix). Results from the PCR 
reactions can be seen in Figure 3.32. 
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The agarose gel in Figure 3.32 shows the successful amplification of idmK (lanes 3 
and 4) and pET(2)idmJ/idmI (lanes 1 and 2). idmK and pET(2)idmJ/idmI were mixed 
in a 1:1 volumetric ratio and digested with DpnI for 1 hour. DpnI digests the 
template DNA from the reaction but is also said to possess a small amount of non-
specific exonuclease activity and randomly removes a few DNA bases off the ends 
of the insert and vector DNA, thus creating complimentary sticky ends. The DpnI 
digested DNA was then transformed into E. coli XL10 Gold cells. Subsequent 
colony growth on 2 × TY agar plates containing ampicillin indicated the presence of 
the pET(2)idmJ/idmK/idmI plasmid. Restriction digests were performed with 
SacI-HF
®
 and XhoI. Digestion of the pET(2)idmJ/idmK/idmI plasmid with these 
restriction enzymes expected to yield three DNA fragments, one 1.8 kb in length 
corresponding to idmJ and idmK as one fragment, one 1.2 kb in length corresponding 
to idmI and finally a band at 5.5 kb corresponding to pETDUET. Figure 3.33 below 
shows the restriction digest of the pET(2)idmJ/idmK/idmI plasmids purified from  a 
colony from the transformation of DpnI digested DNA. 
Figure 3.32- PCR amplification of pET(2)idmJ/idmI and idmK. Both sets of PCR 
reactions were carried out using whole cell lysate of E. coli XL10 Gold cells 
containing either the pET(2)idmJ/idmI or pUCidmK plasmids. M1 is 1 kb marker 
and M2 is 100 bp marker. PCR reactions in lanes 1 and 2 are pET(2)idmJ/idmI 
using 10 and 50 × dilution of the starter culture of . coli XL10 Gold cells 
containing the pET(2)idmJ/idmI plasmid. Presence of a band in both conditions at 
approximately 8.2 kb corresponds successful amplification of the 
pET(2)idmJ/idmI plasmid. PCR reactions in lane 3 and 4 shows the successful 
amplification of idmK from 10 and 50 × dilution of the starter cultures of E. coli 
XL10 Gold cells containing the pUCidmK plasmid. The band at approximately 
350 bp corresponds to idmK. 
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Figure 3.32 illustrates the potential pET(2)idmJ/idmK/idmI plasmid created using the 
FastCloning strategy. This plasmid was subsequently transformed into E. coli XL10 
Gold cells and the plasmid sequenced with the “pETUPSTREAM” and 
“DUETDOWN1” sequencing primers. This confirmed the presence of idmK in the 
pET(2)idmJ/idmK/idmI plasmid from Figure 3.32. The next stage was to attempt 
protein expression.  
 
3.3.7 Recombinant tandem expression of IdmJ, IdmI and IdmK 
The pET(2)idmJ/idmK/idmI plasmid was transformed into E. coli BL21 (DE3) Gold 
cells for the purposes of protein expression. Small scale protein expression trials 
were carried out, testing soluble protein expression in TB, 2 × TY, LB and 
autoinduction medium at 37°C, 21°C and 18°C as described for IdmJ in section 
3.2.4. The soluble cellular fractions for E. coli BL21 (DE3) Gold cells containing the 
pET(2)idmJ/idmK/idmI plasmid were analysed by SDS-PAGE (Figure 3.33). The 
expected masses of IdmJ, IdmI and IdmK are approximately 53 kDa, 41 kDa and 11 
kDa respectively, indicated by the red, blue and green arrows in Figure 3.34. 
 
  
Figure 3.33-0.7 % agarose gel of the pET(2)idmJ/idmK/idmI plasmid 
digested with SacI-HF
®
 and XhoI. The pET(2)idmJ/idmK/idmI clone 
yielded three DNA fragments, one at 5.5 kb, a second at 1.8 kb and a 
third at 1.2 kb corresponding to pETDUET, idmJ and idmK in one 
fragment and idmI respectively. 
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Analysis of the SDS-PAGE gel (Figure 3.34) of soluble cell fractions from the 
IdmJ/IdmK/IdmI tandem expression trials, in comparison to uninduced E. coli BL21 
(DE3) Gold cells (See appendix), suggests that IdmK may have been expressed as 
soluble protein in all media barring autoinduction medium and at all three expression 
temperatures. It is unclear as to whether IdmI and IdmJ had been overexpressed in 
any of these conditions due to a lack of obvious protein bands at the expected 
masses.  
In order to probe the tandem expression of IdmJ and IdmI with IdmK a western blot 
was performed (section 2.2.3.3). Figure 3.34 shows that IdmK was expressed as 
soluble protein in all conditions apart from autoinduction medium. Probing for the 
His6-tag in the soluble fraction may well give a positive result solely due to the 
Figure 3.34- Reducing SDS-PAGE gel analysing soluble cell fractions from 
IdmJ, IdmI and IdmK tandem expression. Tandem expression of IdmJ, 
IdmI and IdmK was attempted by culturing E. coli BL21 (DE3) Gold cells 
containing the pET(2)idmJ/idmK/idmK plasmid in TB medium at 37 °C, 
21 °C, 18 °C (lanes 1, 5 and 9 respectively),  2 ×TY at 37 °C, 21 °C, 18 °C 
(lanes 2, 6 and 10 respectively), LB at 37 °C, 21 °C, 18 °C (lanes 3, 7 and 11 
respectively) and autoinduction medium at 37 °C, 21 °C, 18 °C (lanes 4, 8 
and 12 respectively). Expected molecular masses for IdmJ, IdmI and IdmK 
are highlighted; IdmJ has a molecular mass of approximately 53 kDa (red 
arrow), IdmI has a molecular mass of approximately 41 kDa (blue arrow) 
and IdmK has a mass of approximately 11 kDa (green arrow).  
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presence of IdmK and will provide no further information as to whether IdmJ or 
IdmI were being expressed as soluble proteins. A western blot enabled 
discrimination of which proteins were being expressed as soluble proteins as they are 
separated by size on an SDS-PAGE gel. Figure 3.35 shows the results of the western 
blot performed of expression of pET(2)idmJ/idmK/idmI plasmid in TB and LB 
medium at 21°C, which indicated there was soluble protein expression in a prior 
His6-tag screen. 
 
   
 
 
 
 
The western blot (Figure 3.35) showed that when the pET(2)idmJ/idmK/idmI 
plasmid was expressed in E. coli BL21 (DE3) Gold cells, soluble protein was 
expressed at 21°C in TB (Figure 3.35 Lane 1) and LB (Figure 3.35 Lane 2) medium. 
However, the approximate size of the protein expressed was comparable to that seen 
when expressing the pET(2)idmJ plasmid, indicating that only soluble IdmJ was 
expressed (SDS-PAGE in Figure 3.13). This was also true for expression the 
pET(2)idmJ/idmK/idmI plasmid at 18°C. 
Figure 3.35- Western blot probing for soluble protein expression. A prior dot blot 
was performed to identify soluble protein expression. Samples that indicated the 
presence of soluble protein were run on an SDS-PAGE, and a western blot 
performed probing for the His6-tag. Lane 1 is the pET(2)idmJ/idmK/idmI plasmid 
expressed at 21°C in TB medium. Lane 2 is the pET(2)idmJ/idmK/idmI plasmid 
expressed at 21°C in LB medium. The contrast of the western blot was altered for 
ease of viewing and superimposed on the ladder for reference. 
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3.3.8 Summary and conclusions 
After initial difficulties in cloning idmI into pET23a, the gene was successfully 
cloned into pKK223-3. Expression trials of the pKidmI plasmid however did not 
yield any soluble protein (Figure 3.25). In order to express soluble protein idmI was 
then cloned into a pMAL-c5X vector to create a pMALidmI construct, expressing 
IdmI as a fusion construct with the maltose binding protein (MBP). Again, 
expression of a soluble fusion protein was not achieved. Probing for the His6-tag 
indicated that the expression of IdmI may be somewhat temperature dependent 
(Figure 3.28). Tandem expression of IdmI with IdmJ and IdmK from the 
pET(2)idmJ/idmK/idmI plasmid did not yield soluble IdmI either (Figure 3.35). The 
fact that protein is continually expressed as an insoluble aggregate may indicate that 
IdmI is not being folded correctly. This may be due to E. coli’s inability to form 
disulphide bonds in the cytoplasm. A cell line like Origami2 (DE3) could be used in 
attempts to express soluble protein (Bessette et al., 1999). An additional option 
includes unfolding insoluble aggregates in 8 M urea followed by refolding to 
resolubilise IdmI. The latter of these two options will require screening for a 
refolding buffer and optimisation. No biochemical or structural characterisation 
could be carried out as no soluble protein was purified.  
 
3.4 Discussion 
Attempts at heterologous expression of the proteins responsible for starter unit 
construction in indanomycin biosynthesis began with cloning and expression of IdmJ 
and IdmI, the adenylyltransferase and dehydrogenase. IdmJ was, to some extent, 
successfully expressed heterologously, but contains an unidentified post-translational 
modification. IdmI was unable to be successfully, heterologously expressed in E. coli 
as a soluble protein.  
Figure 3.20 shows a schematic to explain what may be occurring when expressing 
IdmJ and the IdmJ variants. It suggests that mutating C127A could be creating an 
active adenylyltransferase that can load phosphopantetheine, which may be present 
in the cell, with proline. Mechanistic determination of a PKS module by Whicher et 
al. (2014) showed that for successful chain elongation and β-keto processing, 
specific protein-protein interactions with the carrier protein and corresponding 
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enzyme within the module was required. This may indicate that C127A was able to 
load phosphopantetheine with proline but unable to release the subsequent product as 
the system lacked the cognate carrier protein. Further experimental evidence for this 
theory could be provided using traditional feeding as carried out with PKS, using 
radiolabelled proline (Birch et al., 1955; Day and Mantle, 1982; Staunton and 
Weissman, 2001). Optimisation and purification of cysteine variants, especially 
C127A, may also allow biochemical characterisation, and determine if the variants 
were expressing as fully folded and functional enzymes.  
As mentioned previously, other enzymes required for pyrrole formation in the same 
manner have been reconstituted in E. coli. The genes of pyrrole forming enzymes in 
clorobiocin and coumermycin biosynthesis were obtained by PCR amplification 
from cosmids containing genomic DNA, cloned into pET vectors and expressed 
from E. coli BL21 (DE3) cells (Garneau et al., 2005). It is interesting to note that 
expression and MS analysis of these proteins also showed the +178 Da species seen 
when expressing IdmJ (Garneau et al., 2005; Geoghegan et al., 1999).  
There are a number of strategies still available to produce soluble IdmI. One such 
strategy includes obtaining the gene from genomic DNA and introducing a C-
terminal His6-tag as with the dehydrogenase found in clorobiocin biosynthesis. 
Expression could be carried out in E. coli cells which aid in disulphide bond 
formation such as E. coli Origami (DE3) cells. Finally, another option is to unfold 
the IdmI insoluble aggregate and screen for a refolding condition. Biochemical and 
structural characterisation using techniques such as circular dichroism may provide 
evidence a fully folded functional enzyme has been obtained.  Formation of a pyrrole 
by an NRPS in an NRPS/PKS hybrid enzyme, specifically as a starter unit, may 
require the rest of the enzyme, the downstream PKS modules, to dock onto and fold. 
This may have been why difficulties in soluble expression of individual domains 
were encountered. Reconstitution of the starter module with a downstream PKS 
module may provide evidence for this.  
The next chapter in this thesis will cover cloning and expression of the third protein 
in this module, the prolyl carrier protein, IdmK. 
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4.    Cloning, expression and characterisation of the 
peptidyl carrier protein from the starter module in 
indanomycin biosynthesis 
As described in the introduction (section 1.4), nonribosomal peptide synthetases 
(NRPS) are large multimodular proteins, with a minimal module being composed of 
an adenylation domain, condensation domain and finally a peptidyl carrier protein. 
Within the NRPS modules, the carrier protein (CP), a non-catalytic protein, is 
essential for function. The phosphopantetheinylated CP houses the growing 
nonribosomal peptide (NRP) chain, receiving it from the CP within the preceding 
module. The CP then “passes” the extending chain to the CP in the following the 
module. The carrier proteins are post-translationally modified by an auxiliary 
enzyme, a phosphopantetheinyl transferase (PPTase), which modifies a conserved 
serine, adding a 4’-phosphopantetheine, providing a thiol for attachment of the 
extending chain (Lambalot et al., 1996). Chain elongation occurs in an assembly-line 
like fashion with each module responsible for adding a single unit to the extending 
chain. The extending unit selected by the AT/A domain residing on the ACP/PCP 
undergoes condensation with the extending chain catalysed by the KS/C domain 
(Meier and Burkart, 2009; Fischbach and Walsh, 2006). 
The prolyl carrier protein (IdmK) is the post-translationally modified non-catalytic 
essential domain in the starter module of the indanomycin biosynthetic gene cluster. 
After receiving the activated L-proline from the adenylyltransferase (IdmJ) (section 
3.2) the IdmK bound L-proline becomes a substrate for further modification by IdmI 
(section 3.3) before the starter unit, pyrrole-2-carboxylate, is handed onto the next 
module in the NRPS-PKS multienzyme (Li et al., 2009). Figure 3.1 shows the role 
of IdmK in starter unit biosynthesis in the indanomycin biosynthetic gene cluster. 
In a number of previous studies, various NRPS and PKS carrier proteins have been 
recombinantly expressed in E. coli, not only as individual domains but also as part of 
reconstituted modules and extensive structural studies have been carried out (Crosby 
and Crump, 2012; Chan and Vogel, 2010; Meier and Burkart, 2009). Studies have 
been conducted attempting to phosphopantetheinylate the conserved serine with 
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exogenous PPTases, exploring not only the carrier protein but the PPTases tolerance 
for modification (Beld et al., 2014). 
The carrier protein, a small protein of less than 100 amino acids, is an essential part 
of the modular enzymes. The carrier protein must have the ability to “communicate” 
with other domains within its own module to receive substrates and with domains in 
adjacent modules in order to pass and receive the extending chain (Tran et al., 2010; 
Weissman and Muller, 2008; Crosby and Crump, 2012). Structural and dynamic 
information including protein-protein interactions could provide insight into how this 
protein functions, in the hope of engineering it for the production of novel 
compounds. Figure 1.10 shows the proposed mechanism (from cryo-EM data) by 
which acyl carrier proteins interact with each domain involved in substrate selection, 
catalysis and modification meting chain elongation (Dutta et al., 2014; Whicher et 
al., 2014). These mechanistic findings show that chain elongation is very much 
carrier protein centric, with the carrier protein being essential for chain elongation 
and modification, and further emphasises the importance in understanding a carrier 
protein and its interactions with other domains within its own, and subsequent 
modules (Dutta et al., 2014; Whicher et al., 2014; Nguyen et al., 2014).  
Cloning, protein expression and purification followed by structural characterisation 
of IdmK will hopefully enable mechanistic insights into how chain elongation occurs 
during indanomycin biosynthesis as well as allowing the fundamental  protein-
protein interactions of the carrier protein to be determined.  
 
4.1 Cloning the peptidyl carrier protein (idmK) 
4.1.1 Cloning the peptidyl carrier protein (idmK) into pET23a 
The synthetic idmK gene was designed with HindIII and XhoI sites at the 5’ and 3’ 
ends of the gene, respectively. As with the two previous genes (Chapter 3), the sites 
were selected specifically for sub-cloning idmK into pET23a using the cut-and-paste 
method (as illustrated in Figure 3.3). Insert DNA was prepared in an identical 
manner to idmJ and idmI however the restriction enzymes HindIII-HF
®
 and XhoI 
were used to digest the pUCidmK plasmid. The pET23a vector was digested with the 
same restriction enzymes, creating complimentary sticky ends. Vector and insert 
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DNA were then run on a 0.7 % agarose gel and purified as described in section 
2.2.2.3. Ligation reactions between pET23a and idmK were performed as described 
in section 2.2.2.8. 4 µL of this ligation reaction was then transformed into E.coli 
XL10 Gold Ultracompetent cells and cells were subsequently plated onto 2 × TY 
agar plates containing ampicillin. Colony growth on the transformation plates 
suggested the presence of the desired plasmid, pETidmK. To screen for the correct 
plasmid, DNA from 10 colonies was purified and digested with HindIII-HF
®
 and 
XhoI restriction enzymes (section 2.2.2.7). Resulting constructs were analysed by 
running the digested DNA on an agarose gel. Figure 4.1 shows the results of the 
restriction digests of plasmid DNA purified from the 10 colonies selected from the 
ligation between pET23a and idmK. 
 
Figure 4.1-0.7 % agarose gel of isolated plasmid DNA from the 10 colonies selected 
from the transformation plate of the ligation reaction between pET23a and idmK. 
Plasmid DNA was digested with HindIII-HF
®
 and XhoI to screen for the pETidmK 
plasmid. The grey arrow indicates the expected size of the pET23a vector (3666 bp) 
and the green arrow indicates the expected size of idmK (325 bp). Plasmid DNA in lane 
1 appears to remain undigested plasmid DNA. In lanes 2, 4 and 6 plasmid DNA 
digested with HindIII-HF
®
 and XhoI yielded two DNA fragments at approximately 
2700 bp and 325 bp corresponding to the original vector pUC57 and idmK. Plasmid 
DNA in lane 3 digested with HindIII-HF® and XhoI yielded a single band at 
approximately 3000 bp, this corresponds to the pUCidmK plasmid digested at a single 
point. Plasmid DNA in lane 5 appears to be 2700 bp corresponding to empty pUC57. 
The plasmid purification in lane 7 appears to have been unsuccessful. Finally plasmid 
DNA in lanes 8, 9 and 10 digested with HindIII-HF
®
 and XhoI show a single band at 
approximately the correct size for pET23a alone (3666 bp). 
 
A pETidmK plasmid digested with HindIII and XhoI should yield two bands on a 
DNA gel; a band at 3666 bp corresponding to pET23a and a second band at 325 bp 
corresponding to idmK. Figure 4.1 indicates the ligation between pET23a and idmK 
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was unsuccessful. Plasmid DNA in lane 1 appears to have remained undigested by 
HindIII-HF
®
 and XhoI, indicating it is not the pETidmK plasmid. Plasmid DNA in 
lanes 2, 4 and 6 show DNA fragments 2700 bp and 325 bp in length corresponding 
to pUC57 and idmK, this is indicative of pUCidmK contamination of the ligation 
reaction. Plasmid DNA in lanes 3, 5, 8, 9 and 10 digested with HindIII-HF
®
 and 
XhoI show single DNA fragments of varying sizes, none of these plasmids appear to 
contain the expected 325 bp insert corresponding to idmK. Further attempts were 
made to clone idmK into pET23a however this approach was not successful. The 
next strategy was to clone IdmK into pKK223-3 plasmid as attempted with idmJ and 
idmI.  
 
4.1.2 Cloning the peptidyl carrier protein (idmK) into pKK223-3 
As with idmJ and idmI the next vector selected for sub-cloning idmK was pKK223-3 
(as illustrated in Figure 3.6), creating a plasmid designated pKidmK. To prepare the 
insert, restriction digests were carried out with the pUCidmK plasmid and pKnanA 
plasmid using EcoRI-HF
®
 and PstI-HF
®
 creating complimentary sticky ends for 
ligation (section 2.2.2.7). Digested plasmids were run on a 0.7 % agarose gel and 
insert and vector DNA extracted from the gel (section 2.2.2.3). A ligation reaction 
was then carried out between pKK223-3 and idmK digested with EcoRI-HF
®
 and 
PstI-HF
®
. 4 µL of the ligation reaction was transformed into E. coli XL10 Gold 
Ultracompetent cells. Successful ligation of idmK and pKK223-3 was indicated by 
cell growth on 2 × TY agar plates containing ampicillin. 10 colonies were selected 
from the transformation plates, plasmid DNA purified, and the pKidmK plasmid 
screened by restriction digestion with EcoRI-HF
®
 and PstI-HF
®
. A pKidmK plasmid 
digested with EcoRI-HF
®
 and PstI-HF
®
 restriction enzymes should yield two DNA 
fragments, one at 4600 bp and a second at 325 bp corresponding to pKK223-3 and 
idmK respectively. Figure 4.2 below shows the results from the restriction digests 
screening for the pKidmK plasmid. 
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Figure 4.2-0.7 % agarose gel showing restriction digests of purified plasmid DNA from 
the pKK223-3 idmK ligation. Plasmid DNA was purified from 10 colonies and digested 
with EcoRI-HF
®
 and PstI-HF
®
 to screen for the pKidmK plasmid. Plasmid DNA in 
lanes 1 and 2 digested with EcoRI-HF
®
 and PstI-HF
®
 have yielded a single band 
approximately 3000 bp in length, corresponding to incomplete digestion of pUCidmK. 
Digestion of plasmid DNA in lane 3 yielded two DNA fragments, one 2700 bp in length 
corresponding to pUC57 and a second 325 bp corresponding to idmK. Plasmid DNA 
digested by EcoRI-HF
®
 and PstI-HF
®
 in lanes  4 and 7 both yielded DNA fragments of 
approximately 4600 bp and 325 bp corresponding to pKK223-3 and idmK. Digestion of 
plasmid DNA in lane 5, 8 and 10 yielded two DNA fragments, one approximately 2700 
bp (pUC57) and an DNA fragment approximately 1200 bp of unknown origin. Finally 
digestion of plasmid DNA in lanes 6 and 9 yielded a single band at approximately 4600 
bp corresponding to pKK223-3.     
 
Restriction digestion of plasmid DNA in lanes 4 and 9 in Figure 4.2 shows 
successful ligation between idmK and pKK223-3, creating the pKidmK plasmid, 
exhibiting DNA bands 4.6 kb and 325 bp in length corresponding to the correct sizes 
for the pKK223-3 vector and idmK insert respectively. A glycerol stock was made of 
E. coli XL10 Gold Ultracompetent cells transformed with the plasmid from lane 4. 
Confirmation of the pKidmK plasmid was obtained by DNA sequencing of plasmid 
4 with the sequencing primers “PTRC-99A-FOR” and “PTRC-99A-REV” 
(sequences can be located in the appendix). Sequencing showed that the pKK223-3 
vector contained the correct insert. The sequenced pKidmK plasmid was then 
transformed into E. coli BL21 Gold (DE3) cells for protein expression.  
 
4.2 Expression of the prolyl carrier protein (IdmK) 
Expression of the prolyl carrier protein was carried out using E.coli BL21 Gold 
(DE3) cells transformed with the pKidmK plasmid. A small scale protein expression 
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of the putative S. antibioticus prolyl carrier protein (IdmK) was tested on a 5 mL 
scale, in 2 × TY medium at 37°C as with IdmJ (section 3.2.4). Soluble and insoluble 
cellular components of lysed cells were analysed by SDS-PAGE in order to evaluate 
whether IdmK was expressed as a soluble protein (Figure 4.3). 
 
 
 
 
 
      
 
The expected mass of IdmK, as calculated from the amino acid sequence of the 
synthetic gene, is approximately 11044 Da, as indicated by the green arrow in Figure 
4.3. The SDS-PAGE gel in Figure 4.3 suggests that IdmK has been expressed as a 
soluble protein, indicated by the presence of a band at the expected mass in the 
soluble fraction of the E. coli BL21 (DE3) Gold cells transformed with the pKidmK 
plasmid (lane 2). This protein band is absent in the insoluble fraction providing 
validation that IdmK is expressed as a soluble protein. 
 
4.3 Purification of the prolyl carrier protein (IdmK)  
Protein expression was repeated on a larger (1 L) scale. IdmK was then purified by 
nickel affinity chromatography as described in section 2.2.3.4. Samples were taken 
at each stage of the purification and analysed by SDS-PAGE (Figure 4.4). 
 
Figure 4.3- Reducing SDS-PAGE analysis of insoluble (lane 1) and soluble (lane 2) 
fractions suggested that IdmK was successfully expressed as soluble protein 
(indicated by the green arrow) in 2 × TY media at 37 °C. 
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Figure 4.4 (lane 9) suggests that IdmK has successfully been purified using nickel 
affinity chromatography although two bands were seen. To provide further evidence 
IdmK had been successfully purified and to determine more accurate masses of the 
two species, a 70 µL sample of eluted protein was desalted into 50 mM ammonium 
acetate pH 7.4 (section 2.2.3.9) for analysis by ESI-MS (section 2.2.3.12). Figure 4.5 
shows the results of ESI-MS analysis of the purification of IdmK. 
Figure 4.4- Reducing SDS-PAGE analysis of the purification of IdmK by nickel 
affinity chromatography. IdmK was expressed in E. coli BL21 (DE3) gold cells 
induced by IPTG (1), cells were harvested, lysed and the soluble (2) and insoluble (3) 
fractions separated by centrifugation. The soluble supernatant was then incubated 
with nickel resin for one hour, the supernatant (4) was discarded and the resin was 
washed with a low imidazole buffer (20 mM) (5-8) to remove non-specifically bound 
proteins. IdmK was then eluted from the resin using a high imidazole elution buffer 
(0.5 M) (9). Two dominant protein species were eluted from the resin, one 
approximately 11 kDa (dark green arrow) possibly corresponding to IdmK, the 
second (light green arrow) with an approximate mass of 22 kDa. 
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Figure 4.5- ESI-MS of the eluted protein from the purification of IdmK. A sample of 
eluted protein (Figure 4.4, lane 9) was desalted into 50 mM ammonium acetate pH 7.4 
and analysed by ESI-MS to obtain a molecular mass of the species present. (Top) Mass 
spectrum raw data; (bottom) deconvoluted mass spectrum of raw data showing the 
masses of proteins purified. Two species were detected, one at 11 044 Da, and a second 
at 22 768 Da. 
 
The expected mass of IdmK as calculated from the amino acid sequence of the 
synthetic gene is 11045 Da (Table 4.1). This mass of apo-IdmK does not include 
post-translational modification of the carrier protein by phosphopantetheinylation. 
After modification the mass expected for phosphopantetheinylated IdmK, holo-
IdmK, should be 11 386 Da (Table 4.1). The mass spectrum (Figure 4.5) shows that 
apo-IdmK, with a mass of 11 044 Da, was purified as one of the species, while the 
mass of the second protein species eluted during purification (Figure 4.4 lane 9) (22 
768 Da) corresponds to the mass that would be expected for dimeric holo-IdmK. A 
possibility is that dimerisation might occur through the terminal thiol of the 
phosphopantetheine group. This dimerisation would create a non-functional covalent 
dimer with an expected mass of 22 770 Da, compared to the 22 768 Da.   
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Sample Nomenclature  Expected mass 
IdmK apo-IdmK 11 045 
Phosphopantetheinylated IdmK holo-IdmK 11 386 
Table 4.1- Table showing the expected masses of IdmK as calculated from 
the amino acid sequence. 
 
In order to test the idea that a covalent dimer was being formed through disulphide 
bond formation between the terminal thiol groups of the phosphopantetheine 
modification of holo-IdmK the two protein species were further purified and 
characterised. The protein eluted from the nickel affinity purification was subject to 
further purification by size exclusion chromatography, thus separating dimeric and 
monomeric IdmK by size. Figure 4.6 shows the size exclusion chromatography trace 
for IdmK. SDS-PAGE analysis was used to confirm the separation of the two 
species. 
 
Figure 4.6- Purification of IdmK by size exclusion chromatography. Size exclusion 
chromatography trace, the Y axis shows the absorbance of the eluent. The X axis shows 
the volume. Fractions from peak 1 and peak 2 were run on SDS-PAGE gels (inset). The 
light green arrow indicates the potentially dimeric form of IdmK and the dark green 
arrow indicates the monomeric form of IdmK.   
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IdmK was gel filtered using a HiLoad Superdex 75 prep grade (S75) column (Figure 
4.6).  The dimeric species (Figure 4.6 peak 1) eluted from the S75 column between 
160 and 180 mL, while monomeric apo-IdmK (Figure 4.6 peak 2) was eluted 
between 190 mL and 210 mL. Samples from the peak fractions were analysed by 
SDS-PAGE (Figure 4.6). 
To provide evidence that IdmK was assembling as a dimer through the formation a 
disulphide bind between the terminal thiol of the phosphopantetheine modifications, 
Tris (2-carboxyethyl) phosphine (TCEP) was used as a reducing agent to break the 
suspected disulphide bond. A 70 µL sample was taken from peak one of the size 
exclusion chromatography trace shown in Figure 4.6, indicated to be dimeric IdmK, 
and was desalted into 50 mM ammonium acetate pH 7.4. TCEP was added to the 
sample to a final concentration of 5 mM and the reduced protein sample was then 
analysed by ESI-MS (Figure 4.7).  
 
 
 
Figure 4.7- ESI-MS analysis of the reduced IdmK dimer. A sample from peak one 
of size exclusion chromatography was reduced by the addition of TCEP and 
analysed by ESI-MS. A single major protein species at 11 384 Da was observed, 
this corresponds to phosphopantetheinylated IdmK (holo-IdmK). 
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The mass spectrum measured after reduction (Figure 4.7) corresponds to the 
expected mass of the monomeric holo-IdmK, with a mass of 11 384 Da (Table 4.1), 
confirming the possibility that IdmK could be oxidised to form a covalent dimer 
during the growth, cell breakage or purification. The fortuitous discovery of holo-
IdmK forming a homodimer can be utilised to purify homogeneous samples of both 
apo- and holo- IdmK. Incidentally, this result demonstrated that E. coli possesses the 
ability to phosphopantetheinylate the recombinantly expressed carrier protein. 
 
4.3.1 Confirmation of the site of phosphopantetheinylation 
The phosphopantetheinylation of IdmK, or any carrier protein, is required for 
function. The site of post-translational modification is a highly conserved serine 
residue (Quadri et al., 1998; Walsh et al., 1997; Staunton and Weissman, 2001). To 
confirm the presence of the correct post-translational modification, the conserved 
serine residue in IdmK was identified. A BLAST search followed by a multiple 
sequence alignment of similar amino acid sequences was performed identifying 
Ser44 to be conserved (appendix figure 7.3). To confirm that this was the site of 
phosphopantetheinylation, site-directed mutagenesis was used to mutate the 
conserved serine 44 to an alanine (S44A), thereby preventing the modification from 
occurring. To create the S44A variant the  pKidmK plasmid DNA was purified from 
E. coli XL10 Gold Ultracompetent cells and site-directed mutagenesis performed 
using the Stratagene QuikChange
®
 Site-Directed Mutagenesis kit (section 2.2.2.10) 
using the mutagenic primers “S44A For” and “S44A Rev” (sequences located in the 
appendix). DNA sequencing using the “PTRC-99A-FOR” and “PTRC-99A-REV”  
sequencing primers confirmed the presence of the targeted serine to alanine mutation 
(sequences located in the appendix). The pKidmK mutant plasmid was transformed 
into E. coli BL21 (DE3) Gold cells for subsequent protein expression. The IdmK 
variant was expressed and purified in an identical manner to wild-type IdmK and 
analysed by ESI-MS.  
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Figure 4.8 above shows the mass spectrum of the purified S44A IdmK variant. Only 
a single peak was observed (at 11 028 Da) corresponding to the expected mass of the 
apo-S44A variant. The lack of any covalent dimeric species along with the lack of 
any phosphopantetheinylated species confirmed the site of post-translational 
modification to be Ser44. 
Figure 4.8- ESI-MS analysis of the purified S44A IdmK variant. The IdmK S52A 
variant was expressed in E coli BL21 (DE3) Gold cells in an identical manner to 
wild-type IdmK, eluted protein was desalted into 50 mM ammonium acetate pH 7.4 
and analysed by ESI-MS.  (Top) mass spectrum raw data (bottom) deconvoluted 
mass spectrum of raw data showing the mass of the purified protein.The expected 
mass of the IdmK variant was 11 028 Da, this was observed, in addition there is 
another species identified, 57 Da larger than the IdmK variant, the potential adduct 
being a nickel ion. 
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4.4 Structural characterisation of the prolyl carrier protein 
(IdmK)  
Prior to this work a number of carrier protein structures from FAS, PKS and NRPSs 
existed in the protein data bank (PDB) the structures of which were resolved by a 
number of biophysical techniques. Table 4.2 shows examples of carrier proteins with 
structures resolved deposited in the PDB.  
PDB code Structure  Method Reference  
2JU1 Apo-ACP from module 2 of 
6-deoxyerythronalide B 
NMR 
spectroscopy 
Alekseyev et al., 2007 
1T8K Apo-ACP from FAS in E. coli X-Ray 
crystallography 
(Multi-wavelength 
anomalous 
dispersion) 
Qiu and Janson, 2004 
1L0H Butyryl-ACP from FAS in E. 
coli 
X-Ray 
crystallography 
(Multi-wavelength 
anomalous 
dispersion) 
Roujeinikova et al., 
2002 
1DNY Apo-PCP from module 3 of 
tyrocidine synthetase  
NMR 
spectroscopy 
Weber et al., 2000 
2LIU Holo-ACP from the Curacin A 
PKS 
NMR 
spectroscopy 
Busche et al., 2012 
3GZM Holo-ACP from FAS in 
Plasmodium Falciparum  
X-Ray 
crystallography 
(molecular 
replacement) 
Gallagher and Prigge, 
2010 
2LPK/2LL8 Holo/apo-ACP from FAS in 
Rhodopseudomonas palustris  
NMR 
spectroscopy 
Ramelot et al., 2012 
1AF8 Apo-ACP from the actinorhodin 
PKS in S. coelicolor A3(2) 
NMR 
spectroscopy 
Crump et al., 1997 
1NQ4 Apo-ACP from oxytetracycline 
PKS  
NMR 
spectroscopy 
Findlow et al., 2003 
2PNG Apo-ACP from rat FAS   NMR 
spectroscopy 
Ploskon et al., 2008 
1HY8 Apo/Holo-ACP from FAS in B. 
subtilis 
NMR 
spectroscopy 
Xu et al., 2001 
Table 4.2- Examples of carrier protein structures found in the PDB.  
A comprehensive review of carrier protein structures can be found in Crosby and 
Crump (2012). 
4.4.1 Sample preparation and screening crystallisation conditions 
For structural studies of IdmK homogeneous protein samples were required. Due to 
the dimerisation that occurs via the terminal thiol of the phosphopantetheine 
post-translational modification, homogenous samples of both apo and holo IdmK 
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could be obtained by subjecting IdmK to further purification by size exclusion 
chromatography as in Figure 4.6. Fractions collected of apo-IdmK (Figure 4.6, peak 
2) were pooled and concentrated to between 10 mg/mL for the screening of 
crystallisation conditions. 
Due to the considerable differences between the amino acid sequence of IdmK and 
the previous carrier proteins available in the PDB, as well as the disparity in 
crystallisation conditions described, a set of commercially available crystallisation 
screens were set up (Hampton Research (USA) screens; Crystal screen 1 and 2, 
Index 1 and 2, Salt RX and from Emerald BioStructure (Germany) Wizard 3 and 4). 
Crystallisation was attempted by vapour diffusion of 2 µL sitting drops (1:1 protein 
to mother liquor ratio) in 96 well-plates at 18°C. For crystallisation trials apo-IdmK, 
in 50 mM Tris/HCl pH 7.4, was used at a concentration of 10 mg/mL.  A high 
percentage of drops showed protein precipitation, indicating the protein 
concentration was close to supersaturation. Nevertheless, 11 initial crystal hits were 
observed after one week, crystal growth appears to be encouraged in conditions 
containing PEG 3350 and a higher pH (8.5). Figure 4.9 shows some of the crystal 
forms observed. 
Crystals were cryoprotected in 25 % (v/v) glycerol, flash cooled in liquid nitrogen 
and screened for diffraction at 100 K on beamline I04-1 at Diamond Light Source 
Ltd (DLS). High-resolution diffraction data were collected from crystals grown in 
pH 8.2 0.056 M sodium phosphate monobasic monohydrate, 1.344 M potassium 
phosphate dibasic. Further optimisation of the crystallisation conditions was 
attempted by varying protein concentration (6-12 mg/mL), protein to mother liquor 
ratio (1:1, 1:2 and 2:1) and pH (7.8-8.2). Subsequent crystal trays were set up using 
these conditions in a hanging drop format. The best crystal growth was observed at 
pH 8.0 and 8.2 with protein concentrations above 9 mg/mL. 
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X-ray data were collected at I04 beamline at DLS. Data collection and processing 
was carried out by Dr Chi Trinh (Astbury Centre, University of Leeds, UK). The 
data were reduced using the automated processing suit Xia2 at DLS. Data reduction 
statistics and unit cell parameters can be located in the appendix. Phasing by 
molecular replacement (using both Molrep (Vagin and Teplyakov, 1997) and Phaser 
(Mccoy et al., 2007)) was unsuccessful, mainly due to the large number of 
monomers present in the asymmetric unit cell. An estimated 7 or 8 monomers were 
predicted from Matthews co-efficient (Matthews, 1968). Since molecular 
replacement failed for structural characterisation of IdmK there are number of 
alternatives that could be considered, including screening for a different crystal form, 
use anomalous diffraction using selenomethionine labelled protein, or use of another 
biophysical technique. Structural characterisation of IdmK by X-ray crystallography 
was not continued. 
 
4.5 Structure determination using NMR spectroscopy 
As mentioned in section 4.2 a number of carrier protein structures exist in the PDB, 
solved by a number of biophysical techniques. Nuclear magnetic resonance has been 
used to solve a number of apo- and holo- carrier protein structures including the 
peptidyl carrier protein from the third module of the tyrocidine biosynthetic gene 
cluster (Figure 1.16) from Brevibacillus brevis (PDB codes 1DNY, 2GDW, 2GDX, 
2GDY) (Weber et al., 2000; Koglin et al., 2006) and of the acyl carrier protein from 
B. subtilis (PDB code 1HY8) (Xu et al., 2001). These structures illustrate the 
Figure 4.9- The representative crystals in this figure were obtained when crystallisation 
conditions were screened using apo-IdmK in the following conditions; (A) 0.2 M 
Sodium malonate pH 7.0, 20 % (w/v) PEG 3350, (B) 0.2 M ammonium sulphate, 0.1 M 
bis-tris pH 5.5, 25 % (w/v) PEG 3350, (C) 0.2 M sodium chloride, 0.1 M Tris/HCl pH 
8.5, 25 % (w/v) PEG 3350 and (D) pH 8.2, 0.056 M sodium phosphate monobasic 
monohydrate, 1.344 M potassium phosphate dibasic. 
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potential for using NMR to structurally characterise IdmK, and potentially make 
comparisons between the apo- and holo- protein species. The first step in studying 
IdmK by NMR was to express and purify isotopically labelled protein. 
 
4.5.1 Initial analysis of the suitability of IdmK for structural studies by NMR 
spectroscopy  
Previous results in this chapter have shown that IdmK had successfully been 
expressed and purified from E. coli BL21 (DE3) Gold cells transformed with the 
pKidmK construct. In order to assess the suitability of the use of NMR for structural 
studies, expression of IdmK in minimal medium was required. Expression of IdmK 
in minimal medium was carried out in M9 minimal medium (section 2.1.7) and the 
standard expression protocol used (section 2.2.1.5 and 2.2.3.4). The inoculation 
procedure of the minimal medium was augmented to prevent transfer of 2 × TY 
medium from the day culture: cells from the 10 mL day culture were harvested by 
centrifugation and resuspended in 2 mL of minimal medium, and this was used to 
inoculate 500 mL expression cultures. To determine if IdmK could be expressed in 
minimal medium small-scale expression was trialled in minimal medium in the 
absence of labelled medium components. To analyse the expression of IdmK, E.coli 
BL21 (DE3) Gold   whole cell lysate was run on a SDS-PAGE (Figure 4.10). 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10- Reducing SDS-PAGE analysis of the small scale expression trial 
of IdmK in minimal media. Lane 1 is the whole cell lysate from E. coli BL21 
(DE3) Gold cells containing the pKidmK plasmid.  
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As can be seen in the SDS-PAGE gel in Figure 4.10 protein over-expression was 
observed when expressing IdmK in minimal medium, as indicated by the protein 
band at approximately 11 kDa (green arrow).  
Due to the observed over-expression of IdmK in minimal medium, IdmK was then 
expressed in minimal medium containing 
15
NH4Cl as the sole nitrogen source. 
Protein expression and purification were carried out by nickel affinity 
chromatography as previously described (section 2.2.3.4). Samples were taken at 
each stage of the purification and analysed by SDS-PAGE (Figure 4.11). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 shows the successful purification of IdmK when expressed in minimal 
medium. As mentioned beforehand, both monomeric apo- and dimeric holo- species 
of IdmK are present upon purification by nickel affinity chromatography (Figure 
4.11); therefore further purification by size exclusion chromatography was used to 
obtain a homogeneous protein sample of apo-IdmK for structural studies (Figure 
4.12).  
Figure 4.11- Reducing SDS-PAGE gel showing the stages of nickel affinity 
chromatography of IdmK grown in minimal media containing 
15
NH4Cl. Broad range 
protein size markers are displayed (M). Cells expressing IdmK (1) were harvested by 
centrifugation, lysed and the soluble (2) and insoluble (3) fractions separated. 
Although there is a small band at approximately 11 kDa, indicating some insoluble 
material, the majority of protein appears to be expressed as soluble protein. After 
binding the soluble protein to the nickel resin (4), four washes were performed to 
remove any non-specifically bound protein (5-8). The bound protein was eluted by 
washing with 0.5 M imidazole, purified 
15
N labelled
 
IdmK is shown in lane (9). The 
dark green arrow indicates monomeric apo-IdmK and the light green arrow indicates 
the presence of dimeric holo-IdmK.   
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Before collecting any NMR spectra, the extent of [
15
N] labelling of IdmK was 
established. A sample of purified apo-IdmK was desalted into 50 mM ammonium 
acetate pH 7.4 (section 2.2.3.9) and the mass determined by ESI-MS. The amino acid 
sequence of the synthetic gene and the Internet tool Protein Calculator v3.4 
(http://protcalc.sourceforge.net) were used to calculate the mass of uniformly 
labelled monoisotopic IdmK. The expected mass for uniform [
15
N] labelled IdmK 
was 11 191 Da. Figure 4.12 shows the result of attempting to express [
15
N] labelled 
IdmK.  
 
 
 
 
 
 
 
 
 
 
Figure 4.12- ESI-MS spectrum to analyse the extent of isotopic labelling of IdmK. E. 
coli BL21 (DE3) Gold cells containing the plasmid pKidmK were used for expression 
of IdmK in minimal media containing 
15
NH4Cl as the sole nitrogen source. Apo-IdmK 
was purified by nickel affinity chromatography followed by size exclusion 
chromatography. The labelled protein was then desalted into 50 mM ammonium 
acetate pH 7.4 and analysed by ESI-MS. A peak is observed at 11 188 Da, 
corresponding to fully 
15
N-
 
labelled IdmK. (Inset) Reducing SDS-PAGE of a sample of 
15
N- labelled IdmK from size exclusion chromatography used in further NMR 
spectroscopy experiments. 
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Figure 4.12 shows that when IdmK is expressed in minimal medium containing 
15
NH4Cl as the sole nitrogen source 
 
it has an observed mass of 11 188 kDa, which is 
in excellent agreement with the calculated molecular mass of fully [
15
N] labelled 
apo-IdmK. The next stage in determining the suitability of IdmK for structural 
studies using NMR spectroscopy was to collect a 2D 
1
H-
15
N Heteronuclear Single 
Quantum Coherence (
1
H-
15
N HSQC) spectrum. 
 
4.5.2 Collection of a 2D heteronuclear single quantum coherence (HSQC) 
spectrum  
Collection of a 
1
H-
15
N HSQC spectrum allows initial analysis as to whether the 
target protein is suitable for further studies by NMR spectroscopy and therefore is 
the first spectra collected (Cavanagh et al., 2007; Rehm et al., 2002). Spectra were 
collected of apo-IdmK at a concentration of 0.5 mM in 50 mM Tris.HCl pH 7.4, 
0.2% (w/v) sodium azide. D2O was added to the sample to a final concentration of 
10% (v/v). The 
1
H-
15
N HSQC spectrum was collected at 25°C at a field strength of 
500 MHz (Table 2.1 shows experimental parameters). Table 4.3 shows the coherence 
transfer or the path of magnetisation in the 
1
H-
15
N HSQC experiment. 
Experiment Correlation 
observed 
Magnetisation transfer 
 
1
H-
15
N HSQC 
 
1
H
N
i-
15
Ni 
 
Table 4.3- Coherence transfer of the 2D Heteronuclear experiments 
1
H-
15
N HSQC. The 
path of magnetisation is indicated by the double-headed red arrow, indicating the out-
and-back nature of this experiment. The nuclei detected are highlighted in red circles 
(Cavanagh et al., 2007). 
Figure 4.13 shows the 
1
H-
15
N HSQC spectrum collected of [
15
N] labelled apo-IdmK. 
In a 
1
H-
15
N HSQC each peak corresponds to a proton coupled to nitrogen, therefore 
in this experiment each amide in the protein should have a representative peak in the 
1
H-
15
N HSQC spectrum.  
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The good peak dispersion in the spectrum (Figure 4.13) and sharp line intensities 
indicate that the protein is folded and stable in these conditions. IdmK is a 98-residue 
protein including the His6-tag; approximately 90 % of the peaks, representative of 
the amides, are present in the 
1
H-
15
N HSQC. The number and equal intensities of the 
peaks indicates that there is little or no protein dynamics on a mircrosecond-
millisecond timescale that will hinder structure determination by NMR. This 
spectrum indicates that NMR may be able to be used to elucidate an overall fold for 
IdmK.  
As each peak represents an amide in the protein the 
1
H-
15
N HSQC will provide the 
HN resonances, or ‘root’ resonances, to aid in the assignment of the triple resonance 
spectra and consequently structure determination of IdmK (described in chapter 5). 
The next requirement for structure determination by NMR is the expression and 
purification of doubly labelled [
13
C, 
15
N] labelled IdmK. 
Figure 4.13- 
1
H-
15
N HSQC spectrum of apo-IdmK. The spectrum was 
measured in 50 mM Tris.HCl pH 7.4, 0.2% (w/v) sodium azide, at a protein 
concentration of 0.5 mM recorded at 500 MHz at 25 °C. 
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4.5.3 Expression and purification of [13C, 15N] IdmK   
Initial experiments showed that IdmK could be expressed in minimal medium 
containing 4 g/L of glucose; however for cost efficiency when using 
13
C-glucose as 
the carbon source, the concentration of glucose required for protein over expression 
was investigated. Expression trials with minimal medium containing 2, 3 and 4 g of 
glucose per litre were tested. Protein was expressed as previously described (section 
4.3.1), 3 separate cultures were grown with the varying glucose concentrations. Cells 
were harvested by centrifugation and whole cell lysate analysed by SDS-PAGE 
(Figure 4.14).  
 
 
 
 
 
The expression trial showed that 2 g of glucose per litre was sufficient for protein 
expression. Subsequent protein expression for double labelled protein contained 10 
mL 20 % (w/v) D-glucose-
13
C6 purchased from Cambridge Isotope Laboratories in 1 
L. To produce [
13
C,
15
N] labelled protein IdmK was expressed in medium containing 
15
NH4Cl and D-glucose-
13
C6 as the sole nitrogen and carbon sources (section 2.1.7). 
IdmK was purified by nickel affinity chromatography. Samples from each stage of 
purification were run on a SDS-PAGE gel for analysis (Figure 4.15).  
Figure 4.14- Reducing SDS-PAGE to analyse the effects of changing the concentration 
of glucose in minimal media on protein expression. Lane 1 is the whole cell lysate of 
IdmK grown in minimal media containing 2 g/L of glucose, lane 2 contains 3 g/L of 
glucose and lane 3 contains 4 g/L of glucose.    
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As before, a homogeneous sample of apo-IdmK was obtained by size exclusion 
chromatography. The protein sample was then concentrated to 0.5 mM and the 
extent of labelling analysed by mass spectrometry (Figure 4.16). 
Figure 4.15- Reducing SDS-PAGE gel of [
13
C, 
15
N] IdmK purification. E. coli 
BL21 (DE3) Gold cells containing the pKidmK plasmid were expressed in 
minimal medium containing 2 g L
-1
 of  
13
C6 glucose. Cells expressing labelled 
IdmK (1) were harvested and lysed (2). The soluble (3) and insoluble (4) 
fractions were separated by centrifugation. The soluble cell fraction was loaded 
onto nickel resin for one hour. The supernatant was then removed (5) and the 
resin washed with a low imidazole (20 mM) buffer (6-9). Finally protein was 
eluted from the resin using a high imidazole buffer (0.5 M). (10) Protein species 
eluted from the nickel resin correspond to monomer apo-IdmK (dark green 
arrow) and dimeric holo-IdmK (light green arrow).  
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Figure 4.16- ESI-MS spectrum to analyse the extent of 
13
C and 
15
N isotopic labelling of 
IdmK. E. coli BL21 (DE3) Gold cells containing the plasmid pKidmK were used for 
expression of IdmK in minimal medium containing 
15
NH4Cl as the sole nitrogen source 
and D-Glucose-
13
C6 as the sole carbon source. Apo-IdmK was purified by nickel affinity 
chromatography followed by size exclusion chromatography. The labelled protein was 
then desalted into 50 mM ammonium acetate pH 7.4 and analysed by ESI-MS. A peak 
is observed at 11 663 Da, corresponding to fully 
13
C, 
15
N-
 
labelled IdmK. (Inset) 
Reducing SDS-PAGE of 
13
C, 
15
N-
 
labelled IdmK purified by size exclusion 
chromatography used in further NMR spectroscopy experiments.  
The expected mass for 
13
C, 
15
N labelled IdmK as calculated by Protein Calculator 
v3.4 (http://protcalc.sourceforge.net) using the amino acid sequence of the synthetic 
gene was 11 668 Da. The observed mass for IdmK expressed in minimal medium 
containing 
15
NH4Cl and D-glucose-
13
C6 as the sole nitrogen and carbon sources was 
11 663 Da indicating that 99.9 % of the protein was isotopically labelled.  
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Having successfully labelled apo-IdmK (
15
N and 
13
C) the next step in structure 
determination is assignment of the protein backbone, determining the chemical shifts 
of not only the 
1
H and 
15
N nuclei of the amide bond but also the Cα, Cβ and carbonyl 
nuclei. To do this 3D NMR spectra need to be collected. Chapter 5 will discuss the 
stages of structure determination by NMR spectroscopy.    
  
4.6 Summary 
IdmK was successfully cloned into pK223-3 and protein expressed and purified, as 
confirmed by SDS-PAGE and ESI-MS (Figures 4.4 and 4.5). Expression of IdmK 
produced both monomeric and dimeric species. Treatment of the dimeric IdmK 
species with TCEP, a reducing agent, showed that during expression of IdmK a 
PPTase endogenous to E. coli was able to phosphopantetheinylate IdmK. The 
dimeric species occurs due to the formation of a disulphide bond between the 
terminal thiol groups of two phosphopantetheine modifications. Contrary to 
expectations, both apo- and holo species were expressed in E. coli. BLAST searches 
in combination with multiple sequence alignments identified the potential serine, 
which becomes phosphopantetheinylated; this was confirmed by making a single 
point mutation of the identified serine and analysis by SDS-PAGE and ESI-MS. This 
showed only monomeric apo-IdmK was expressed when serine 44 was mutated to an 
alanine. The dimerisation of holo-IdmK allows purification of the apo- or holo- 
IdmK thus enabling a homogenous protein sample to be obtained. IdmK is an 
essential non-catalytic protein; it requires IdmJ to activate the amino acid it is to be 
loaded with. Initial attempts at structural characterisation of IdmK identified protein 
crystallisation conditions which produced crystals used for high resolution data 
collection. Subsequent analysis of the data collected showed that there were a large 
number of IdmK monomers within the asymmetric unit cell which meant molecular 
replacement could not be used for structure elucidation. Of the alternative options for 
structure determination NMR spectroscopy seemed a promising alternative, with a 
number of carrier protein structures having previously being solved by 
multidimensional NMR spectroscopy. Expression of 
15
N labelled IdmK followed by 
analysis by collecting a 
1
H-
15
N HSQC spectrum suggested that IdmK was suitable 
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for structural studies by NMR and thus [
13
C,
15
N] labelled IdmK was expressed and 
purified for backbone assignments. 
 
4.7 Discussion 
Successful cloning and expression of IdmK has allowed characterisation of the site 
of post-translational modification. The unexpected post-translational modification, 
carried out by a PPTase endogenous to E. coli such as EntD (Lambalot et al., 1996; 
Gehring et al., 1997), enables purification of homogeneous apo- and holo- IdmK 
samples for biochemical and structural characterisation. Although structure 
determination using X-ray crystallography was problematic, screening for a new 
crystallisation condition, could open up this avenue for further structural 
characterisation. Expression of IdmK in minimal medium with 
15
NH4Cl and D-
glucose-
13
C6 enabled expression of single, [
15
N], labelled IdmK and double, [
13
C, 
15
N], labelled IdmK. An initial 
1
H-
15
N-HSQC showed that IdmK was suitable for 
structural studies using NMR. Chapter 5 describes the use of NMR for structure 
determination and how this was carried out for determining an overall fold for IdmK. 
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5. Structural characterisation of IdmK by nuclear magnetic 
resonance spectroscopy  
The previous chapter presented the results of cloning and expressing the putative 
proline carrier protein from S. antibioticus NRRL 8167 in E. coli. Although 
structural characterisation by X-ray crystallography began, difficulties in solving the 
phase problem due to the high number of monomers in the asymmetric unit cell 
hindered the continued use of this method. Initial investigation into the suitability of 
IdmK for structural studies by NMR revealed that IdmK could be isotopically 
labelled, and collection and analysis of an 
1
H-
15
N HSQC spectrum showed that 
IdmK was in a folded and a single monomeric conformer, thus suitable for structure 
determination by NMR.
  
NMR as a tool for structure determination is particularly suitable for proteins of 
approximately 30 kDa or less, and is possible due to the intrinsic spin properties of  
particular nuclei (Cavanagh et al., 2007). Below, a brief introduction to NMR 
spectroscopy will be given.  
In 1946 the occurrence of nuclear magnetism was reported when Purcell et al. (1946) 
and Bloch et al. (1946) measured the NMR spectra of paraffin and water, 
respectively. This was possible due to nuclei possessing nuclear spin angular 
momentum. Nuclear spin angular momentum is a quantum mechanical property, 
characterised by the nuclear spin quantum number, I (Cavanagh et al., 2007; Teng, 
2005). Any nuclei with odd numbers of either neutrons or protons have a spin 
quantum number >0, some nuclei have half integer numbers if the neutrons and 
protons are not both odd e.g. 
1
H has a spin quantum number of a ½; and 
12
C has a 
spin quantum number of 0. Nuclei with a spin quantum number of 0 are NMR 
inactive (Cavanagh et al., 2007; Teng, 2005). Table 5.1 shows the properties of 
nuclei used in biological NMR experiments.  
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Nucleus 
Spin quantum 
number, I 
Gyromagnetic 
ratio, γ (T-1s-1) 
Natural abundance 
(%) 
1
H ½ 2.6752 × 10
8 
99.99 
2
H 1 4.107 × 10
7 
0.012 
13
C ½ 6.728 × 10
7
 1.07 
15
N ½ -2.713 × 10
7
 0.37 
19
F ½ 2.518× 10
7
 100.0 
31
P ½ 1.0839 × 10
8
 100.0 
Table 5.1- Properties of biologically relevant nuclei in NMR spectroscopy. I is the 
nuclear spin quantum number, γ is the gyromagnetic ratio. The natural abundance 
for each particular isotope is given (%) (Cavanagh et al., 2007). 
Nuclei with spin angular momentum, i.e. NMR active nuclei with nonzero spin 
quantum numbers, also have nuclear magnetic moments (μ) (Cavanagh et al., 2007). 
The nuclear magnetic moment of each nucleus is characterised by an individual 
unique constant, the gyromagnetic ratio (γ), which indicates how large its magnetic 
field is and is related to how receptive that particular nucleus is in NMR 
spectroscopy (shown for each isotope in Table 5.1) (Cavanagh et al., 2007; Teng, 
2005)). It is the interaction of the nuclear magnetic moment with an applied, external 
magnetic field (B0), which gives rise to populations of nuclei with measurable 
differences in energy states. The NMR signal or resonance is produced as a result of 
the nuclear magnetic moment dictating the nuclear rotation frequency in relation to 
the external magnetic field. It is the differences between the energy states which 
leads to different resonance frequencies. The volume of the signal from the 
resonance is proportional to the population difference of the states. When the spin 
quantum number is half an integral, for example 
1
H, (Table 5.1) the nuclear magnetic 
moment can occupy one of two states due to the quantisation of angular momentum, 
either pointing with the main magnetic field Bo, which is typically on the Z axis 
(low energy, α) or against it (low energy, β). Spins in the α and β states precess 
around the magnetic field at their Larmor frequency (ω0), and are randomly 
distributed with respect to the x-y plane (Cavanagh et al., 2007; Keeler, 2002; Teng, 
2005). Figure 5.1 illustrates the behaviour of nuclei in an applied magnetic field (B0). 
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The Larmor frequency describes the frequency of the precession (Cavanagh et al., 
2007; Teng, 2005) and is defined by: 
𝜔𝑥 = −𝛾𝑥𝐵0 
Equation 5.1- Equation defining the Larmor frequency. Where γ is the gyromagnetic 
ratio and B0 is the strength of the magnetic field, x is the nucleus (Cavanagh et al., 
2007; Teng, 2005). 
 
As the Larmor frequency is dependent on the susceptibly of a nuclei to a magnetic 
field (γ) and also to the strength of the magnetic field, the frequency of precession 
increases in a linear manner when B0 increases (Equation 5.1). When B0 increases 
the energy difference between the two spin states that the nuclei can occupy 
increases, and the population difference between the two states increases due to the 
Boltzmann distribution. This results in a 1 in 10 000 population difference for 
protons at a magnetic field strength of 14.1 tesla. An NMR signal can only be 
observed when there is a difference in the populations of the two levels. At 
equilibrium, spins in the two states can be viewed as precessing as two cones 
pointing with and against the magnetic field (B0) (Cavanagh et al., 2007; Keeler, 
2002; Teng, 2005). Summation of these spins gives a bulk magnetisation aligned 
with the field (Figure 5.2). 
 
Figure 5.1- Precession of nuclear magnetic moment, 
µ, with a spin ½ or – ½. The vector diagram 
illustrates a simplification of the procession of the 
magnetic moment about a magnetic field (B0) Figure 
adapted from Teng (2005) and Keeler (2002). 
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The field strength of an NMR magnet is measured in Tesla, however the strength of 
an NMR magnet is more often referred to by the proton Larmor frequency, for 
example a magnet with a field strength of 14.1 Tesla has a proton Larmor frequency 
of 600 MHz (Teng, 2005).  
In the course of an NMR experiment, NMR active nuclei are excited by short 
radiofrequency pulse of defined power and time, which pushes the spin state away 
from equilibrium. Figure 5.3 shows the effects of applying a 90° pulse on the y axis 
(90°y), which excites the bulk magnetisation from the z axis to the xy plane where it 
can be detected (Teng, 2005; Keeler, 2002).  
  
 
 
 
Figure 5.2- Bulk magnetisation of nuclei in an applied magnetic 
field (B0) at equilibrium. At equilibrium the magnetic moments 
are aligned with the applied magnetic field (B0), this is the bulk 
magnetisation (bold arrow) (Teng, 2005).       
Figure 5.3- Behaviour of nuclear spins upon excitation by a radiofrequency 
pulse of 90° on the y axis. The red arrow illustrates the behaviour of the nuclei, 
as a magnetisation vector. Upon excitation by a 90°y pulse (a) the magnetisation 
vector, nuclei, are rotated towards the xy plane (blue arrow) (b), the nuclei 
then begin to return to equilibrium aligning with the external magnetic field 
(B0) over time (c) (Keeler, 2002). 
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After excitation nuclei take time to return to equilibrium, this is known as relaxation. 
T1, or longitudinal relaxation describes one process for a return to equilibrium, and 
occurs by the nuclei exchanging energy with the environment over time leading to 
random spin flips from α to β and vice versa. The nuclei can undergo a second form 
of relaxation, T2, spin-spin relaxation. This describes the loss of magnetisation on the 
xy plane due to local loss of magnetic field homogeneity in a molecule (Teng, 2005). 
An NMR signal is observed in the form of Free Induction Decay (FID), which is 
produced by the oscillating magnetic field of all excited nuclei in the sample 
following a radio frequency pulse, The FID is measured by a receiver coil in the xy 
plane and is measured over time (typically < 1s). The FID signal is Fourier 
transformed to convert it into frequencies suitable for analysis, resulting in a NMR 
spectrum (Cavanagh et al., 2007; Teng, 2005). 
Different signals arise from nuclei within a molecule, including those from nuclei of 
the same isotope, due to the dependence of the magnetic field at the nucleus on the 
environment it is in. This dependence can be described as a chemical shift and 
moves the position of an NMR signal (Cavanagh et al., 2007; Teng, 2005). The two 
main causes of the chemical shift are bonding electrons and aromatic rings, double 
bonds which contain pi orbitals (Cavanagh et al., 2007; Teng, 2005).  Bonding 
electrons in a molecule produces a magnetic field which opposes the induced bulk 
magnetisation. Therefore the greater the density of electrons, the smaller the local 
magnetic field and a lower frequency for the NMR transition is recorded. Aromatic 
rings and double bonds contain circular regions of pi electrons which can also induce 
large orientation dependant magnetic fields which are often described as ring current 
shifts and provide much of the dispersion of chemical shifts for proteins.  The origin 
of the name chemical shift is due to its great dependence on the chemical 
environment, and it therefore provides a unique fingerprint of signals for a particular 
protein (Cavanagh et al., 2007; Teng, 2005).  
The normalisation of chemical shifts between different samples is achieved by 
referencing with compounds with chemical shifts defined as zero, such as 
tetramethylsilane (TMS), which is soluble in organic solvents, and the water soluble 
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form of TMS, DSS (4,4-demethyl-4-silapentane-1-sulfonic acid) (Teng, 2005). 
Chemical shift differences measured in ppm of the main magnetic field strength are 
not influenced by magnetic field strength though the frequencies that determine them 
are; therefore the same sample will produce identical spectra on the chemical shift 
scale when using any NMR spectrometers (Teng, 2005). 
In structure determination and assignment, scalar (J) couplings provide information 
about the two atoms separated by one or more bonds due to interactions between 
bonded electrons. This is exploited for chemical shift assignments of atoms (Teng, 
2005; Cavanagh et al., 2007; Bax and Grzesiek, 1993), how scalar couplings are 
used for chemical shift assignments is described in section 5.2.  
Dipolar couplings describe through space interactions of two nuclei, and are 
described in structure validation (section 5.3). Nuclear Overhauser effects (NOEs) 
arise from the transfer of energy from one spin to another spin through space by 
dipole-dipole interactions. NOEs can typically be observed between two protons 
which a distance of ˂6 Å and will produce NOE cross peaks in 1H-1H NOESY 
spectra which can be used in structure determination (section 5.4) (Cavanagh et al., 
2007; Teng, 2005). 
While X-ray crystallography gives a static picture of the structure of proteins, NMR 
has the ability to provide dynamic information about the target protein. Figure 5.4 
below illustrates the range of timescales of NMR spectroscopy can monitor via a 
range of techniques (Markwick et al., 2008).  
  
  
Figure 5.4- Timescales to illustrate the molecular dynamics (dark blue) that can 
be measured by NMR experiments (light blue) giving measurable data (green), 
Adapted from Markwick et al. (2008). 
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As mentioned in chapter 4, IdmK is the carrier protein in the first NRPS module of 
the indanomycin biosynthetic gene cluster. As with all carrier proteins, IdmK is a 
non-catalytic protein, phosphopantetheinylated for function.  Structure determination 
of apo- carrier proteins shows a conserved canonical fold (Crosby and Crump, 2012; 
Li et al., 2003).  Figure 5.5 and 5.6 illustrate an alignment of an acyl carrier protein 
structures from FAS, PKS and an NRPS and a schematic of the canonical fold 
observed. 
   
 
 
Figure 5.5- Canonical fold of carrier proteins. (Top) Structure of ACP from a 
fatty acid synthase (pdb code 2AVA) (Zornetzer et al., 2006). (Bottom) An 
overlay of carrier proteins from a FAS (red, PDB code: 2AVA), a PKS (yellow, 
PDB code: 2JU2) and an NRPS (blue, PDB code 2GDW) (Zornetzer et al., 2006; 
Alekseyev et al., 2007; Koglin et al., 2006). 
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Figure 5.6 shows a schematic of the secondary structural elements of the canonical 
fold of the homologous carrier protein structure. Helix 1 and helix 2 are antiparallel 
to each other, and helix 3 runs parallel to helix 2. Although slight deviations in helix 
lengths are seen in carrier proteins, generally they all appear to adopt the same fold 
(Crosby and Crump, 2012).  
 
 
 
 
 
 
Structural studies by NMR spectroscopy of the TycC3 peptidyl carrier protein 
revealed conformational changes are required for access to the pantetheine co-factor, 
showing significant conformational changes between what is described as the A/H 
state, an equilibrium state adopted by both apo- and holo- conformers of the PCP, 
and the holo- and apo- states. These conformational changes are suggested to bring 
the terminal thiol, where the NRP chain is located in proximity with the adenylation 
and condensation domains (Weber et al., 2000; Koglin et al., 2006). Structure 
determination of IdmK by NMR spectroscopy will provide both a structure and basic 
dynamic information for the protein, providing a foundation for investigation into 
the dynamics and mechanisms of starter unit construction in indanomycin 
biosynthesis. This chapter describes the experiments and stages required for structure 
determination and validation of the initial structure calculation of the apo-state of 
IdmK.   
 
Figure 5.6- Schematic of the canonical fold of carrier proteins.  
Slight variations are seen in helix length. A fourth small pseudo 
helix is also sometimes observed between helix 2 and 3, this is 
more variable. 
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5.1 Backbone assignments of IdmK 
5.1.1 Triple resonance experiments 
Prior to committing to structure determination of IdmK using NMR spectroscopy a 
1
H-
15
N HSQC spectrum was collected. This spectrum provided information on the 
conformational state of the protein and if it is folded in solution, thus indicating the 
suitability for further NMR experiments (Cavanagh et al., 2007; Rehm et al., 2002). 
The 
1
H-
15
N HSQC spectrum of IdmK (Chapter 4, Figure 4.13) indicated that the 
protein was suitable for structural studies by NMR as it contained the correct number 
of peaks and was well resolved and sharp. The next step was to collect triple 
resonance spectra for the sequential assignment of the protein backbone. Triple 
resonance experiments, originally described in 1990 for the backbone assignment of 
calmodulin (Ikura et al., 1990; Kay et al., 1990), are an alternative means of 
backbone assignments from the previous use of short range NOEs (Wuthrich et al., 
1982). Unlike the short range NOEs which use distances between protons for 
sequential backbone assignments, triple resonance experiments use one-bond and 
two-bond scalar couplings, or J couplings, which are easier to measure and interpret 
once the molecule has been uniformly labelled with 
13
C and 
15
N isotopes (Cavanagh 
et al., 2007). Figure 5.7 illustrates the one-bond scalar couplings exploited in triple 
resonance experiments.  
 
 
Exploitation of these one-bond couplings (and two-bond in the case of the HN and 
Cα of the preceding residue) has led to the design of several sets of triple resonance 
experiments which correlate the spins of NMR active nuclei in the protein backbone 
(Bax and Grzesiek, 1993; Grzesiek and Bax, 1992; Ikura et al., 1990; Cavanagh et 
Figure 5.7- Scalar couplings observed in the protein backbone. The red 
arrows indicate the one and two bond scalar couplings used in triple 
resonance experiments (Teng, 2005). 
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al., 2007). Running triple resonance experiments; HNCA, HNcoCA, HNCO, 
HNcaCO, HNCACB CBCAcoNH experiments gives chemical shift information 
about the 
1
H
N
, 
15
N, 
13Cα, 13CO and 13Cβ of either the nuclei within the same residue 
as the H and N resonances observed (i) or the nuclei i-1 to the H and N resonances 
being measured and are used for sequential backbone assignments (Cavanagh et al., 
2007; Kay et al., 1990; Grzesiek and Bax, 1992; Farmer et al., 1992; Bax and Ikura, 
1991; Clubb et al., 1992; Bax and Grzesiek, 1993; Ikura et al., 1990). Table 5.2 
illustrates the transfer path used for each of the triple resonance experiments. 
Experiment Correlation 
observed 
Magnetisation transfer 
   
 
HNCO 
 
1
H
N
i-
15
Ni-
13
COi-1 
 
 
HNcaCO 
 
1
H
N
i-
15
Ni-(
13
C
α
i-1)-
13
COi-1 
1
H
N
i-
15
Ni-(
13
C
α
i)-
13
COi 
 
 
HNCA 
 
1
H
N
i-
15
Ni-
13
C
α
i 
1
H
N
i-
15
Ni-
13
C
α
i-1 
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The triple resonance spectra HNCA, HNcoCA, HNCO, HNcaCO, HNCACB 
CBCAcoNH were collected for apo-IdmK, at a concentration of 0.5 mM, 50 mM 
Tris.HCl pH 7.4, 0.02% sodium azide containing 10 % (v/v) D2O. Data were 
collected at 25 °C at a field strength of 600 MHz. Spectra were then processed as 
described in section 2.2.5.2, and imported into CCPNmr Analysis (Vranken et al., 
2005). CCPNmr analysis was used to peak pick the 
1
H-
15
N HSQC and all triple 
resonance spectra. Analysis was also used to assign anonymous spin systems in the 
triple resonance spectra to their root resonance in the 
1
H-
15
N HSQC. Once this was 
completed, semi-automated sequential backbone assignments were carried out.  
Experiment Correlation 
observed 
Magnetisation transfer 
 
HNcoCA 
 
1
H
N
i-
15
Ni-(
13
COi-1)-
13
C
α
i-1 
 
 
HNCACB 
 
13
C
β
i/
13
C
α
i-
15
Ni-
1
H
N
i 
13
C
β
i-1/
13
C
α
i-1-
15
Ni-
1
H
N
i 
 
 
 
CBCAcoNH 
 
13
C
β
i/
13
C
α
i-
15
Ni+1-
1
H
N
i+1 
 
Table 5.2- The coherence transfer in triple resonance experiments used for sequential 
backbone assignments. The arrows indicate the path of magnetisation; double headed 
arrows indicate transfer of an “out-and-back” nature. Red circles indicate nuclei that 
were detected, blue circles are those that were on the pathway but no chemical shift 
information was collected.  Figure adapted from Cavanagh et al. (2007). 
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5.1.2 Semi-automated backbone assignments using MARS 
Sequential protein backbone assignments rely on the correlation of an NH group 
with the Cα, Cβ and carbonyl (CO) nuclei within the same residue and the preceding 
residue (i and i-1). Table 5.2 illustrates the correlation of nuclei within each 
experiment, and indicates whether they are used to collect chemical shift information 
from nuclei within the same or preceding residue. Collection of the HNCA spectra 
provides chemical shifts for the Cα peaks of residues (i) and (i-1) and collection of 
HNcoCA spectra provides chemical shift information for just the preceding residue 
(i-1). Superimposition of these two spectra enables the i and i-1 peaks in the HNCA 
spectra to be distinguished. The i-1 peak can then be matched to an i peak with an 
identical chemical shift in another residue, linking two residues together, 
sequentially. The HNCO and HNcaCO can be used to sequentially link the CO, and 
the HNCACB and CBCAcoNH can be used to sequentially assign residues using the 
Cα and Cβ nuclei in a similar manner and are important for overcoming 
degeneracies. Strip plots can be used to perform the sequential assignments. An 
example strip plot can be seen in Figure 5.8.  
In order to speed up the complete backbone assignments of IdmK an automated 
assignment program called MARS was used (Jung and Zweckstetter, 2004). MARS 
works by trying to optimise local and global assignments in order to reduce the carry 
through of initial errors to final assignments, is conservative in the assignments it 
makes and is able to complete assignments with missing chemical shift data (Jung 
and Zweckstetter, 2004). Prior to the use of MARS both the 
1
H-
15
N HSQC and triple 
resonance spectra had been peak picked and the triple resonance peaks had been 
assigned to the same spin system as their root resonances in the 
1
H-
15
N HSQC as 
described above. Peaks in the same spin system are referred to as pseudoresidues 
(PR) prior to their assignments. Once PRs are linked into segments and then mapped 
onto the amino acid sequence of the protein, MARS identifies the amino acid types 
by characteristic chemical shifts, such as the Cβ chemical shifts of serine and 
threonine residues and detects sequential connectivities of the PR (Moseley and 
Montelione, 1999; Jung and Zweckstetter, 2004). MARS evaluates the assignments 
and its output indicates the reliability of assignments, classing the confidence of the 
assignment as High (H), Medium (M) or Low (L) (Jung and Zweckstetter, 2004). All 
assignments by MARS were also manually checked using strip plots (Figure 5.8). 
Results three 
163 
 
Further analysis of side chain assignments also showed all MARS assignments used 
subsequently were correct. A total of 92% of backbone nuclei were assigned using 
this method. Chemical shifts can be found in a table in the appendix.
  
 
Figure 5.8- Strip plot of the last 10 residues of the backbone of IdmK. Strip plots were used to manually check the automated 
assignments completed by MARS. (Top) HNCA (red) and HNcoCA (blue) spectra were used to assign the Cα chemical shifts. 
(Bottom) HNCO (pink) and HNcaCO (purple) spectra were used to assign the carbonyl chemical shifts. Triple resonance spectra 
were measured in 50 mM Tris.HCl pH 7.4, 0.2% (w/v) sodium azide, at a concentration of 0.5 mM recorded at 600 MHz at 25 °C. 
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The successful assignment of the 
1
H-
15
N HSQC spectrum is shown in Figure 5.9. 
The triple resonance spectra provided the chemical shift information for the 
following nuclei of IdmK; N, HN, Cα, Cβ and CO which are given in table the 
chemical shift table in the appendix. 
 
  
As discussed above, the good peak dispersion and sharp lines indicate a well-folded 
and stable protein in solution. Recent developments in NMR structure calculations 
now allow the use of chemical shifts alone to determine an overall protein backbone 
fold (Shen et al., 2008; Shen et al., 2009b). The chemical shifts for HN, N, Hα, Cα, 
Cβ and CO generated by backbone assignments were subsequently used in 
secondary and tertiary structure calculations. 
Figure 5.9- Assigned 
1
H-
15
N HSQC of apo-IdmK collected in 50 mM Tris.HCl 
pH 7.4, 0.2% (w/v) sodium azide, at a concentration of 0.5 mM recorded at 500 
MHz at 25 °C. 92 % of the backbone residues were assigned using MARS, 
providing chemical shifts for the NH nuclei. 
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5.2 Structure determination using chemical shifts 
The unique chemical shifts for the backbone nuclei in particular secondary structure 
shifts and the effect of the ring current can be used to determine secondary, and more 
recently, tertiary chemical structures using +TALOS and CS-ROSETTA respectively 
(Shen et al., 2009a; Shen et al., 2008; Shen et al., 2009b) and this approach was 
adopted to determine a preliminary overall fold of IdmK. 
 
5.2.1 Determination of secondary structure 
To predict the secondary structural elements of IdmK +TALOS was used (Shen et 
al., 2009a). TALOS, Torsion Angle Likelihood Obtained from Shifts and sequence 
similarity, uses experimentally determined chemical shifts of HN, N, Hα, Cα, Cβ and 
CO nuclei to predict the phi and psi torsion angles of the protein backbone using a 
database of chemical shifts and the random coil shifts predicted by the primary 
sequence (Cornilescu et al., 1999; Shen et al., 2009a). TALOS is also able to predict 
how dynamic the residue is, quantified by an approximate value for the order 
parameter, S
2
 (Figure 5.10 - bottom panel) (Berjanskii and Wishart, 2007).   
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The secondary chemical shifts depend on the orientation of the Cα-Hα bond in 
relation to each adjacent carbonyl (Tjandra and Bax, 1997b; Shen et al., 2009a; 
Teng, 2005). Figure 5.10 shows the results of the secondary structure predictions for 
IdmK using +TALOS (Shen et al. 2009a). The top panel shows that the secondary 
chemical shifts of the Cα are positive, indicating that IdmK is an α-helical protein. 
This is reinforced by the fact that the Cβ chemical shifts show no overall pattern 
possibly due to slightly incorrect chemical shift referencing of the spectra. Chemical 
shift referencing will be completed with an internal reference compound (DSS). The 
positive ΔCα values indicated that IdmK has 3 helices, with helix 1 composed of 
Figure 5.10- Secondary structure predictions by +TALOS (Shen et al. 2009a).  
(Top) Secondary chemical shifts of Cα atoms (ΔCα) and (middle) Cβ atoms 
(ΔCβ). ΔCα and ΔCβ describes the difference between measured chemical shifts 
and random coil chemical shifts. (Bottom) Predicted order parameter based on 
the secondary chemical shifts, the dashed line shows an typical cut-off of 0.7, 
below which residues are assumed to be dynamic and disordered (Engelke and 
Rüterjans, 1999). The grey boxes represent the α-helices predicted by TALOS. 
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residues 6-20, helix 2 composed of residues 45-57 and helix 3 composed of residues 
75-85. To compare the predicted secondary structure elements of IdmK with those of 
other carrier proteins the Dali server was used (Holm and Rosenstrom, 2010). Dali 
performs a 3D structure alignment of a target protein with those deposited in the 
PDB. Figure 5.11 shows the results of the alignment by Dali. 
 
 
 
 
 
This analysis revealed that carrier proteins consist of: helix 1, centred around residue 
10, with a length of 14 residues (+/- 2), helix 2, centred around residue 46, with a 
length of 11 residues (+/- 4), this is followed by a small “pseudo” helix which is not 
always present and helix 3, centred around residue 74, which is 13 residues long (+/- 
3). Exact locations of the helices vary slightly due to differences in the lengths of the 
carrier proteins. IdmK shows comparable helix lengths and relative locations in the 
sequence. 
 An order parameter of 0 indicates a completely disordered residue and an order 
parameter of 1 is a completely rigid protein (Berjanskii and Wishart, 2007; Engelke 
and Rüterjans, 1999). The order parameters shown in Figure 5.10 indicated that 
IdmK is a well-ordered protein, apart from the extreme N-and C-terminal residues. 
These results provide the first evidence that IdmK may have the canonical carrier 
protein fold. Phi and psi angles predicted by TALOS can be used as restraints in 
structure calculations (Section 5.2.2). The chemical shifts were then used to 
determine the overall fold of IdmK using CS-ROSETTA.  
 
PDB code
10 20 30 40 50 60 70 80
Figure 5.11- Secondary structure alignments of carrier proteins by Dali. H 
indicates the residue resides within a helix and L indicates the residue is in a 
loop. The PDB codes refer to carrier protein structures with comparable 
secondary structure selected by DALI deposited in the PDB.  
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5.2.2 Determination of the overall fold of IdmK using CS-ROSETTA 
Until recently, it was not possible to define the fold of a protein structure by use of 
the torsion angles determined by TALOS (Cornilescu et al., 1999; Shen et al., 
2009a), and structure determination from assigned side chain proton requires the 
addition of large numbers of standard NOE distance restraints. The past seven years 
has seen the emergence of programs which determine a protein fold solely from the 
chemical shifts of backbone and Cβ nuclei; CHESHIRE, CS-ROSETTA and CS23D 
(Cavalli et al., 2007; Shen et al., 2008; Wishart et al., 2008). CS-ROSETTA, a 
program developed by the Baker lab (Shen et al., 2008; Shen et al., 2009b), utilises 
the experimentally determined chemical shifts to determine an overall protein fold de 
novo. The ROSETTA protein structure prediction algorithm is a software package 
that allows the determination of a protein fold based only on the amino acid 
sequence and chemical shifts determined in backbone assignments. The general 
strategy involves the selection of fragments based on the target amino acid sequence. 
9 and 3 residue fragments are slected from known structures in a database, which are 
then assembled using a Monte Carlo simulated annealing approach. CS-ROSETTA 
uses the 
13Cα, 13Cβ, 13CO, 1HA, 1HN and 15N chemical shifts to bias the fragment 
selection, so as that the selected fragments have chemical shifts that agree with the 
experimentally measured ones and so occupy the correct part of Ramachandran 
space. The lack of NMR assignments in structural databases may have previously 
hindered searches, however development of SPARTA (which is based on TALOS 
(Shen and Bax, 2013)), a program that can predict the chemical shifts during 
ROSETTA modelling and thus allows correctly folded structures to be selected. CS-
ROSETTA has been evaluated using a number of proteins up to 15 kDa in size 
adopting a range of conformations (Shen et al., 2009b), indicating that this program 
may be appropriate for determination of an overall fold of IdmK. Dr Gary Thompson 
aided in running the CS-ROSETTA calculations.  
5000 ROSETTA models were calculated using the experimentally determined 
13Cα, 
13Cβ, 13CO, 1HA, 1HN and 15N chemical shifts, and were ranked by their CS-
ROSETTA scores (Shen et al., 2008; Shen et al., 2009b). The results showed that the 
five best ROSETTA structures show an overall similar fold, with helix 1 antiparallel 
to helix 2 and 3 which are parallel to each other, as expected for a canonical carrier 
protein fold (Figure 5.12 and 5.6). 
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Figure 5.12 shows a chevron plot with the best ROSETTA scored model highlighted. 
The models are analysed by plotting their all atom energy against the Cα RMSD 
indicates how similar the other models are to the lowest energy model. Although the 
CS-ROSETTA models appear to show the same overall orientation, i.e. helix 1 
antiparallel to helix 2 and 3, which are parallel to each other, the exact angles 
between the helices deviate somewhat from the known canonical fold and between 
the models themselves. Though the observed structures don’t show the clearest 
deviation in the energy vs Cα RMSD this may be attributed to the large content of 
loops or long meanders between helices. Figure 5.18 shows a comparison of the CS-
ROSETTA model of IdmK with an acyl carrier protein from FAS.  
Although CS-ROSETTA is able to predict the correct overall fold of IdmK, further 
experimental validation is required to assess the quality of the models. An easy 
experimental restraint to determine, that can be used to validate the models, are 
residual dipolar couplings (RDCs). 
 
Figure 5.12- Chemical shift structure of IdmK using CS-ROSETTA. (a) Chevron plot of 
a subset of 500 of the best ROSETTA scored models from the 5000 models generated, 
the red circle indicated the model with the best ROSETTA score (b) Overlay of the 5 
models with the best ROSETTA score.  
 
Results three 
171 
 
5.3 Structure validation using residual dipolar couplings 
To validate the calculated CS-ROSETTA structures of IdmK, residual dipolar 
couplings (RDCs) were measured. RDCs depend on the distance between two NMR 
active nuclei (i and j) and the angle between them. As the distance between the 
nuclei which are directly bonded to one another is a known constant based on 
classical chemistry (bond lengths), RDCs (Dij) provide accurate relative angular 
information between bonds (θij) that is difficult to determine by other NMR 
methodologies (Bax, 2003; Ottiger et al., 1998; Lipsitz and Tjandra, 2004; Teng, 
2005). 
𝐷𝑖𝑗 =  −
𝛾𝑖𝛾𝑗𝜇0ℎ
8𝜋3
 ⟨
(3𝑐𝑜𝑠2𝜃𝑖𝑗(𝑡) − 1)
2𝑟𝑖𝑗
3(𝑡)
⟩ = 0 
Equation 5.2- Determination of the RDC between two nuclei. Where γi and γj are the 
gyromagnetic ratios of the two NMR active nuclei, μ0 is the vacuum permeability, h is 
Planks constant, r is the distance between the two nuclei and θ is the angle between 
them and t is time (Bax, 2003; Ottiger et al., 1998). 
Figure 5.12 shows the relationship between two nuclei within an external magnetic 
field, (B0) defining the distance and angle between them. 
 
 
 
 
 
 
In an isotropic solution, when a molecule is tumbling freely is solution, the RDCs 
are averaged to close to zero. However, in an anisotropic solution the molecular 
orientation is slightly restricted and this introduces measurable dipolar couplings 
(Equation 5.2 is no longer equal to zero).  
Figure 5.13- Dipole-dipole interaction between 
two magnetic moments. B0 is the external 
magnetic field, r is the distance between the two 
nuclei and θ is the angle between them (Teng, 
2005; Blackledge, M., personal communication). 
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As mentioned previously, partial alignment of the protein is required to introduce 
measureable dipolar couplings (Fleming and Matthews, 2004; de Alba and Tjandra, 
2004). Figure 5.14 shows the partial alignment of molecules in an anisotropic 
solution, in order to introduce measurable dipolar couplings. 
 
 
 
 
Figure 5.15 shows a simple method by which RDCs can be directly measured by 
comparison of a coupled spectrum in anisotropic and isotropic solutions. It shows 
how the residual dipolar coupling can be measured by subtraction of the known one-
bond J coupling from the coupling measured in the experiment performed in an 
anisotropic solution. However, for IdmK instead of measuring the difference in peak 
positions in an undecoupled HSQC as shown in Figure 5.14, a series of decoupled 
1
H-
15
N HSQC J-modulated spectra (Tjandra and Bax, 1997c) were collected with 
different time intervals (Δ) during which the coupling is encoded in the intensities of 
the peaks. This approach was used to accurately measure the RDCs in IdmK. 
  
 
 
 
 
 
Figure 5.14- Partial alignment of a protein in an anisotropic solution. In an isotropic 
solution (a) the protein is tumbling freely in solution and RDCs are averaged to zero. 
In an anisotropic solution (b) the range of motion is partially restricted and this 
introduces measurable dipolar couplings (Blackledge M, personal communication). 
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Partial alignment of the protein is often achieved using a liquid crystalline medium 
which can introduce measurable dipolar couplings (Tjandra and Bax, 1997a). A 
variety of different media can be used to partially align protein molecules such as 
bicelles, filamentous bacteriophage and SDS-PAGE gels (Fleming and Matthews, 
2004; de Alba and Tjandra, 2004). The first liquid crystalline medium trialled for 
partial alignment of IdmK was Pf1 bacteriophage. Pf1 bacteriophage is a filamentous 
bacteriophage which aligns in parallel with the magnetic field due to being naturally 
susceptible to the magnetic field, thus creating a liquid crystalline medium and 
partially aligning the phage and the protein (Hansen et al., 1998; Torbet and Maret, 
1979). A 
1
H-
15
N HSQC spectrum was collected of IdmK at 0.5 mM in Tris.HCl pH 
7.4, i.e. in an isotropic solution. Pf1 bacteriophage was then added to the isotropic 
solution at a final concentration of 8 mg mL
-1
 and a second 
1
H-
15
N HSQC spectrum 
was collected. Analysis of the anisotropic 
1
H-
15
N HSQC spectrum showed 
significant peak broadening also occurring, indicating an interaction of the Pf1 
bacteriophage with IdmK, as indicated by by a decreased T2. Calculation of the 
theoretical isoelectric point (pI) of IdmK using ExPASy ProtParam (Gasteiger et al., 
2003) gives a pI of 5.82. At pH 7.4 IdmK would have an overall positive charge and 
the Pf1 bacteriophage has an overall negative charge, explaining the interaction 
between the two molecules. This alignment medium was therefore unsuitable for 
determination of the RDCs and a new alignment medium was required. 
The second alignment medium tried was a n-alkyl-poly(ethylene glycol)/n-alkyl 
alcohol mixture (Section 2.2.5.5) (Rückert, 2000), if these molecules are mixed in 
Figure 5.15- Measuring residual dipolar couplings in an isotropic and anisotropic 
solution. Panel (a) shows a peak in a decoupled 
1
H-
15
N HSQC spectrum. (b) Shows 
the decoupled HSQC in isotropic solution where the one one-bond j coupling is 
measured. (c) Shows a decoupled HSQC in an anisotropic solution where the one 
bond j-coupling and dipolar coupling are active (Ottiger et al., 1998). 
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the appropriate concentration they create a liquid crystalline medium that partially 
aligns the protein. This liquid crystalline medium is not charged, and is relatively 
insensitive to pH and applicable over a range of temperatures (Rückert, 2000). The 
nomenclature for the n-alkyl-poly(ethylene glycol)/n-alkyl alcohol mixture is CmEn, 
denoting the number of carbons in the alkyl group (m) and the glycol groups in the 
PEG (n) (Rückert, 2000). A C12E6, hexanol mixture (0.64 molar ratio)  containing 
5% PEG was selected for the alignment of IdmK. An initial 
1
H-
15
N HSQC spectrum 
was collected of IdmK in anisotropic conditions and no significant chemical shift 
differences were observed in the in this alignment medium. A J modulated series was 
then carried out. Figure 5.15 shows the how the raw data are fitted to calculate the 
RDCs from the change in peak intensity (Section 2.2.5.5, Equation 2.3) (Tjandra et 
al., 1996).  
 
 
 
 
 
 
 
The RDC value extracted from the raw data by fitting a modified cosine function 
(see materials and methods (2.2.5.5) using the in-house python script FitR_bs (Dr 
Gary Thompson) which uses appropriate heuristics to determine initial values for 
fitting. Statistical errors were analysed using duplicate values and Monte Carlo 
simulations (Tjandra et al., 1996). RDCS can then be plotted against residue number, 
for comparison with RDC values calculated from models. Figure 5.17 shows the plot 
of all RDCs measured for IdmK for each residue. 
 
 
Figure 5.16- Raw RDC data of three residues from IdmK. The Raw RDC data shows a 
change in the peak intensities in the J modulated series as a function of time. A cosine 
function is fitted to extract 2 × the dipolar coupling for a residue. Error bars represent 
propagated errors calculated from duplicate measurements for each peak.  
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PALES, Prediction of alignment from structure, is a program that can fit the RDCs 
to a known structure (Zweckstetter, 2000), in this case the ROSETTA models. The 
measured RDCs define an average alignment of the molecule in three orthogonal 
directions, defining the alignment tensor frame (Zweckstetter, 2000). To do this the 
structures from ROSETTA calculation were used. To validate the CS-ROSETTA 
models generated, the 10 best CS-ROSETTA models were analysed using PALES in 
order to compare the experimentally determined RDCs with those predicted from the 
models. For validation of the models generated by CS-ROSETTA only RDCs for the 
secondary structure elements as determined by TALOS+ were used. This is because 
residues in loop regions tend to be less well defined and do not have well defined 
angles in relation to the rest of the molecule and the aligning medium. The RDC 
waves in figure 5.18 indicate the presence of α-helices (Mesleh et al., 2002). 
Figure 5.17- Measured RDCs for IdmK collected in 50 mM Tris.HCl pH 7.4, 
0.2% (w/v) sodium azide in a C12E6, hexanol mixture (0.64 molar ratio)  
containing 5% PEG, at a concentration of 0.5 mM apo-IdmK  recorded at 
500 MHz at 25 °C. RDC data collected for IdmK. The grey boxes designate 
secondary structure elements. Error bars represent propagated errors 
calculated from duplicate measurements for each peak. 
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Figure 5.18 shows the three models that agree the best with the experimentally 
determined RDCs for secondary structure. All structures show the canonical fold of a 
carrier protein (Figure 5.5 and 5.6). Each model is ranked by their Q factor, which 
indicates the quality of the fit of the experimental RDCs to the model. Equation 2.3 
illustrates how the Q factor is calculated to determine the overall quality of the fit of 
the data. A low Q factor indicates a better fit (Zweckstetter, 2000). 
The structure with the lowest Q factor (Figure 5.18, top panel) was not the lowest 
energy ROSETTA model. Although the 2
nd
 model selected by RDCs (middle panel) 
has a higher Q factor, it is clear from the RDC plots (right) that the secondary 
structure elements agree better with the experimentally determined data (red and 
blue lines overlay). 
Table 5.3 shows the Q factors calculated for the 10 best CS-ROSETTA, including 
those in Figure 5.18.  
  
 
 
 
The best Q factor as calculated from the experimental data set for IdmK is 0.1, the Q 
factors states in Table 5.3 are 0.479 and above. Clearly, the Q factor calculated for 
illustrates that these models still require refinement. However, the pattern of the 
RDCs is comparable.  
Model Q factor 
1.1 0.479 
1.2 0.527 
1.3 0.528 
1.4 0.544 
1.5 0.561 
Table 5.3- Q factors of five best CS-ROSETTA models. The best Q factor can be 
calculated from the experimental errors, in this case the best Q factor for the 
dataset is 0.1 (Tang et al., 2008;  Karamanos et al., 2014). 
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Figure 5.18- Three CS-ROSETTA models selected by RDCs. (Top panel) model 1.1, 
(middle panel) model 1.2 and (bottom panel) model 1.3 are the three models with 
calculated RDCs that agree the best with experimentally determined RDCs, as 
indicated by the Q factor. Dotted lines represent the residues in loops that were not 
used in fitting. Blue line is the expected RDCs calculated from the models. Red lines are 
the experimentally determined RDCs. Error bars represent propagated errors 
calculated from duplicate measurements for each peak. 
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The agreement of RDCs predicted from the models with the experimentally 
determined RDCs, and the overall fold predicted by ROSETTA are strong 
indications that IdmK probably has the canonical fold as seen for other carrier 
proteins. Figure 5.19 illustrates the differences in angles of the helices, comparing 
model 1.2 (Figure 5.17) with a carrier protein from a FAS. While helix 2 and 3 
appear to be in the correct, same, orientation as the canonical fold, helix 1 appears to 
be rotated by 90°. 
 
 
 
 
 
 
To guide the ROSETTA structure calculation, and taking advantage of further 
features of the CS-ROSETTA software package, instead of scoring the structures 
that were produced by CS-ROSETTA with chemical shifts alone the HN RDCs were 
also incorporated as additional restraints in the calculation. Figure 5.20 shows an 
overlay of the five new CS-ROSETTA structures that agreed the best with the RDC 
restraints for secondary structure regions. Table 5.4 shows the Q factors for these 
structures. 
Figure 5.19- Comparison of the best CS-ROSETTA model with an ACP. Overlay of 
model 1.2 of IdmK (pink), selected as the best CS-ROSETTA module, of the 5 lowest 
energy models, this was selected due to the agreement with experimentally 
determined RDcs  (Figure 5.12, Table 5.3) with an ACP from FAS (yellow) (PDB 
code: 2AVA) (Zornetzer et al., 2006). 
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Figure 5.20-Overlay of ROSETTA structures generated with RDCs as an additional 
restraint. 5 models selected that best fit the RDC data as well as sharing the same 
secondary structure, as judged by backbone RMSD Table 5.4 shows Q factors related 
to RDC fits 
 
Model Q factor 
2.1 (Green) 0.411 
2.2 (Blue) 0.460 
2.3 (Pink) 0.487 
2.4 (Yellow) 0.503 
2.5 (Orange) 0.533 
Table 5.4- CS-ROSETTA structure Q factors. Q factors for secondary structure 
elements of CS-ROSETTA structures generated with RDCs as a restraint in the 
calculation. The best Q factor can be calculated from the experimental errors, in this 
case the best Q factor for the dataset is 0.1 (Tang et al., 2008;  Karamanos et al., 2014). 
 
This round of structure calculations by CS-ROSETTA produced models comparable 
to the initial CS-ROSETTA calculation, as illustrated by the Q factors (Figure 5.17). 
As expected the fit to the RDC data is improved.  However, within these ensembles 
the exact angles of the helices still appears to deviate from the canonical fold, and 
from each other somewhat. The 20 structures that showed the best agreement with 
the structure selected using RDCs were then taken forward to seed an ARIA NOE 
based structure calculation (section 5.4). 
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5.4 NOE restraints and ARIA structure calculation  
In order to generate a higher resolution structure 
1
H-
1
H NOE distance restraints were 
required. In order to assign the NOE distance restraints in NOESY spectra, full 
amino acid side chain assignments were required. HccoNH and HBHAcbcacoNH 
spectra of IdmK were collected. These spectra provide a link between the 
1
H-
15
N 
HSQC and and 
1
H shifts in the 
1
H-
13
C HSQC, and were used in combination with 
the HNCA and HNcoCA to assign cross peaks in the 
1
H-
13
C HSQC, this provided a 
starting point for side chain assignments. Structure calculations by ARIA were 
carried out by Dr Gary Thompson.  
 
5.4.1 Aliphatic side chain assignments 
To assign the aliphatic side chains, especially the methyl bearing side chains such as 
leucine, isoleucine, valine, threonine and alanine, 
13
C-HSQC (Cavanagh et al., 
2007), hCCH-TOCSY and HcCH-TOCSY spectra were collected (Bax et al., 1990; 
Olejniczak et al., 1992). A 
13
C HSQC spectrum detects all of the carbon nuclei in the 
protein through one bond H-C correlations and is the carbon equivalent to the 
1
H-
15
N 
spectrum. This spectrum is assigned through the use of hCCH-TOCSY and HcCH-
TOCSY spectra and provides the basis for assigning NOE peaks in 
1
H-
13
C-NOESY-
HSQC spectra during structure determination. An HcCH-TOCSY spectrum provides 
chemical shifts for the side chain protons by correlating them with their 
corresponding 
13
C nuclei. By identification of the carbon chemical shifts in an 
hCCH-TOCSY spectrum, navigation to the carbon plane in the HcCH-TOCSY 
spectrum can match the side chain protons to the corresponding carbons. The Cα and 
Cβ chemical shifts assigned in the triple resonance experiments can be used as a 
starting place to identify the rest of the carbon nuclei in the side chain using this 
approach. Figure 5.21 and 5.22 below show the hCCH-TOCSY and HCCH-TOCSY 
spectra assignment of Leu85, respectively.  
Currently, this assignment process has been carried out for assignment of 
approximately 77% of all amino acid side chain protons of IdmK, and 60% of heavy 
side chain atoms of IdmK, including all of the methyl bearing side chains. A 
chemical shift table can be located in the appendix.  
  
 
Figure 5.21- hCCH TOCSY assignment of Leu 85. The hCCH TOCSY was used to assign the Cβ, Cδ1 and Cδ2 carbon nuclei in Leu 85. The 
carbon planes for Cβ, Cδ1 and Cδ2 were identified in strip 1, where the peaks marked are the Cα, Cβ, Cδ1 and Cδ2 (bottom to top) identified by 
characteristic chemical shifts. The dotted lines indicate corresponding carbon peaks in another carbon plane. Spectrum was collected in 50 mM 
Tris.HCl pH 7.4, 0.2% (w/v) sodium azide with apo-IdmK at a concentration of 0.5 mM. 
  
 
Figure 5.22-  HcCH TOCSY assignment of Leu 85. The HCCH TOCSY was used to assign protons in the amino acid side chain. The hCCH-
TOCSY was used to identify the carbon chemical shifts for the Cα, Cβ, Cδ1 and Cδ2. Navigation to these carbon planes in the HCCH-
TOCSY enabled identification of the corresponding protons. The dotted lines indicate the same protons in another carbon plane. Spectrum 
was collected in 50 mM Tris.HCl pH 7.4, 0.2% (w/v) sodium azide with apo-IdmK at a concentration of 0.5 mM. 
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5.4.2 Aromatic side chain assignments 
The amino acid sequence of IdmK contains four aromatic residues, not including the 
His6-tag, three phenylalanine residues and one tryptophan. Aromatic residues usually 
form part of the hydrophobic core of a protein and provide useful NOE restraints for 
structure determination (Prompers et al., 1998). The methodology used for 
assignment of aromatic residue side chains differed from assignment of the other 
amino acid side chains. To assign the phenylalanine residues in IdmK a combination 
of a 2D hbCBcgcdHDceHE spectrum and a 2D aromatic 
13
C filtered 
1
H-
1
H NOE 
spectrum were used (Yamazaki et al., 1993; Marion et al., 1989a; Marion et al., 
1989b; Cavanagh et al., 2007). The hbCBcgcdHDceHE exploits the chain of one 
bond (J coupling) between the Cβ chemical shifts and the Hδ and Hε in the 
connected ring making it possible to assign the Hδ protons and Hε protons of the 
aromatic side chains. However, this spectrum has relatively low resolution in the 
1
H 
dimension due to the use of constant time and power limits imposed by the pulse 
sequence and spectrometer (Yamazaki et al., 1993). In addition to this the peaks in 
this spectrum can also be masked by those generated by the mobile His6-tag and the 
overlap of Hβ chemical shifts in IdmK. To combat these problems a 1H-1H-aromatic 
13
C filtered NOE spectrum was also collected, this experiment uses the 
1
H-
1
H NOEs 
observed between the Hβ and Hδ protons for assignment. The Hβ and Hδ NOE cross 
peaks are always, at least weakly, present due to the restraints of the covalent 
geometry of the ring and side chain. To assign the tryptophan residue in IdmK, short 
1
H-
1
H NOE distance restraints were used in addition to assignment of the 
characteristic chemical shifts in the 
1
H-
13
C aromatic optimised HSQC. This resulted 
in assignment of all four of the non-histidine aromatic side chains.  
After assignment of of the amino acid side chains of IdmK had begun, once a good 
proportion had been assigned, especially those suspected to form the hydrophobic 
core, were used to peak pick the 
13
C-NOESY-HSQC. In addition the 
1
H-
15
N HSQC 
was used to peak pick the 
15
N-NOESY-HSQC (Marion et al., 1989a; Marion et al., 
1989b; Zuiderweg and Fesik, 1989). 
5.4.3 Progress towards a high resolution solution structure of IdmK   
To calculate a higher resolution structure of IdmK the program ARIA, Ambiguous 
restraints for iterative assignment, was used (Rieping, 2007). Historically, NMR 
structure calculations were performed using unambiguously assigned NOE cross 
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peaks, converting them into distance restraints. However, the manual unambiguous 
assignment of cross peaks in NOESY spectra is time consuming and inaccurate (one 
peak may contain several distances due to resolution limitations). To deal with this 
issue, structure calculations have relied on iterative process where an initial 3D 
structure model created from the unambiguous NOEs is used to seed further NOE 
assignments which can be obtained by quantifying the agreement of the ambiguous 
NOEs with a model (Nilges, 1995; Teng, 2005). ARIA uses an automated iterative 
version of this strategy, however all possible assignments from an ambiguous NOE 
are considered for the initial structure calculation. The correct assignments of NOEs 
is achieved through several rounds of simulated annealing energy minimisation 
interspersed with automated assignment. Typically calculations start with a structure 
with random coordinates i.e. an unfolded polypeptide chain. During each round 
following an increasingly rigourous selection of assignments based on the current 
model the improved restraint set is used to calculate further structures, trying to 
satisfy as many distance restraints as possible. Over 8 rounds, only NOEs that agree 
with the structure generated in the previous round are selected and therefore the 
population of incorrect NOE assignments decreases leading to convergence 
(Rieping, 2007; Fossi et al., 2005a).   
The ARIA structure calculation of IdmK was carried out using 
1
H-
1
H NOEs from the 
filtered 
13
C-NOESY-HSQC and 
15
N-NOESY-HSQC spectra. The 
1
H-
13
C-HSQC, 
assigned by the HCCH- and hCCH-TOCSY experiments, was used as the root 
spectrum for the 
13
C-HSQC shifts of NOE peaks used in the ARIA calculation.  
1
H 
NOE chemical shifts were assigned using the ARIA protocol during the structure 
calculation. A total of 1123 distance restraints were obtained for IdmK, this includes 
long and short range NOEs as summarised in Table 5.5.  
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Distance constraints  IdmK 
Total NOE 1123 
Intraresidue 449 
Interresidue i+1 317 
 i+2-4 184 
Long range  173 
Violations 28 
Table 5.5- Unambiguous distance restraints assigned 
by ARIA during the structure calculation of IdmK. 
To assist the convergence of the structures generated by ARIA rather than starting 
from a random structure, the first round of the calculation (it0) was seeded with the 
CS-ROSETTA structures generated when RDCs were included as a restraint (Figure 
5.20). 20 structures were used to seed the first round of the calculation, and 20 
structures were carried through to the next round of the calculations (it1-8). 
Refinement in a bath of TIP3 water was carried out for 10 structures from it8 to give 
the final ensemble. During the calculation, the hot and slow cooling stages were 
extended by a factor of four as described in (Fossi et al., 2005c) in an effort to aid 
convergence. As mentioned previously, +TALOS phi and psi angles derived from 
the Cα and Cβ chemical shifts for residues shown to form the α-helices were 
included in the calculations.  
To further improve convergence in the first round of structure calculations only the 
HN chemical shifts were used and the 
1
H-
15
N NOEs initially assigned. In this round 
of calculations a structure composed of three α-helices was generated, however there 
was no consistent overall tertiary fold. The 
1
H-(
15
N)-
1
H NOEs assigned in this round 
of calculations for the secondary structure elements were fixed in subsequent 
calculations, this included 64 unambiguous and 3 ambiguous distance restraints, 
each of which had two ambiguous assignments (Fossi et al., 2005a).  
The second round of calculations used a subset of assignments, specifically those of 
of the methyl groups from Ile, Leu Thr and Val methyl protons and shifts Hα and Hβ 
protons in order to separate the spectrum into two sub-spectra for which clear and 
confident assignments could be made. Any other assignments within the two sub-
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spectra were assigned to prevent miss-assignment of chemical shifts. The regions 
used were 6-3.5ppm and 1.3- -1ppm. 
Finally, for the calculations initial weak NOEs restraints of those identified by the 
CS-ROSETTA models, between secondary structure elements, were introduced into 
the calculation and used with their upper bounds extended by 5 Å. Any restraints 
between the secondary structure elements that were assigned and violated by greater 
than 10 Å were removed and flagged for further investigation. RDCs were not used 
in the second round of calculations and so were able to be used for subsequent 
structure validation. Figure 5.23 shows the ensemble of IdmK structures generated 
by ARIA.   
 
Figure 5.23- Structure ensemble of IdmK calculated by ARIA and validation. (a) 
Overlay of the 10 lowest energy structures generated by ARIA through unambiguous 
assignment of NOE distance restraints. (b) Structure ensemble was validated by 
comparison of the calculated RDCs against experimentally determined RDCs.   
The ARIA structure ensemble shows a three α-helical bundle, with helix one 
(residues 6-19) running antiparallel to helix two (residues 44-54) and three (74-86). 
The conserved serine required for post-translational modification is located at the top 
of helix 2. Contrary to the CS-ROSETTA structure, the ARIA structure does not 
have the small-helix (or turn) seen in the long loop between helices 2 and 3. In 
carrier proteins this is termed as a pseudo helix, and is variable between structures, 
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this may be because of the limited restraint set used. This fold shows the same 
topology of the helices and loops as the canonical fold; however the meanders are 
not well ordered between the helices and relative angles of the helices to each other 
vary somewhat from those seen In the canonical fold of the carrier proteins (Figure 
5.5). Figure 5.24 shows a comparison of the IdmK structure generated by ARIA in 
comparison with an acyl carrier protein from FAS.  
 
 
 
 
Although the Q factor for the ARIA ensemble indicates that the agreement with the 
measured RDCs is slightly worse than that seen for the CS-ROSETTA structures, 
ARIA has been able to improve the convergence of the ensemble structures 
generated. This is shown by a lower RMSD of the secondary structure elements, an 
average of 0.66 Å compared with 3.43 Å of the RDC restrained CS-ROSETTA 
structures. The initial structure calculated with ARIA provides a solid starting point 
for further refinement of the structure and introduction of further NOEs to achieve a 
complete structural model of IdmK. Figure 5.25 shows the short range NOE 
assigned by ARIA. The resulting pattern of short range NOEs are in good agreement 
with the location and lengths of the secondary structure elements. 
Figure 5.24- Comparison of the 3D structures of acyl carrier protein and IdmK. 
View of the 3D structures of 2AVA (yellow) with the best ARIA structure (blue) 
showing to compare orientation and positioning of helices (Zornetzer et al., 
2006). 
  
 
Figure 5.25- Plot showing short range NOEs assigned by ARIA. Comparison of the short range NOEs assigned by ARIA with the secondary structural 
elements predicted from the chemical shifts by TALOS show good agreement for the location and lengths of helices. 
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5.5 Initial phosphopantetheine characterisation 
As with other carrier proteins, phosphopantetheinylation of IdmK is required for 
function. Chapter 4 showed that when IdmK is expressed in E. coli it is 
phosphopantetheinylated by an endogenous PPTase (Chapter 4, Figure 4.7). 
Furthermore, it was shown that it was possible to purify holo-IdmK (Chapter 4, 
Figure 4.6 and 4.7). In order to elucidate the mechanism of this module, the next step 
taken was to investigate structural changes observed in holo-IdmK, and investigate 
the location of the modification. Chemical shifts provide a sensitive monitor of 
changes in structure and dynamics (Teng, 2005). 
 
 
 
 
 
Figure 5.26- An overlay of 
1
H-
15
N HSQC spectra collected in 50 mM 
Tris.HCl pH 7.4, 0.2% (w/v) sodium azide of apo- and holo-IdmK. 
Chemical shift differences of the apo- (black) and holo- (red) spectra 
are shown by peak shifts, which indicates changes in the local 
environment of the nuclei. Green arrows identify peaks that have 
altered chemical shifts in the holo- spectrum. The blue arrows 
identify two new peaks observed in the holo- spectrum. Insert 
illustrates peak shifts observed in the overlay of the two spectra. 
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Superimposition of the 
1
H-
15
N HSQC spectra of the apo- and holo- states of IdmK 
identified two new peaks (blue arrows), indicating the presence of two new amides 
in the protein, comparable to the structure of phosphopantetheine though two amides 
are also missing from the apo spectrum. Chemical shift differences, characterised by 
peaks shifts were also observed for some other residues. Figure 5.27 shows a graph 
of the differences of chemical shifts between the apo- and holo- IdmK, identified 
using conservative shift mapping (Williamson et al., 1997) (section 2.2.5.6 Equation 
2.5) and those above 0.2 ppm were mapped onto the most recent, ARIA, structure for 
reference.  
 
 
 
 
 
Figure 5.27- Chemical shift perturbations of apo- and holo- IdmK. The graph 
shows the chemical shift differences measured from the 
1
H-
15
N HSQSC spectra 
of apo- and holo- IdmK. Chemical shift differences were then mapped onto the 
best ARIA structure. The red patches indicate residues with chemical shift 
differences ≥0.2 ppm. The residue highlighted in green is the conserved serine 
that gets phosphopantetheinylated. 
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When the chemical shift differences observed in the 
1
H-
15
N HSQC spectra of apo- 
and holo-IdmK were mapped onto the apo- ARIA structure of IdmK, it indicated that 
the phosphopantetheine was lying down the side of helix 2, directed into the core of 
the protein. Chemical shift differences were also observed in residues within the loop 
between helix 1 and 2. For complete validation of the structure of IdmK with 
phosphopantetheine a full assignment of the phosphopantetheine moiety is required, 
and in addition a full set of NOE restraints need to be measured before the full holo 
state of the protein can be determined. However, this initial data suggests that the 
phosphopantetheine may be more occluded with a different orientation to those 
previously observed, unless major movements in the secondary structure elements 
occur (Johnson et al., 2014; Nguyen et al., 2014; Masoudi et al., 2014). 
 
5.6 Summary 
Structure determination by NMR spectroscopy began with collection of a 
1
H-
15
N 
HSQC spectrum. This spectrum indicated that apo-IdmK would be suitable for 
structure determination by NMR spectroscopy. Backbone assignments of IdmK were 
completed by collection of triple resonance spectra, and using the semi-automated 
assignment program MARS (Jung and Zweckstetter, 2004). MARS was able to 
assign approximately 92% of the protein backbone; the MARS output was manually 
checked using strip plots (Figure 5.8). Assignment of the protein backbone provided 
chemical shifts for 
1
H
N
, 
15
N, 
13Cα, 13CO and 13Cβ nuclei. These chemical shifts were 
then used in a structure calculation by CS-ROSETTA to generate an overall fold for 
IdmK (Shen et al., 2008; Shen et al., 2009b). The models generated were validated 
by RDCs measured by collection of a J modulated series. CS-ROSETTA models 
were also generated using RDCs as a restraint in the calculation. Models generated 
by CS-ROSETTA showed the observed topology expected for a carrier protein 
(Figure 5.6), however the angles of the helices and relative positioning differed from 
the observed expected canonical fold of other carrier proteins (Figure 5.19). RDC 
data (Figure 5.18) indicated that the secondary structure elements in the models 
agreed with experimental data collected. In an effort to elucidate a higher resolution 
structure short and long range NOEs were used. Side chain assignments were 
completed for 60-77% of side chains atoms of residues, assisting in assignment of 
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NOE distance restraints by ARIA (Rieping et al., 2007). Structure calculations 
carried out by ARIA generated a converged ensemble. The structures showed a 
three-helix bundle with the expected topology for carrier proteins. The ARIA 
structures satisfy NOEs expected from the canonical fold, the orientations of the 
helices are comparable to the CS-ROSETTA structures. Although the fit of the RDC 
data is slightly worse than the CS-ROSETTA structures this data provides a strong 
foundation for determination of a high-resolution structure, using ARIA. 
 
5.7 Discussion 
Initial analysis of the solution structure ensemble of IdmK generated by ARIA with 
other carrier proteins from fatty acid synthases and polyketide synthases has inferred 
that IdmK adopts an almost canonical carrier protein fold differing in the orientations 
of the helices, although more work needs to be done to complete the models 
generated. Investigations into the protein dynamics of peptidyl carrier proteins has 
been carried out on the TycC3 PCP. Figure 5.27 shows the multiple conformers this 
carrier protein was seen to adopt in the apo- and holo- forms, the A/H state is seen in 
both apo- and holo- PCP states. The first solution structure (PDB code: 1DNY) of 
the TycC3 PCP is comparable to the A/H state elucidated some years later (Weber et 
al., 2000; Koglin et al., 2006). The PCP from the tyrocidine biosynthetic gene 
cluster appears to adopt different conformations, with the holo-state being the most 
expanded, and the A/H state being the most compact. Variations in helix angles with 
respect to each other differ between states, as does the length of helices. The small 
helix/turn between in the A/H state is also missing in the A and H states (Koglin et 
al., 2006). The dynamic nature and more open conformation of holo-TycC3-PCP 
may be to assist in protein-protein interactions and access of the phosphopantetheine 
modification to other domains and downstream modules to elongate the growing 
peptidyl chain.  
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So far, there has been no obvious evidence of IdmK being as dynamic in nature as 
the TycC3-PCP. However, collection of perhaps a [
15
N, 
1
H]-TROSY spectrum and 
full characterisation of the phosphopantetheine co-factor and holo-state of IdmK may 
shed some light on whether IdmK is as dynamic, as the TycC3-PCP (Koglin et al., 
2006).  
Characterisation of the phosphopantetheine modification and holo-state of the carrier 
protein is in its preliminary stages. Results so far indicate that the 
phosphopantetheine may be positioned down the side of helix 2, directed into the 
hydrophobic core of the protein. Further validation of the current ARIA models is 
required before assuming any definitive conformations of the phosphopantetheine 
modification. Assignment of the phosphopantetheine can be carried out using a 
standard triple resonance HNCA experiment that has already been collected, in 
addition to collection of 
1
H-
15
N-NOESY data. Recently, vibrational spectroscopy 
and crystallography were able to probe the movements of the phosphopantetheine 
arm in a holo-ACP, showing that prior to being loaded with its substrate the 
Figure 5.28- Conformational states of the TycC3-PCP. (a) and (c) are the 
conformations TycC3-PCP adopts when unmodified and phosphopantetheinylated, 
respectively (PDB codes: 2GDY and 2GDX) (Koglin et al., 2008). The A/H state, 
equivalent to the TycC3-PCP structure 1DNY, is an equilibrium state seen in both apo- 
and holo- states of TycC3-PCP (Weber et al., 2000; Koglin et al., 2006). (d) Overlay of 
three structures illustrating deviations in helix angles and lengths.   
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phosphopantetheine arm is solvent exposed, directed away from the core of the 
protein, upon acylation large conformational changes were observed in helix 2 and 3, 
causing dissociation from the loading enzyme, potentially in preparation for 
subsequent protein-protein interactions downstream (Johnson et al., 2014; Nguyen et 
al., 2014; Masoudi et al., 2014). It would be interesting to probe the conformational 
changes that may occur when loading holo-IdmK with L-proline, either 
enzymatically or chemically.   
NMR structure calculations are difficult as they require the assignment of the entire 
protein backbone, amino acid side chains and NOE distance restraints (Teng, 2005). 
This chapter described the use of MARS to assign the backbone of IdmK. This 
program provided fast and reliable assignments. MARS is a powerful program for 
small proteins such as IdmK (Jung and Zweckstetter, 2004). The increasing number 
of assignments required for structure calculations can be difficult and laborious, 
especially as confidence in the assignment is important as mistakes can severely 
affect the outcome (Markwick et al., 2008; Nilges, 1995).   
ROSETTA has been used successfully for ab initio protein structure prediction for 
proteins up to 20 kDa (Shen et al., 2008; Sgourakis et al., 2014; Bouvignies et al., 
2011). A combination of unambiguous NOE assignments in the ROSETTA structure 
calculation could and has been used to help higher resolution structure prediction, 
even for larger proteins (Loquet et al., 2012; Raman et al., 2010; Sgourakis et al., 
2011). In the structure determination of IdmK using CS-ROSETTA, RDCs were 
used as a restraint to aid the structure calculations, producing a carrier protein with 
the same topology as the canonical fold. The structures produced were equivalent to 
the CS-ROSETTA structure calculation without the RDCs, showing the high 
predictive power of the technique. 
Assignment of NOESY spectra can be very tedious even for small proteins. ARIA 
performs an iterative assignment of ambiguous NOEs to determine long range 
distance restraints for structure determination (Rieping et al., 2007). Although this 
program has obviously sped up structure determination, it still requires the input of 
good quality NOESY spectra. Overlap and miss assignment of peaks will hinder the 
ARIA structure calculation and severely affect the outcome of the structure 
calculation. More recently, CS-ROSETTA structure calculations have been 
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completed using RDCs and sparse Ile, Leu and Val NOE restraints, making it 
possible to calculate a structure with an RMSD of 0.5 Å with respect to the crystal 
structure (Sgourakis et al., 2014).  
Structure determination of IdmK using CS-ROSETTA provided a solid foundation 
for high resolution structure determination using ARIA. Seeding ARIA calculations 
with the CS-ROSETTA models, in addition to including some weak initial NOE 
restraints was able to produce a structure of IdmK in some agreement with other 
carrier proteins. Further structure refinement is required of IdmK. Once the high-
resolution structure is complete, investigation into protein-protein interactions and 
dynamics of both apo- and holo- IdmK will provide some insight into peptidyl chain 
elongation and starter unit construction in indanomycin biosynthesis. 
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6. Summary, future work and perspectives 
6.1 Summary 
This thesis has described the successes and difficulties in heterologous expression of 
the indanomycin nonribosomal peptide synthetase (NRPS) proteins in E. coli. 
Attempts to clone and express the three proteins, IdmJ, IdmI and IdmK, from 
indanomycin starter unit biosynthesis are presented.  
Chapter 1, the introduction to the focus of this thesis, outlined a huge foundation of 
research into NRPS and PKSs, from their biosynthetic gene clusters to production of 
novel compounds. It was decided that a heterologous expression of the target module 
would be the appropriate first step to take in engineering substrate specificity in the 
domains required for starter unit biosynthesis of indanomycin. This research began 
by designing and purchasing synthetic genes, codon optimised for expression in E. 
coli. These genes encoded an adenylyltransferase (IdmJ), responsible for selection of 
L-proline and activating it, a carrier protein (IdmK), responsible for transfer of the 
substrate to the downstream module, and the dehydrogenase (IdmI), which oxidises 
the L-proline to a pyrrole. Chapter three presented the issues encountered when 
attempting to express IdmJ and IdmI in E. coli outlining the approaches taken in 
order to produce soluble protein. Complications encountered with expression of 
IdmJ and investigation into a potential post-translational modification is outlined in 
this work. Unfortunately, the measures taken to express IdmI as a soluble protein did 
not solve the problem. Chapter four discussed the successes of cloning and 
expressing IdmK followed by the fortuitous discovery that IdmK was also post-
translationally modified in E. coli. This chapter also described the first attempts at 
structural characterisation by crystallography, and why NMR was chosen as an 
alternative for structure determination. Chapter five describes the steps taken for 
structure determination by NMR and has presented a protein fold elucidated solely 
from chemical shifts in addition to a higher resolution structure of IdmK. The first 
steps in characterisation of holo-IdmK and the phosphopantetheine are also 
described. This data so far suggests that IdmK has canonical carrier protein fold, and 
the phosphopantetheine modification may be pointing into the core of the protein.  
Structure determination of IdmK has provided a solid foundation for investigations 
into dynamics of the NRPS module, and potentially the carrier proteins interactions 
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with an adjacent PKS module. Including refinement of the carrier protein structure 
and assignment of the phosphopantetheine modification, there are a number of 
directions for future work.  
 
6.2 Extension of current work  
6.2.1 Expression and purification of the dehydrogenase (IdmI) 
Soluble protein expression of IdmI was not achieved; however there are still a 
number of strategies which could be trialled, including expression in Origami
™
 2 
(DE3) cells, to aid in disulphide bond formation in E. coli. Although genes were 
synthesised to be codon optimised for expression in E. coli, previous dehydrogenases 
from aminocoumarin biosynthetic gene clusters have been cloned from genomic 
DNA with a C-terminal His6-tag (Garneau et al., 2005), therefore this could be 
attempted. Finally, insoluble aggregates could be unfolded, and refolded for 
purification. 
 
6.2.2 Purification and characterisation of the adenylyltransferase  
Expression and purification of IdmJ resulted in an unknown post-translational 
modification at C127. Site directed mutagenesis of the cysteine residues resulted in 
purification of IdmJ variants without the post-translational modification. Further 
purification by size exclusion chromatography of IdmJ alanine variants (C104A, 
C127A, C169A and C308A), characterisation of secondary structure by CD and 
assaying activity using an ATP/PPi exchange assay could provide insight into to 
whether the alanine variants are folded correctly and functional.  
 
6.2.3 Structural characterisation of the carrier protein (IdmK) 
The current solution structure of IdmK requires further refinement and validation; 
once this has been achieved it provides the basis for investigation into structural 
changes that may occur when the carrier protein is phosphopantetheinylated or 
loaded with its substrate. Exploration into protein-protein interactions with a variety 
of PPTases could be carried out, investigating the binding surface of the protein. In 
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lieu of the adenylyltransferase, investigation into the use of chemical modification 
using thiols as an alternative method to chemically load the carrier protein with the 
substrate, using the method described for conversion of cysteines into 
dehydroalanine followed by a reaction with a thiol, could be carried out (Chalker et 
al., 2011; Bernardes et al., 2008; Timms et al., 2013). NMR could be used to 
investigate structural changes that have occurred as a consequence of holo-IdmK 
being loaded with the appropriate and alternate substrates. 
 
6.3 Future perspectives 
Following any successes highlighted above structural and biochemical 
characterisation could be carried out. Alternatively, investigation into substrate 
specificity could be carried out by substituting IdmJ with the adenylation domains 
found in clorobiocin and coumermycin biosynthesis, known to be successfully 
cloned and expressed in E. coli (Garneau et al., 2005). Identification of residues 
which contribute to substrate specificity and mutagenesis could aid in engineering 
substrate specificity in the adenylation domains (Stachelhaus et al., 1999). In 
addition to biochemical assays such as ATP/PPi exchange, NMR could be used to 
follow the progress of loading the carrier protein with alternative substrates. 
IdmK is a peptidyl carrier protein, located in an NRPS module, that is required for 
the transfer of the starter unit, pyrrole-2-carboxylate, to a downstream PKS module. 
Investigating the interaction of IdmK with PKS domains could provide insight into 
communication between NRPS and PKS modules in hybrid enzymes. However, this 
would require the simultaneous expression of PKS modules, such as the downstream 
PKS module in indanomycin biosynthesis IdmL (Li et al., 2009).    
Combining chemical loading of the carrier proteins via a dehydroalanine or 
enzymatically through the use of an adenylation domain able to accept alternative 
substrates, with investigation of the interaction of IdmK with the downstream 
module IdmL could generate novel products.  
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6.4 Concluding remarks 
This research has provided a basis for investigation into NRPS module dynamics 
based around the carrier protein using NMR spectroscopy as a tool. Although 
difficulties were experienced when attempting to clone and express the 
adenylyltransferase and dehydrogenase, characterisation of the carrier protein has 
been successful. Structure determination of a carrier protein involved in 
communication between an NRPS and PKS module could provide insight into this 
interaction, potentially highlighting differences between the interactions of carrier 
proteins in NRPS and PKS only multienzymes. This could aid in the efforts to create 
an NRPS/PKS toolbox for combinatorial synthesis of novel compounds. 
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7. Appendix 
7.1 Sequences 
7.1.1 Adenylyltransferase (idmJ) DNA sequence  
GAGCTCAAGGAGATATACCATGGAACATCATCATCATCACCACAACCTGCATCAACTGCTGGTCGA
TACGGCGGCTAAAGAACCGGATCGTCTGGCTGTCGCTGGCACCGCAGCACGTCTGACGTACGCAGA
ACTGGATTCTACCGCAAACGCACTGGCACATCGTCTGCGCGCCCTGGGTGTTGGTCCGGGTGACCG
CGTGGTTCTGTGGAGTGATAAATCCCCGGCAGTCGTGGCAGCTATGCAGGCAGTGCTGCGTCTGGG
TGCAGCATATGTTCCGGCTGATGGCGCGCTGCCGATTGCCCGCGTGGCAGCTATGGCAGATGACTG
CAGCGCAGCAGCACTGCTGGCTCCGGCAGACCGTCTGGCACCGGTTGCAGATGTCCTGGGTCCGCG
TTGTCCGGCTGCAGACCTGGCACAGCGTCCGGACCCGGCAGCAGAACCGCTGAATGCTCTGGTTGC
GCCGGATGACCTGGCCTATATTCTGTACACCAGCGGTTCTACGGGCGCACCGAAGGGTGTGTGCAT
CAGCCATCGTAACGCCCGCGCATTTGTGGATTGGGCTGTGGAAGAACTGGCACCGGGTCCGCAAGA
TCGTTTCAGTAATCACGCCCCGTTTACCTTCGACCTGTCCGTTCTGGATCTGTATGCTGCGTTTAGCG
CTGGTGCGTCTGTCCATCTGATTCCGTCTGAACTGGCCTACGCACCGGAACAGCTGGTTGAATTTCT
GCACGATCGCCAAATCACCGTTTGGTATTCAGTCCCGTCGGCGCTGACGCTGATGATGCGTGACGG
TGGTCTGCTGGATCGTCCGGCACCGCGTGCACTGCGCACCGTCCTGTTTGCAGGTGAACCGTTCCCG
CTGCCGGGTGTGCGTGCTCTGGCAGGTTGGACGGATGCACGCCTGCTGAACCTGTATGGTCCGACC
GAAACGAATGTTTGTACCCGTCATGAAGTCCGTCCGACGGATCTGGACGGTGATCGTCCGCTGCCG
ATCGGTACCGCAGTGAGTGGTGACCGTGCATGGGCAGAAGGTCCGGATGGCCGCCTGGCAGCACC
GGGTGAAGAAGGCGAACTGCTGGTCGATGGTCCGACGGTGATGCTGGGCTATTGGGGTGGTGAACC
GCACACCGGTCCGTACCGTACGGGTGACCTGGTGCGTCCGCTGCCGGATGGTTCCTTTGCGTACCTG
GGCCGTCGCGACCATATGGTGAAAGTTCGTGGTCACCGCGTTGAACTGGGCGAAGTGGAATCAGTT
CTGGCTCTGCATCCGGATGTGGCCGAAGCTGCGGCCGTTGTCGTGGGTTCGGGCATGGACGGTCGC
CTGGTTGCCTTCGTTGTCCCGGAACCGGATCGTCGCCCGGGTGTGCTGAGTCTGGTTCGTCACGCAG
CTCAACGTCTGCCGCGCTATATGGTGGCAGATGAAGTCCGTGTGCTGCCGGGTCTGCCGCGTACCC
GCAACGGCAAAGTTGATCGTCTGGCACTGCGTGATACGGCTGAAGCACCGGCACCGGGCGCTGCGG
CACAGTAATAAGTCGAC 
7.1.2 Adenylyltransferase (IdmJ) amino acid sequence  
MEHHHHHHNLHQLLVDTAAKEPDRLAVAGTAARLTYAELDSTANALAHRLRALGVGPGDRVVLWSD
KSPAVVAAMQAVLRLGAAYVPADGALPIARVAAMADDCSAAALLAPADRLAPVADVLGPRCPAADL
AQRPDPAAEPLNALVAPDDLAYILYTSGSTGAPKGVCISHRNARAFVDWAVEELAPGPQDRFSNHAPFT
FDLSVLDLYAAFSAGASVHLIPSELAYAPEQLVEFLHDRQITVWYSVPSALTLMMRDGGLLDRPAPRAL
RTVLFAGEPFPLPGVRALAGWTDARLLNLYGPTETNVCTRHEVRPTDLDGDRPLPIGTAVSGDRAWAE
GPDGRLAAPGEEGELLVDGPTVMLGYWGGEPHTGPYRTGDLVRPLPDGSFAYLGRRDHMVKVRGHRV
ELGEVESVLALHPDVAEAAAVVVGSGMDGRLVAFVVPEPDRRPGVLSLVRHAAQRLPRYMVADEVRV
LPGLPRTRNGKVDRLALRDTAEAPAPGAAAQ 
7.1.3 Prolyl dehydrogenase (idmI) DNA sequence  
GGATCCAAGGAGATATACCATGGAACACCACCACCACCACCACGACTTTGACCTGACCGAAAAAC
AACGCCAACGCTACGACGATGTGCTGTCCGCCGTCCGCGAACGTCTGGGTGAACCGCCGAGCGGTG
AACCGTTTACCCCGGCACGTTGGCAGGATGCAGCACGTATTGGTCTGACCGGCCTGTGCCTGCCGA
Appendix 
202 
 
CGGAATTTGGCGGTGGCGGTCTGGGTGCACTGGATACCGCTCTGTGCCTGGAAGCCTTTGGTCGTG
GTTGTCCGGACACGGGTCTGGTCTTCGCAGTGAGCGCACATCTGCTGGCATGTGCTGTGCCGATCCG
CGATTTTGCGGACGTCTCTGTGCGTGGTGAACTGCTGTCAGGTCTGGCCTCGGGCGAACTGGTTGCA
GCTAACGCAATGACCGAAGATGACGCTGGCAGCGATCTGTCTCGCCTGGCAGTCACGGCTGAACGT
AAAGATGACGGTTATCTGCTGAACGGCGAAAAAAGTTTCGCGTCCAATGCCCCGGCGGCCGATGTT
CTGGTCACCTACGGTACGAGCGACCCGGCAGCTGGTTTTCTGGGTGTTACCGCATTCGTCCTGCGTG
CAGATCTGCCGGGTGTGCAGGTTGGCGAACCGTTTCGTAAAATGGGTCTGAGTGGTTGCCCGGCAG
GTCGTGTCGCATTCCGTGATTGTCATGTGCCGACCTCCCACCGTCTGGGTACGGAGGGTCAGGGTTC
AATTATCTTTCAACACTCGATGGGCTGGGAACGCGCAATTCTGTTCGCTGGTTATCTGGGCCTGATG
GAACGTCAGCTGGAACAATGCGTGCGTCATGCGCGCGAACGTCGCCAGTTTGGCCACGGTATCGGC
GAATTTCAAGCCGTTAGCCATCGCGTGGTTGGTATGAAACAGCGTCTGGAAGCAGCACGTCTGCTG
CTGTATCGTGCGTGTTGGCTGATGGATCAAGGTCGTGACCACTCAACCGCGGTGGCCCTGAGTAAA
ACGGCCGTGTCCGAAGGCGCAGTTGCTAATTCGCTGGATGCAATTCAGATCTTTGGCGGTAGCGGT
TACCTGTCTCCGGCAGGCATTGAACAGCAACTGCGTGACGCGGTTCCGTCTACCATCTTCAGCGGCA
CGACGGACATCCAACGCGAAATTGTGGCACGCGAAATCGGTCTGTAATAAGAATTC 
7.1.4 Prolyl dehydrogenase (IdmI) amino acid sequence  
MEHHHHHHDFDLTEKQRQRYDDVLSAVRERLGEPPSGEPFTPARWQDAARIGLTGLCLPTEFGGGGLG
ALDTALCLEAFGRGCPDTGLVFAVSAHLLACAVPIRDFADVSVRGELLSGLASGELVAANAMTEDDAG
SDLSRLAVTAERKDDGYLLNGEKSFASNAPAADVLVTYGTSDPAAGFLGVTAFVLRADLPGVQVGEPF
RKMGLSGCPAGRVAFRDCHVPTSHRLGTEGQGSIIFQHSMGWERAILFAGYLGLMERQLEQCVRHARE
RRQFGHGIGEFQAVSHRVVGMKQRLEAARLLLYRACWLMDQGRDHSTAVALSKTAVSEGAVANSLD
AIQIFGGSGYLSPAGIEQQLRDAVPSTIFSGTTDIQREIVAREIGL 
7.1.5 Prolyl carrier protein (idmK) DNA sequence  
AAGCTTAAGGAGATATACCATGGAACATCATCATCATCATCATAGCCAGCCGGTTAGCGAAGAAGA
AACGAGCAAACGCATCACCGAATTTATCCGCGAACGCTTTCTGGATGGCGACCCGCAGGGTGAACT
GGAACCGGGCAGTCCGCTGCTGGAATGGGGTGTCCTGAACAGCCTGCGTGTTGCGCGCCTGATTGC
CTTTATCCGTAGCGACCTGGGCGTGCCGGTTAGTGCGATGGAAATTAATCCGGACAACCTGCGTGA
TGTTCGCTCTATTACCGCTATGGTGACCCGTCTGGCCCGTGCTGGTGCCTAATAACTCGAG 
7.1.6 Prolyl carrier protein (IdmK) amino acid sequence  
MEHHHHHHSQPVSEEETSKRITEFIRERFLDGDPQGELEPGSPLLEWGVLNSLRVARLIAFIRSDLGVPVS
AMEINPDNLRDVRSITAMVTRLARAGA  
7.2 Vector maps 
7.2.1 pET23a 
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Figure 7.1- Vector map of the pET23a vector purchased from 
Merck4Biosciences (Nottingham, UK) highlighting key features such as the 
multiple cloning site (MCS), origin or replication, antibiotic resistance and 
promoter.  
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7.2.2 pKnanA plasmid map 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2-Plasmid map of the pKnanA plasmid (Timms et al., 2013) The 
nanA gene (933 bp) resides between the EcoRI and PstI restriction sites. 
The origin of replication, antibiotic resistance and promoter are also 
highlighted.  
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7.2.3 pETDUET 
 
 
 
Figure 7.3- Vector map of the pETDUET vector purchased from 
Merck4Biosciences (Nottingham, UK) highlighting key features 
such as the multiple cloning sites 1 and 2 (MCS1 and 2), origin or 
replication, antibiotic resistance and promoter for each multiple 
cloning site. 
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7.2.4 pMAL c5X 
 
Figure 7.4- Vector map of pMAL c5X purchased from New 
England Biolabs (Ipswich, MA, USA) highlighting key 
features such as the multiple cloning site, promoter, maltose 
binding protein (MBP) and antibiotic resistance marker. 
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7.3 Oligonucleotide sequences 
Oligonucleotide primers Sequence  
Sequencing primers  
pTRC-99A-FOR 5’-GAC ATC ATA ACG GTT CTG-3’ 
pTRC-99A-REV 5’-CTG AGT TCG GCA TGG GG-3’ 
pET-UPSTREAM 5’-ATG CGT CCG GCG TAG A-3’ 
T7 Term 5’-CTA GTT ATT GCT CAG CGG-3’ 
DUETDOWN1 5’-GAT TAT GCG GCC GTG TAC AA-3’ 
MAL-E 5’-GGT CGT CAG ACT GTC GAT GAA GCC-3’ 
M13-40FOR 5’-GTT TTC CCA GTC ACG AC-3’ 
PCR amplification primers 
Upstream-idmI-EcoRI 5’-GGG CCC GGA ATT CAA GGA G-3’  
Downstream-idmI-PstI 5’-AAC GAC GGC CAG TCT GCA GTT ATT ACA GAC CG-3’  
idmI-For-TripleClone 5’-CGT ATT GTA CAC GGC C-3’ 
idmJ-Rev-TripleClone 5’-CTG CAG CGC AAG CTT GTC GAC TTA TTA-3’ 
idmK-For-TripleClone 5’-AAG CTT GCG CTG CAG AAG GAG ATA TAC CAT GGA A-3’ 
idmK-Rev-TripleClone 5’-GGC CGT GTA CAA TAC GCT CGA GTT ATT AGG CAC C-3’ 
idmI-pMAL-Upstream-NdeI 5’-TCA GAT CAT ATG GAA CAC CAC CAC CAC-3’ 
idmI-pMAL-Downstream-EcoRI 5’-CTA GCT GAA TTC ATT ATT CAG ACC GAT TTC-3’ 
Site-directed mutagenesis primers 
idmJ-C104A-For 5’-GCT ATG GCA GAT GAC GCC AGC GCA GCA GCA CTG-3’ 
idmJ-C104A-Rev 5’-CAG TGC TGC TGC GCT GGC GTC ATC TGC CAT AGC-3’ 
idmJ-C127A-For 5’-CTG GGT CCG CGT GCT CCG GCT GCA GAC-3’ 
idmJ-C127A-Rev 5’-GTC TGC AGC CGG AGC ACG CGG ACC CAG-3’ 
idmJ-C169A-For 5’-GCA CCG AAG GGT GTG GCC ATC AGC CAT CGT AAC-3’ 
idmJ-C169A-Rev 5’-GTT ACG ATG GCT GAT GGC CAC ACC CTT CGG TGC-3’ 
idmJ-C308A-For 5’-CGA CCG AAA CGA ATG TTG CTA CCC GTC ATG AAG TCC G-3’ 
idmJ-C308A-Rev 5’-CGG ACT TCA TGA CGG GTA GCA ACA TTC GTT TCG GTC G-3’ 
idmK-S44A-For 5’-TGT CCT GAA CGC CCT GCG TGT TG-3’   
idmK-S44A-Rev 5’-CAA CAC GCA GGG CGT TCA GGA CA-3’   
Table 7.1- Table of sequences of oligonucleotide used.  
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7.4 PSI-BLAST search  
 
Figure 7.5-Top 10 sequences from the PSI-BLAST search with IdmK as the 
target sequence. The conserved serine is highlighted in the sequence. 
 
7.5 SDS-PAGE analysis of uninduced E. coli  BL21 (DE3) Gold  
 
7.6 Chemical shift assignments
Figure 7.6- Reducing SDS-PAGE of uninduced E. coli BL21 (DE3) Gold 
cells. Expected masses for IdmJ, IdmI, IdmI-MBP and IdmK are 
highlighted for comparison.   
  
 
Table 7.2-Table of chemical shift assignments (ppm) of IdmK. The protons have not been stereospecifically assigned.  
seq type H N Hɑ Hβ CO Cɑ Cβ         
1 Ser - - 4.42 - 173.90 59.30 64.90         
2 Gln 8.30 122.80 - - 173.68 54.70 30.00         
3 Pro - - 4.34 - 175.90 63.40 31.70 3.79-Hδ2 3.62-Hδ3 51.9-Cδ      
4 Val 7.84 122.80 3.96 1.80 175.00 63.10 35.00 0.86-Hɣ1* 0.85-Hɣ2* 22.9-Cɣ1 23.0-Cɣ2     
5 Ser 8.24 123.20 4.51 4.09,3.91 174.80 58.50 65.70         
6 Glu - - 3.87 2.04,2.04 178.10 61.30 30.60 2.30-Hɣ1 2.30-Hɣ2 37.9-Cɣ      
7 Glu 8.69 119.50 4.03 1.96,2.08 179.10 60.90 30.30 2.31-Hɣ2 2.31-Hɣ3 37.5-Cɣ      
8 Glu 7.96 120.70 4.09 2.06,2.06 178.60 60.00 30.60 2.27-Hɣ2 2.27-Hɣ3 37.1-Cɣ      
9 Thr 8.18 117.90 3.69 4.26 175.60 68.90 68.80 1.22-Hɣ2* 23.6-Cɣ2       
10 Ser 8.46 115.60 4.09 3.92,4.02 178.50 62.60 63.80         
11 Lys 7.94 124.30 4.06 2.00,2.00 178.80 61.20 33.60 1.69-Hδ2 1.69-Hδ3 2.96-Hε2 2.96-Hε3 30.7-Cδ 43.1-Cε   
12 Arg 8.29 118.30 4.24 2.09,2.09 180.30 60.20 31.50 1.86-Hɣ2 1.86-Hɣ3 3.15-Hδ1 3.27-Hδ2 28.2-Cɣ 44.4-Cδ   
13 Ile 8.56 119.90 3.77 2.04 177.10 65.90 38.50 1.84-Hɣ12 1.26-Hɣ13 0.97-Hɣ2* 0.81-Hδ1* 30.2-Cɣ1 19.2-Cɣ2 14.1-Cδ1  
14 Thr 8.44 117.50 3.57 4.35 175.60 69.50 69.40 1.22-Hɣ2* 22.7-Cɣ2       
15 Glu 8.30 119.70 3.92 1.95,2.08 177.80 60.50 30.60 2.30-Hɣ1 2.44-Hɣ2 37.5-Cɣ      
16 Phe 7.61 120.00 3.82 2.59,2.39 176.50 62.60 40.20 6.38-Hδ* 6.86-Hε* 6.83-Hζ 131.7-Cδ* 130.1-Cε* 128.1-Cζ   
17 Ile 8.12 117.80 3.06 1.85 178.80 66.10 38.80 1.08-Hɣ12 1.08-Hɣ13 0.95-Hɣ2* 0.86-Hδ1* 30.8-Cɣ1 18.9-Cɣ2 15.2-Cδ1  
18 Arg 8.67 118.20 3.73 - 178.60 62.00 32.30         
19 Glu 8.20 116.00 3.72 1.92,1.80 178.30 60.20 31.30 2.07-Hɣ1 2.29-Hɣ2 37.3-Cɣ      
20 Arg 8.04 113.50 4.00 0.75,0.30 178.40 57.30 30.10 0.45-Hɣ1 0.86-Hɣ2 2.55-Hδ1 2.66-Hδ2 27.1-Cɣ 43.2-Cδ   
  
seq type H N Hɑ Hβ CO Cɑ Cβ         
21 Phe 7.69 114.40 5.28 - 176.00 55.40 40.80 6.90-Hζ 130.1-Cζ 7.09-Hδ* 7.22-Hε* 130.8-Cδ* 133.5-
Cε* 
  
22 Leu 6.95 116.90 4.95 2.11,1.97 178.20 54.60 43.70 1.01-Hδ1* 0.99-Hδ2* 28.6-Cδ1 24.0-Cδ2     
23 Asp 8.80 121.90 4.37 2.99,2.62 175.10 56.70 40.80         
24 Gly 8.38 104.10 4.26,3.25 - 174.10 45.90 -         
25 Asp 8.15 117.40 4.52 2.24,2.99 174.21 54.90 42.70         
26 Pro - - 4.28 2.31,2.31 178.60 66.00 32.60 3.92-Hδ2 3.50-Hδ3 28.6-Cɣ 51.8-Cδ     
27 Gln 8.91 115.80 4.38 2.30,2.00 176.80 56.60 29.70         
28 Gly 8.28 112.30 3.78,3.67 - 175.60 48.70 -         
29 Glu 9.81 121.60 4.09 2.16,1.99 178.00 58.80 32.40 2.18-Hɣ1 38.4-Cɣ       
30 Leu 9.48 121.40 4.34 1.86,1.21 175.60 57.50 43.00 1.50-Hɣ 0.92-Hδ1* 1.02-Hδ2* 27.9-Cɣ 28.6-Cδ1 25.4-Cδ2   
31 Glu 8.98 128.20 - - 175.72 54.90 31.50         
32 Pro - - 4.21 1.79,2.35 175.30 66.70 32.70 3.87-Hδ2 51.8-Cδ       
33 Gly 7.79 98.80 4.51,3.49 - 175.80 45.00 -         
34 Ser 7.80 121.30 - - 172.55 59.10 62.70         
35 Pro - - - - 175.00 - -         
36 Leu 7.95 125.80 3.63 1.85,1.13 179.50 58.90 43.70 0.78-Hδ1* 0.76-Hδ2* 27.4-Cδ1 23.7-Cδ2     
37 Leu 8.78 118.30 4.30 1.51,1.89 180.70 58.00 41.70 1.65-Hɣ 0.84-Hδ1* 0.69-Hδ2* 27.8-Cɣ 26.4-Cδ1 24.1-Cδ2   
38 Glu 7.34 121.30 4.14 2.22,2.22 182.50 60.20 30.50 2.36-Hɣ3 2.36-Hɣ2 37.4-Cɣ      
39 Trp 8.46 116.30 4.83 3.14,3.42 177.20 57.10 32.10 127.8-Nε1 
121.2-Cζ3 
7.13-Hδ1 
124.9-Ch2 
10.25-Hε1 
7.33-Hε3 
7.58-Hζ2 6.99-Hζ3 7.33-Hh2 123.9-Cδ1 114.7-Cζ2 
40 Gly 7.62 105.80 4.17,3.85 - 174.70 46.80 -         
41 Val 7.70 117.60 3.69 2.04 176.20 65.30 33.60 1.10-Hɣ1* 0.93-Hɣ2* 23.6-Cɣ1 23.0-Cɣ2     
42 Leu 7.01 113.60 4.21 1.16,1.42 174.30 53.80 43.80 1.43-Hɣ 0.88-Hδ1* 0.71-Hδ2* 28.1-Cɣ 27.7-Cδ1 24.6-Cδ2   
  
seq type H N Hɑ Hβ CO Cɑ Cβ         
43 Asn 6.61 116.40 4.53 3.18,2.96 175.26 52.50 39.80         
44 - - - - - - -          
45 Leu 7.92 123.60 4.21 1.64,1.74 179.70 59.00 42.80 0.91-Hδ1* 0.90-Hδ2* 28.5-Cδ1 25.3-Cδ2     
46 Arg 8.20 119.40 3.86 - 178.90 60.90 32.20         
47 Val 8.79 120.00 - - 177.20 68.80 32.40         
48 Ala 7.49 120.90 4.08 1.59 181.20 56.80 18.50         
49 Arg 7.74 118.10 4.30 2.29,2.07 179.10 59.90 31.40         
50 Leu 8.78 123.30 4.21 2.42,1.75 177.90 59.20 43.60 0.90-Hδ1* 1.00-Hδ2* 25.2-Cδ1 28.1-Cδ2     
51 Ile 8.94 119.30 3.66 2.17 178.00 64.20 36.50 1.41-Hɣ12 1.41-Hɣ13 0.86-Hɣ2* 0.68-Hδ1* 28.5-Cɣ1 18.3-Cɣ2 11.1-Cδ1  
52 Ala 7.92 122.20 4.18 1.60 179.80 56.50 18.90         
53 Phe 7.62 120.80 4.44 2.73,2.73 177.10 60.90 39.90 6.84-Hδ* 6.99-Hε* 132.4-Cδ* 130.0-Cε* 7.00-Hζ 129.0-Cζ   
54 Ile 8.26 122.00 3.04 1.88 177.50 66.60 39.60 0.73-Hɣ12 0.73-Hɣ13 0.92-Hɣ2* 0.64-Hδ1* 30.4-Cɣ1 19.8-Cɣ2 14.7-Cδ1  
55 Arg 8.15 117.00 4.14 1.84 179.10 59.80 32.20 1.67-Hɣ2 1.67-Hɣ3 3.05-Hδ2 3.05-Hδ3 29.2-Cɣ 44.7-Cδ   
56 Ser 8.43 112.50 4.25 3.86,3.91 175.20 61.60 64.50         
57 Asp 8.48 122.80 4.47 1.99,2.14 177.50 57.40 42.40         
58 Leu 6.92 114.10 4.30 1.38,2.25 177.60 56.00 40.90 0.67-Hδ1* 1.02-Hδ2* 23.7-Cδ1 27.7-Cδ2     
59 Gly 6.63 105.80 3.71,3.77 - 174.40 47.50 -         
60 Val 7.49 121.50 4.47 1.65 173.03 60.00 35.40 0.73-Hɣ1* 0.73-Hɣ2* 22.0-Cɣ1 22.0-Cɣ2     
61 Pro - - 4.43 2.20,1.85 176.80 64.00 33.10 3.78-Hδ2 3.62-Hδ3 28.5-Cɣ 51.6-Cδ     
62 Val 8.27 120.60 4.11 1.98 175.90 63.10 33.80 0.89-Hɣ1* 0.89-Hɣ2* 22.4-Cɣ1 22.4-Cɣ2     
63 Ser 8.48 119.80 4.56 4.24,3.99 175.78 58.30 66.00         
64  - - - - - - -         
65 Met - - 4.22 2.58,2.58 177.50 58.40 33.10 2.05-Hɣ2 2.05-Hɣ3 32.8-Cɣ      
66 Glu 7.48 116.60 4.17 2.35,1.90 176.10 57.40 30.70 2.20-Hɣ1 2.31-Hɣ2 36.3-Cɣ      
  
seq type H N Hɑ Hβ CO Cɑ Cβ         
67 Ile 7.29 120.00 3.76 2.05 173.30 62.20 36.70 1.71-Hɣ12 1.71-Hɣ13 0.78-Hɣ2* 0.78-Hδ1* 27.9-Cɣ1 19.4-Cɣ2 14.4-Cδ1  
68 Asn 7.46 123.10 5.01 2.95,2.69 173.24 52.10 39.90         
69 Pro - - 4.02 2.27,1.88 177.60 66.40 33.20         
70 Asp 7.91 116.10 4.40 2.59,2.59 178.20 58.10 41.30         
71 Asn 7.76 115.30 4.59 3.15,2.69 175.10 55.30 41.10         
72 Leu 7.05 114.80 4.30 1.43,1.67 174.70 54.80 43.20 0.71-Hδ1* 0.76-Hδ2* 23.8-Cδ1 27.7-Cδ2     
73 Arg 6.62 113.90 3.73 1.73,2.03 175.80 60.50 32.30 1.63-Hɣ2 1.63-Hɣ3 3.17-Hδ1 3.22-Hδ2 27.6-Cɣ 44.7-Cδ   
74 Asp 7.71 110.40 4.48 3.12,3.35 175.40 53.30 43.30         
75 Val 9.95 121.30 3.50 2.20 179.20 68.80 33.40 0.93-Hɣ1* 1.12-Hɣ2* 22.1-Cɣ1 24.7-Cɣ2     
76 Arg 8.49 123.00 4.05 1.78,1.59 179.30 61.30 30.50 1.58-Hɣ2 1.58-Hɣ3 3.13-Hδ2 3.13-Hδ3 28.3-Cɣ 44.4-Cδ   
77 Ser 9.38 120.30 4.34 - 177.60 63.50 -         
78 Ile 8.70 127.80 3.88 1.83 178.40 66.90 40.00 2.34-Hɣ12 2.34-Hɣ13 0.90-Hɣ2* 0.66-Hδ1* 31.4-Cɣ1 19.8-Cɣ2 15.2-Cδ1  
79 Thr 8.80 117.40 3.53 3.52 176.50 68.90 69.20         
80 Ala 8.18 124.90 4.15 1.53 179.60 56.20 18.80         
81 Met 7.82 119.50 3.97 2.15,2.15 176.90 60.30 33.10         
82 Val 8.40 119.00 3.30 2.14 177.30 68.70 32.70 0.88-Hɣ1* 0.96-Hɣ2* 23.2-Cɣ1 25.7-Cɣ2     
83 Thr 8.58 112.00 3.86 4.19 176.80 67.10 69.80         
84 Arg 7.81 122.00 4.10 2.05,1.88 179.20 60.40 31.00         
85 Leu 8.16 120.10 4.09 1.39,1.76 179.70 58.00 42.70 0.86-Hδ1* 0.88-Hδ2* 23.5-Cδ1 27.5-Cδ2     
86 Ala 8.45 122.20 4.14 1.47 179.10 55.20 19.70         
87 Arg 7.56 116.30 4.23 1.84,1.95 176.80 58.00 31.40 1.68-Hɣ1 1.82-Hɣ2 3.18-Hδ2 3.18-Hδ3 28.7-Cɣ 44.6-Cδ   
88 Ala 7.72 122.70 4.28 1.46 178.20 54.20 19.90         
89 Gly 8.09 107.60 3.90,3.94 - 173.00 46.30 -         
90 Ala 7.68 129.00 4.12 1.34 182.51 54.80 21.20         
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7.7 Crystallography statistics 
 
Parameter  
Space group C2221 
a, b, c (Å) 48.8, 237.5, 
128.1 
Α, β, γ 90, 90, 90 
High resolution limit 
(Å) 
118.75-2.70 
Rmerge 0.062(0.498) 
Rpim (I) 0.030(0.249) 
Observed reflections 117 058 
Unique reflections 20 716 
Completeness (%) 98.6 
Multiplicity  5.7 
I/σ 11.5(2.2) 
Table 7.3- Table of crystallography statistics of IdmK. Values in 
parentheses correspond to the lowest resolution range. Rpim indicates 
precision (multiplicity-weighted) Rmerge. 
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